¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>ÃĵØÂåÃÄ
ªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C

6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C

(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C



¶}ª©·|­û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ­«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M

·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/25 ¤U¤È 06:41:55²Ä 3469 ½g¦^À³
©Ò¥H©O¡H

¤j¥ë§âªÑ²¼½æ¤@½æ¥H¥Ü§Üij¡K

ÁÙ¬O®Ú¥»¦³¨Ç¤H´N¬OªÅ¤â¨Ó³Û¿Nªº¡K«¢

¨S³o»òÄY­«°Õ

¤½¥q¦pªG¦³¤ß­nÁô¿f¡A©ú¦~¤T¤ë©³¦A¤½§i¡K

EMA­n¨D¸É¥ó©Ò¥H©µ¨ì¤­¤ë©³¤£´N¦n¤F

­@¤ßªºµ¥¡K

¦³¨Ç¨Æ¤£¬O¦Û¤v¯à§¹¥þ´x´¤ªº

§Ì§Ì¤£¤]¦]¥DºÞ¾÷Ãö­ì¦]´N©µ´Á¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤¸®ð¤j¨k«Ä10142490  µoªí®É¶¡:2017/12/25 ¤U¤È 06:24:40²Ä 3468 ½g¦^À³
§Ú±q¥h¦~ÃĵؤWÂd´N«ù¦³¨ì²{¦b¤F

¦¨¥»¦b190¥ª¥k¡A´N¬O¦b³o¸Ì¬Ý¨ì¨C­Ó¤H¹ï¥¦ªº¥¼¨Ó¬O¦³¦h»òªº¬Ý¦n~

²{¦bÃĵءA¤Ñ¤Ñ³£«K©y¡A¶V¨Ó¶V«K©y

¦­ª¾¹D¶R­Ó¥xÆW50¡A¤µ¦~¦Ü¤Ö³£ÁÙ¦³¤£¿ùªº¥¿³ø¹S~

¥u¯à»¡ÃĵجOÀɤ£³Q¥«³õ»{¦PªºªÑ²¼§r

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±i±M­û10145380  µoªí®É¶¡:2017/12/25 ¤U¤È 06:18:11²Ä 3467 ½g¦^À³
µØ¤Í­ÌÀ³¸Ó§â³o¨Ç©ê«è¡A«Ø¨¥¯d¨¥µ¹¤½¥qºô¯¸¤~¹ï¡A¦b³o½×¾Â¦Û«è¦Û¦ã«è¤Ñ¤×¤H¡A¤½¥qª¾¾å¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/25 ¤U¤È 06:02:37²Ä 3466 ½g¦^À³
¹ïÃĵؤ@ª½©ê«ù¼ÖÆ[ºA«×ªÌ,ÁÙ¯uªº¬O¤j¦³¤H¦b,

·d¤£¦n¨ì¤F5¤ë,¤S¦³¨ä¥L¥¼Ãz¼u¦A«×©ì©µÃÄÃҮɶ¡~

ªÑ»ù´N¬O¤Ï¬M²{ªp,ªp¥B¥H¸ê°T³o»ò¤£³z©úªºªÑ²¼©Ê½è,

ÁÙ¯u¬OÅý®¼ÃĵتºªÑ¥Á±¡¦ó¥H³ô~

¥Ã»·³£¦³ÂǤf¨Ó¸ò®¼ÃĵتºªÑ¥Á SAY SORRY ¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2017/12/25 ¤U¤È 05:39:34²Ä 3465 ½g¦^À³
ÃĵجO¯¸¦b²Ä¤@½u¤£¬O¯¸¦b²Ä¤G½u¤£­n±Àµ¹AOP

¼Ú¬wÁ{§É²Ä¤@½u¬OAOP¦Ó¥Bº}«G§¹¦¨CONTI-PV¼Æ¾Ú,¦Ó¥Ó½Ð¼Ú¬wÃÄÃÒªº¬O¶È¥HAOP¦W¸q¡AÃĵجO¯¸¦b²Ä¤@½u¤£¬O¯¸¦b²Ä¤G½u¡A¦pp1101¥Í²£,¥x¤¤¼t,¥x¥_¬d¼t,¹A¬ì°|¬d¼tÃöÁä¯Ê¥¢,CTD°eEMA¤Î´£¥æ§¹¾ã¸ê®Æµ¹EMA¥H¤F¸ÑPEG¥Í²£¬yµ{¡B±±¨îµ¦²¤¤Î¬ÛÃö¤ÀªR¤èªkµ¥,§¡¬OÃĵإ²¶·§¹¦¨,¤£¬OAOP.«ØijÃĵاâ©Ò¦³­«¤ß¸ê·½©ñ¦b«ö­pµe®³¨ìEMA²Ä¤@­ÓÃÄÃÒ¤W.½Ð¤£­n±N©Ò¦³ºë¤O©ñ¦b¥«³õ¦æ¾P¤Î¤£¤Î­¢ªº¶µ¥Ø,¤£­n¦n°ªÄE»·.EMAÃÄÃÒ®³¤£¨ì,¤£­n°ø·QFDAÃÄÃҤάü°ê¥«³õ¦æ¾P.²³³¾¦bªL¤£¦p¤@³¾¦b¤â,ÃĵØÅ¥¤£¶i¥h¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/25 ¤U¤È 05:20:31²Ä 3464 ½g¦^À³
¦pªG·Ó¤½¥q¤½¶}¸ê°T¯¸¤½§i®É¶¡...

106/12/25 00:37:50¥B¨Æ¹êµo¥Í¤é¬°106/12/24AOP§iª¾...¨Ó¬Ý(°²¤é²`©]ÁÙ¦bµo¤½§i...«Ü»{¯u¤F)

¤½¥q¤w¸g¶Ç¹F«Ü¤Î®Éªº¸ê°T¤F¡C

¨Ã¨S¦³¨è·NÁô¿f!!

²¦³ºEMAÃÄÃÒ¥D¨¤¬OAOP¡AAOP¤£»¡¡AÃĵؤ]¤£·|ª¾¹D¡C

¥»¨Ó¦^ÂаÝÃD®É¶¡¬°12/24¦Ó´£¨Ñ§¹¾ã¸ê®Æ®É¶¡¬°¤T¤ë©³

²{¦b¥u¬O´£¨Ñ§¹¾ã¸ê®Æ©µ¦Ü¤­¤ë©³¡A¦Ó¥B¥i¥H´£¦­....

´«¨¥¤§¡B¾ã­Ó®Éµ{³Ì¦h¤]©µ¤G­Ó¤ë½}¤F....¦³³o»òÄY­«¶Ü???

´«­Ó¨¤«×¨Ó¬Ý¡B¥i¨£­n®³ÃÄÃÒ¦³¦h»ò¤£®e©ö...

§ó¬ðÅã....¥¼¨Ó®³¨ìEMA»PFDAÃÄÃҫ᤽¥qªº»ù­È....

ªÑ¥«¦W¨¥...­n©Ô«eÁ`·|¥ý±þ¤@ªi....

¬Ý¨Ó2018¦nÀ¸­n¤W³õ¤F...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/25 ¤U¤È 05:19:48²Ä 3463 ½g¦^À³
°Ý¤Q¤G¡G¼Ú¬w°e¥ó¦^ÂЬO12¤ë22¸¹¡A¶i«×³£¦³ºû«ù¶Ü¡H¼Ú¬wÃÄÃÒ®³¨ì«á·|¥ý¦b¨º¸Ì¤W¥«¡H

µª¡G²{¦b³£¦b¶i«×¤W¡A¥Ø«e¹w­p7¤ë2¸¹¤§«e·|¦³µ²ªG¡CAOP¤@©w·|¥ý¦b¶ø¦a§Q¤W¥«¡A¥Ø«eAOP¦³­pµe¡A¦ý¤£¯à³zÅS¡C

³o¬O¤§«eªk»¡ªº´£°Ý,À³¸Ó¦b3¤ë©³«e·|¦^ÂÐEMA

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/25 ¤U¤È 01:36:59²Ä 3462 ½g¦^À³
¦n´Î´Î ¦¬³Ì§C

ÁÙ¶^¯}ªñ´Á½L¾ã¥­¥x

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/25 ¤U¤È 01:34:07²Ä 3461 ½g¦^À³
½Ðª÷ºÞ·|ÄY¬d

¤½§i«e¦³§_¤º½u¥æ©ö

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Glee-sen10145657  µoªí®É¶¡:2017/12/25 ¤U¤È 12:41:21²Ä 3460 ½g¦^À³
¥Hµ²ªG½×¨Ó»¡¡A¬Ý°_¨Ó

¯uªº¬O¦³Áo©ú¿ú¡BÁo©ú¤H¦b°µÁo©ú¨Æ

¥u¬O§Ú­Ì³o¨Ç¤p´²¤á¦ü¥G¤]...¥u¯à³o¼Ë¤F

¥H¥Ø«eªº¶i«×¨Ó¬Ý

¥ý¨Ó¥h°µ·R´þªº¤j­ô¨ºÃ䶤@¤U

¤£ª¾¬O¤£¬O¤@­Ó¦nªº¿ï¾Ü....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/25 ¤U¤È 12:18:15²Ä 3459 ½g¦^À³
¤µ¦~¨ì¤W©P¤­¥æ©ö¶×Á`

¶R¶W«e¤T¦W¬O

ªáºX(2957 x 167.85)

²Ä¤@ª÷°ª¶¯(1360 x 146.68)

ªáºX(884 x 161.25)

½æ¶W«e¤T¦W¬O

¤¤°ê«H°U(769 x 153.52)

¤¸¤j´°«n(756 x 146.53)

´I¨¹¤¯·R(740 x 147.1)==> ®ü­ô

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/25 ¤W¤È 11:51:54²Ä 3458 ½g¦^À³
©Ò¥H§Ú»¡135¦A¨Ó±µ

¤£µM´Nµ¥©ú¦~2¤ë3¤ë¦A¨Ó±µ

²¦³º®É¶¡¤ÓªøÃø«O°ê»Ú¬F¸g§½¶Õ¤£·|¦³¼@¯PÅܤÆ

¦Ü¤Ö¬Ý¬Ý°ª¶¯²Ä¤@ª÷­þ¤Ñ¶}©l³sÄò¶R¶W¦A¨Ó»¡

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/25 ¤W¤È 11:25:38²Ä 3457 ½g¦^À³
Æ~½Ðª÷ºÞ·|ÄY¬d¡I¡I

¦³¨S¦³¤º³¡¤H¦b¤½§i«e½æªÑ¡H

¬Û«H¤§«e¨º¨Ç³æµ§¼Æ¤Q±i¥Î¤º½L¥á¥Xªº½æ³æ¡A¤£¬O´²¤á©Ò¬°

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/12/25 ¤W¤È 11:22:19²Ä 3456 ½g¦^À³
½Ð¬Û«HAOPªº´¼¼z

³o¤C¡B¤K¦~¨Ó§Ú­Ì¬Ý¨ìAOP³B¥@ªº±M·~»P¼ô½m¡A¯uªºµL©Ò¬D±§¡C

¥Ó½ÐÃÄÃÒªº¬OAOP¡AÃĵإu¬O¯¸¦b²Ä¤G½u¡A¶¡±µ±µ¦¬AOP¸ê°T¡A¤]°t¦XAOPªº¸}¨B¡A¹ï©óEMA¦h¾lªº­n¨D¡A§Ú¤@ª½¬Û«HAOP¥æ¯Aªº¯à­@¡A¦h¤@ÂI®É¶¡·Ç³Æ¡A¤]¥iÀH®É¥æ¨÷¡C

¥u­n¯à§Ö³t¨ú±oÃÄÃÒ»P¡¨³Ì¦nªº±ø¥ó¡¨¡A¤~¬O­«ÂI¡C¦ó®É¥æ¨÷¡A¸ê®Æ¦p¦ó§e²{¡A¬Û«HAOPªº±M·~¡C¬Ý¬Ý³o»ò¦nªºÃĮĻP¹êÅçµ²ªG¡A©Ò¥H¸£µ¬¤£­n¦Ñ¦¡¥d¦bÃÄÃÒ¨ú±o¥i¯à¦h´X¤Ñ¤W¡AÀ³¸Ó©ïÀY¬Ý¬Ý¤j¾Ô²¤ªºÆ[ÂI¡C

³o´X¦~¡A¦h¤Ö¤j­·¤j®ö³£¤w¸g¹L¡A¾ã­ÓÄ¥¶¤ÁÙ¬O¤@ª½©¹«e¦æ¡A¥¼¨Ó¨ÌµM¦p¦¹¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/25 ¤W¤È 10:50:11²Ä 3455 ½g¦^À³
¤@¶¡¤£¦Ñ¹êªº¤½¥q,Ãø©Çªk¤H¸ò¥~¸ê³£¤£·Q©Ô©ï¤]¤£¬Ý¦n,

¦Ñ¥~³Ì­«µøªº´N¬O«H¥Î,¤@¦Ó¦A¦A¦Ó¤TªºÁô¿f¸ò´ÛÄF~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/25 ¤W¤È 10:24:16²Ä 3454 ½g¦^À³
³o¦¸ªº¤½§i

¤p§Ìªº¬Ýªk´N¬O¾÷Ãö­n¨D¨ä¥L¸ê®Æ

¦ý¬°¤F¸ÉÀv¦h­n¨DªºªF¦è

©Ò¥H­ì¥»©ú¦~¤T¤ë­n¨D°e§¹¥óªº

µ¹§A¨ì¤­¤ë

·íµM¦pªG§AÄ@·N´£«e°e¡KEMA¤]±µ¨ü

ÁÙ¦n°Ú¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2017/12/25 ¤W¤È 10:14:05²Ä 3453 ½g¦^À³
1.2018/2/15 ¨ºÁÙ­n¸òFDA½Í¤°»ò©O?

2.´N¤µ¤Ñªº¨Æ¥ó,½Ð°Ý½èºÃ»P¬¶ÅFªºµØ¤Í¦³»{½ß±þ¥X¤F¶Ü?

­Ó¤H¬O´Á¬ßÃĵئb¦Xªk­ì«h¤U¯à§ó©Z¸Û¤Î§ó³z©úªºº¡¨¬¦U¦ìµØ¦³©Ò«Øijªº¸ê°T;¤ÏÆ[¦U¦ìµØ¤Í¤Î«e½úÀ³µ¹¤©Ãĵاó¦h¤ä«ù»P¥[ªo,¯uªº¬O¤½³¡ªù»¡¤Fºâ,¦Ó«DÃĵئۼoªZ¥\¤£·Q¦­¤@¤ÑÀò§Q°Ú~

~¸t½Ï¸`§Ö¼Ö~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¹Å10138576  µoªí®É¶¡:2017/12/25 ¤W¤È 10:01:48²Ä 3452 ½g¦^À³
¨ä¹ê¤½¥q¤è­±ªº°ÝÃD¡A¤p§Ì§Ú¦b¤Q¤@¤ëªìÁ{§É¼Æ¾Ú¤½§i·í¤é§Ú¦³¸ß°Ý¹L¤½¥q¡A·í®É´Nı±o¤½¥q¦^ÂФ譱´N©Ç©Çªº¡C

¡q¤@¡r¹êÅç²ÕÀù¯gµo¯fªº´X¦ì¹ê»Ú­ì¦]µLªkµªÂСC

¡q¤G¡r¦b¼Ú·ù査¼tªº¦P®É¡A¤½¥q¦³¬£¤@²Õ¸òFED¨ó°Ó°e¬ü¼f¬d¡A¦ýµ²ªG¬O¤°»ò­ì¦]¥H­PµLªk°eFED¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/25 ¤W¤È 09:56:15²Ä 3451 ½g¦^À³
¦pªG¡K§Ú¬O»¡¦pªG¡K

¦³¤H¶X°²§QªÅ¦b¦¬Äw½X©O?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü«Â10140483  µoªí®É¶¡:2017/12/25 ¤W¤È 09:56:02²Ä 3450 ½g¦^À³
­ì¥»¤T­Ó¤ëªº®É¶¡¼È°±¼f¬d,¤½¥q©µªø¨ì¤F¤»­Ó¤ë,¤»­Ó¤ë³Ì«á¤@¤Ñ¤~µo¤½§i»¡¦³°ÝÃD­n©µªø¼f¬d,¦ý´X¤Ñ«eªºªk»¡·|¤½¥q¤~»¡¼f¬d³£¨Ì·Ó¶i«×¡C©Ò¥H²{¦b¬O®É¶¡¼È°±¨ì¤­¤ë©³(¸ê®Æ¥i´£¦­°e¤J),¤~Ä~Äò²Ä¤G¶¥¬qÃÄÃÒ¼f¬d¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/25 ¤W¤È 09:52:53²Ä 3449 ½g¦^À³
¤º½Lªº¤j³æ¥Ã»·³£¯à³Q®ø¤Æ

°¶«v

§Ú­Ì¯uªº¹ï¥ô¦ó¨Æ³£­n¦³¦sºÃ¤§¤ß

¸g¹L°ò¨È¯E¹©

§Ú­Ì¯uªº¤£¯à¤Ó³æ¯Â¤Ñ¯u

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/25 ¤W¤È 09:42:21²Ä 3448 ½g¦^À³
©ú©ú¬O¤j§Q¦h

¬°¦ó¤Ñ¤Ñ¦³¤j³æ¥Î¤º½L¦b½æ

¯u¶H¥X¨Ó¤F,´N¬O¸ê°T¤£¹ïµ¥

½Ðª÷ºÞ·|¬d¤@¤U

¨º¨Ç¤j³æ¬O½Ö¦b½æ?

ÄY¬d

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/12/25 ¤W¤È 09:20:58²Ä 3447 ½g¦^À³
§ïÅÜ´NÅܧQªÅ?

¸ò¬F©²¾÷Ãö¥æ¯A¥»¨Ó´N¥H¥L­n¨D¬°¥D¡A¥L·Q«ç»ò¼Ë´N«ç»ò¼Ë¡A¦Ó¥BÀH®É·|µo¥Í¡C¥L­n§A¤@¦¸¥æ¨÷¡A¦bµ¹¨â­Ó¤ë¤§¼e­­«ç»ò·|¬O§QªÅ?

­Y¯à´£¦­¥æ¨÷¡A¤£´NÅܦ¨§Q¦h?

¬Û«HAOP¥æ¯A¯à­@¡A¤]¤£­n§â§ïÅܳ£Åܦ¨§QªÅ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/12/25 ¤W¤È 09:14:10²Ä 3446 ½g¦^À³
¤½¥q¦³§V¤O¦b°µ¡AÅýp1101¥þ²y¯à¨£«×´£°ª¡A§ë¸ê¤H¦³¬Ý¨ì¡A¦ý¸ê°T¤£¹ïºÙ°ÝÃD¬O¤½¥qªº£¸¤j±Ñµ§¡A¥ý«eªk»¡À³¸Ó´Nª¾³o°ÝÃD©Ò¦b¡A¦ýÁÙ¬O»¡¤£¼vÅTÃÄÃÒ®Öµo®É¶¡¡A³Ì±ß7/2·|¦³µ²ªG(·Q·Qgenet¤§«eÁ¿ªº¤]¨S¦³¿ù¡A¤½¥q¦b©ó¹ï¥~¦æ¾P¸Ü³NÅý¤H·P¨ì¥¢±æ¡A¦]¬°¬O·í¤ÑÁ¿ªº·í¤Ñºâ¡A²{¦b¦³°ÝÃD¤½§i¤S¥t¥~ºâ)¡A¤½¥q¦³¥²­n¼á²M¡AÅý§ë¸ê¤H¬Û«H¨S¦³ÅU¼{¤~¹ï!!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/25 ¤W¤È 08:58:16²Ä 3445 ½g¦^À³
©Ò¥H§Ú»¡ªÑ»ù¤~¬O¯uªº

ªÖ©w¬O¦³¤£¥i§i¤Hªº¨Æ¤~·|ªÑ»ù³£°_¤£¨Ó

§A­Ìªº§Q¦h³£¬O¦Û§Ú¦w¼¢¥Îªº

¹L¥h¨â¤T¶g½L¤¤³£¥á¤j³æ

·Q¤]ª¾¹D¦³°­

ÁöµM¤£¬O¤°»ò¤j§QªÅ

¦ýªÖ©w·|©ì©µ®Éµ{¼vÅTµû»ù

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/12/25 ¤W¤È 08:54:32²Ä 3444 ½g¦^À³
¸ê®Æ¥»¨Ó¤À¨â¦¸°e¡A¨ì¤T¤ë©³¤î¡A²{¦bEMA»¡¦h¨â­Ó¤ë¨ì¤­¤ë¡A¤@¦¸°e¡A¡¨¤]¥i´£¦­°e¡¨¡C

¥»¨Ó¼Ú·ù´£°Ýªº¸ê®Æ¥i¯à¤­ªá¤Kªù¡A¶·ÀH®É±µ©Û¡A³o¬O¥¿±`¤§¨Æ¡C

¡§¬F©²¾÷Ãö¡¨ÀH®É«ç»ò­n¨D´N«ç»ò°t¦X¡C¦ý§Æ±æ¤½¥q¸ê®Æ¯à´£¦­ºÉ§Ö°e¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/25 ¤W¤È 08:28:06²Ä 3443 ½g¦^À³
¨Æ±¡¬J¤wµo¥Í¡A­«ÂI¬O·|¤£·|¼vÅTÃÄÃҥӽлP®Öµo®Éµ{?

­Y·|¦³©Ò¼vÅTÃÄÃÒ¶i«×¡A¤½¥qÀ³¾Ú¹ê¥H§i¡AÅý§ë¸ê¤H§PÂ_¡C

¸ê°T¤£¹ïºÙªº±¡§Î¡AÀ³­°¦Ü³Ì§C¡C

Q¡B­Y·|¦³©Ò¼vÅT¡AÃÄÃÒ¼f¬d¡A®Éµ{¬°¦ó?

­¤AOP©ó2018¦~5¤ë©³°e¥ó¡G

1.2018¦~6¤ë1¤é¦Ü8¤ë31¤é¡G(²Ä121¦Ü210¤Ñ)²Ä¤G¶¥¬q¼f®Ö¡A¨Ã±µÄò­p®É¡F¦b¼f®Ö¹F¨ì²Ä210¤Ñ¡AEMA·|¥X¨ã¤W¥«³\¥i·N¨£®Ñ§tCHMP opinion¡A­Y¬°¥¿­±·N¨£¡A«h¥i´£¥æ¼Ú·ù©e­û·|¡]European Commission¡^½Æ®Ö?

2.2018¦~11¤ë7¤é¡G(²Ä211¤Ñ¦Ü277¤Ñ)¡A¨Ã©ó67¤Ñ¤º§¹¦¨¦U¶µ¦æ¬Fµ{§Ç¡A¥ç§Y²Ä277¤Ñ¡AEMA´N·|°µ¥X®ÖµoÃÄÃÒªº³Ì²×¨M©w¡]Final Commission decision¡^?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦n¹B10137114  µoªí®É¶¡:2017/12/25 ¤W¤È 08:08:57²Ä 3442 ½g¦^À³
¸ê°T¤£³z©ú¡A¼f¼t§¹´Nª¾¹Dªº¨Æ±¡²{¦b¤~¤½§i¡AÁ{§É¤W¬ì¾Ç¤WÃĪ«¬O¦¨¥\ªº¡A¦ý¦p¦ó¦¨¥\µo®i¨ì¤W¥«¬O¥t¤@¥ó¨Æ¡Cµ¥«Ý«á­±¨}¾÷¦A¦Ò¼{¶i³õ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2017/12/25 ¤W¤È 07:34:58²Ä 3441 ½g¦^À³
Ãø©Ç³Ìªñ³£¦³¤j³æ¤@ª½½æ¡CAnderson¤j¤j¦ü¥G¦­¤wª¾¹D?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/25 ¤W¤È 05:45:35²Ä 3440 ½g¦^À³
¬Ý¼Ë¤l¤]¤£¬O«Ü¤jªº°ÝÃD

¤£µM¤½¥q¤]¤£·|¦b2018¦~³Wµe¦æ¾P¥¬§½

©³³¡­n¥Î§QªÅ¥h´ú¸Õ,¦~©³«e¤âí140¤j·§¨£©³¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/25 ¤W¤È 05:22:19²Ä 3439 ½g¦^À³
©Ò¥H¤§«e´Nı±o©_©Ç¬°¦ó­n©ì¨ì®É¶¡§Ö¨ìÁÙ¨S¦^ÂÐEMA°ÝÃD

¤£¬O¤½¥q¤£·Q¦­ÂI°e

¬OÁÙ¦³°ÝÃD¨S¸Ñ¨M

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/25 ¤W¤È 05:09:55²Ä 3438 ½g¦^À³
¥»¤½¥q±µÀòAOP¤½¥q³qª¾¨ä±N¨Ì´`EMA­n¨D©ó2018¦~5¤ë¤@¦¸´£°e§¹¾ã¸ê®Æ¨ÑEMA¼f®Ö

6.¦]À³±¹¬I:

¨ÌEMAÃÄÃҥӽгW½d¡AAOP¤½¥q­ì¥»¹w­p©ó12¤ë©³°e¥æ²Ä¤@¶¥¬qªº°ÝÃD¦^ÂЪì½Z¡A¨Ã

©ó2018¦~3¤ë©³±N¥þ³¡§¹¾ãªº¸ê®Æ´£°eEMA¶i¦æ¼f®Ö¡C¦ý¥Ñ©óEMA¼f®Ö»P¬d¼t¹Lµ{¤¤¡A

­n¨D¡u­«·s©w¸q°_©lª«¡v(Designation of starting material ) ¡V «Y»E¤A¤G¾J

(PEG)¤À¤lªº³¡¤À¨Ã­×¥¿³¡¤À¤ÀªR¤èªkªº³Ì¤p°»´ú­È¡A¥»¤½¥q§¹¥þ±µ¨üEMA­n¨D¡A¨Ã

¤w§¹¦¨ªì¨B¹êÅç¡C¥t³o³¡¤Àªº¤å¥ó­ì¨Ã¤£¥]¬A¦b¤w°e¥æEMAªº¡u³q¥Î§Þ³N¤å¥ó¡v

(Common Technical Document (CTD))¤¤¡AEMA§Æ±æ´£¥æ§¹¾ã¸ê®Æ¥H¤F¸ÑPEG¥Í²£¬yµ{

¡B±±¨îµ¦²¤¤Î¬ÛÃö¤ÀªR¤èªkµ¥¡A¹E­n¨D2018¦~5¤ë¤@¦¸°e¥æ§¹¾ã¸ê®Æ¥H§Q¼f®Ö¡C¨Ì¾Ú

EMAÃÄÃҥӽгW½d¦b³o´Á¶¡¤º­Y¸ê®Æ¤w§¹¾ã³Æ»ô¡A¤]¥i¥H´£«e°e¤J¥H¶i¦æ¼f¬d¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï

§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GBESREMi10143176  µoªí®É¶¡:2017/12/23 ¤U¤È 05:06:13²Ä 3437 ½g¦^À³
Angela Fleischman ´£¨ì¤zÂZ¯À¦bMPN »â°ìÃÒ©ú¥X¦³Àø®Ä, ¦o«Ü¿³¾Ä¯à¬Ý¨ì P1101 ¦b¥»¦¸¦å²G¦~·|¤W©Òµoªíªº¼Æ¾Ú, ¦]¬°³o¸Ñ¨M¹L¥h¤zÂZ¯À¦³«Ü¦h¯f¤H¦]¬°°Æ§@¥Î½t¬G, ¥X²{¤£­@¨üªº±¡ªp¡CP1101²Å¦X¦³¤zÂZ¯ÀªºÀø®Ä, ¤SµL°Æ§@¥Î, ¬O«Ü´Îªº¤@¥ó¨Æ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/23 ¤W¤È 09:03:35²Ä 3436 ½g¦^À³

https://patientpower.info/video/the-latest-mpn-news-what-the-experts-learned-at-ash

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/23 ¤W¤È 08:59:08²Ä 3435 ½g¦^À³
¼v¤ù¤¤17:49¦³­^¤å¦r¹õ´£¤Îropeginterferon¡A

¦ý Angela Fleischman§¹¾ã½Í¸Ü¡A¨ü­­©ó­Ó¤H­^¤å¯à¤O¡A

¥²¶·½Ð°ª¤â¨ó§U½Ķ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/23 ¤W¤È 08:15:13²Ä 3434 ½g¦^À³
The Latest MPN News: What the Experts Learned at ASH 2017

Published on December 21, 2017

What¡¦s the latest information about MPN treatment and research? As part of our ASH 2017 coverage, Dr. John Crispino and Dr. Angela Fleischman, Joined Patient Power to share what they learned at this year¡¦s annual meeting in Atlanta. Both researchers in the condition of myeloproliferative neoplasms (MPNs), they discussed treatment advances, particularly related to JAK inhibitors and interferon, the study of somatic mutations and how these learnings will aid in the development of future medicines. Tune in now to learn more from these MPN experts.

Produced by Patient Power. We thank Incyte Corporation for their support.

MPNªvÀø©M¬ã¨sªº³Ì·s«H®§¬O¤°»ò¡H §@¬°§Ú­ÌASH 2017¦~³ø¾Éªº¤@³¡¤À¡AJohn Crispino³Õ¤h©MAngela Fleischman³Õ¤h¡A¥[¤J¤FPatient Power¡A¤À¨É¤F¥L­Ì¦b¨È¯SÄõ¤jÁ|¦æªº¤µ¦~¦~·|¤Wªº¸gÅç¡C ¨â¦ì¬ã¨s¤H­û¦b¬ã¨s°©Åè¼W´Þ©Ê¸~½F¡]MPNs¡^ªº±¡ªp®É¡A³£°Q½×¤FªvÀø¤è­±ªº¶i®i¡A¯S§O¬O»PJAK§í»s¾¯©M°®ÂZ¯À¬ÛÃöªº¬ã¨s¡A¥H¤ÎÅé²Ó­M¬ðÅܪº¬ã¨s¥H¤Î³o¨Ç¾Ç²ß±N¦p¦óÀ°§U¥¼¨ÓÃĪ«ªºµo®i¡C ²{¦b¦¬Å¥³o¨ÇMPN±M®aªº§ó¦h«H®§¡C

¥Ñ¯f¤H¤O¶q¥Í²£¡C §Ú­Ì·PÁÂIncyte¤½¥qªº¤ä«ù¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/12/22 ¤U¤È 04:43:35²Ä 3433 ½g¦^À³
À³¸Ó¬O¦bASHµoªíªºÂ²³øÀÉ:

www.pharmaessentia.com/english/news_2017121901.html

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü«Â10140483  µoªí®É¶¡:2017/12/22 ¤U¤È 03:36:13²Ä 3432 ½g¦^À³
¤µ¤Ñ¬O¦^µªEMA°ÝÃDªº³Ì«á¤@¤Ñ,¦³¤H¦³®ø®§¤½¥q¬O§_¤w¸g±N°ÝÃD¦^ÂФF?©xºô¤W¼g¦^µª°ÝÃD´Á¶¡¬O3­Ó¤ë,ªk»¡·|ªL°õ¦æªø¦³»¡¥i¥H©µªø¨ì6­Ó¤ë,¤µ¤Ñ¤w¸g¬O³Ì«á¤@¤Ñ¤F,¤£ª¾¹D¤½¥q¬O§_¦³·ÓµÛ¶i«×¦A¨«¡C

¸`¿ý©xºô¤Wªº¤@¬q¸Ü:

ªL°êÄÁªí¥Ü¡A¡u¦b²Ä80¤Ñ©Ò¥X¨ãªºªì¨B·N¨£®Ñ¬Û·íÃöÁä¡A¥Ø«eÁöµM¥u¶i¤J¼f®Öªº²Ä¤@­Ó¬P´Á¡A§Ú­Ì·|¿n·¥©MAOP¤½¥q¦P¤¯¨F½L¥i¯àªº´£°Ý¡A¨Ã©ó²Ä120¤ÑÀòª¾©Ò¦³°ÝÃD«eÁܽÐAOP¤½¥q¬ÛÃö¦P¤¯¨Ó§Ú­Ì¥x¤¤¼t¤@°_ÀÀ¦n¦^ÂЩҦ³ªº´£°Ý¡A¥H½T«O¦b³Ìµu®É¶¡¤º§¹¦¨©Ò¦³ªº¦^ÂСA¨Ï¦A±Ò°Êªº®É¶¡¾¨¦­¶}©l¡A¥Hª§¨ú¦b³Ìµu®É¶¡¤º¨ú±oÃÄÃÒ¡A¦b¼Ú¬w°ê®a¤W¥«¾P°â¡C¡v

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/12/22 ¤U¤È 02:23:49²Ä 3431 ½g¦^À³
2017/12/22 ¤¸´I§ëÅU¬ã¨s³ø§i

Almost There!!!

 CONTI-PV ¼Æ¾ÚÅã¥ÜP1101 Àø®ÄÅãµÛÀu©ó²{¦³Àøªk¡AÃĪ«»ù­È¤w¸û

PROUD-PV ¤j´T´£¤É¡GÃĵØÃöÁäÃĪ«¥þ·sªø®Ä«¬¤zÂZ¯ÀP1101

(Ropeginterferon)ªº¨â¦~´ÁÁ{§É¸ÕÅçµ²ªG¦bASH ¦~·|µoªí¡A¦¹¦¸¼Æ¾Ú

³Ì¨ã»ù­È¦b©ó¡A·íªìPROUD-PV(12 ­Ó¤ë¼Æ¾Ú)¤¤¡AP1101 ªºÀø®Ä¶È»P

HU Àø®Ä¬Û·í(CHR¡G43.1% VS 45.6%)¡A¦ý®Ú¾ÚCONTI-PV¡A¦bº¡24

­Ó¤ë«á¡A¨Ï¥ÎP1101 ±wªÌªºCHR «ùÄò¼W¥[¦Ü70.5%¡A¤w©úÅãÀu©ó±Ä

¥ÎHU/BAT ªvÀøªº±wªÌªº49.3%¡AP ­È0.0101¡A¨ã²Î­p¤WÅãµÛ·N¸q¡F

P1101 ÃĪ«ªº»ù­È¤w¸û¤@¦~«e¤j´T´£¤É¡C

 ¥Ø«e PV ¤G½uªvÀøÃĪ«JAKAFI ¬ü°ê¥«³õ¹F3-4 »õ¬ü¤¸¡AÃĵØP1101

ºË·Ç¤@½u¥«³õ¡A¼ç¦b¾P°â°ª®p±N¶W¹L¦¹¤@»ù­È¡GFDA ¦Ü¤µ¨Ã¥¼®Ö­ã

¥ô¦ó¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera¡APV)ªº¤@½uÃÄ

ª«¡A¥Ø«e´¶¹M¥HÃÄ»ù§C·GªºHU °µªvÀø¡AµMPV ±wªÌ¦b¨Ï¥ÎHU ¤@¬q

®É¶¡«á­Y²£¥Í§ÜÃÄ©Ê¡A«h¶È¯àÂ੹¤G½uÃĪ«JAKAFI¡A¨C¦~ªvÀø¶O¥Î

°ª¹F13 ¸U¬ü¤¸¡A¦¹¤@¥«³õ§Y¹F3-4 »õ¬ü¤¸¡F¦ÓÃĵتºP1101¡AÀø®Ä

¤wÀu©ó²{¦³ÀøªkHU¡A¥B¥ç¦³§í¨îJAK2(³y¦¨PV ªº­«­n¦]¯À)ªº¯à¤O¡A

¥¼¨Ó­Y¯à¨ú±oFDA ®Ö­ã¥Î©ó¤@½uªvÀø¡A¦¨¬°ªvÀøPV ªº¼Ð·ÇÀøªk¡A¥«

³õ»ù­È¥i´Á¡C

 ¼Ú¬wÃÄÃÒ¹w­p2H18 ¨ú±o¡AµM±K¤ÁÃöª`FDA ¬O§_¦P·N¨Ì¾Ú²{¦³¸ê®Æ

°e¥ó¡A¹w­p1Q18 ±N¦³µ²½×¡G¦bÃÄÃҥӽжi«×¤è­±¡AEMA ¤w¦b9 ¤ë

¨Ó¥x¶i¦æ¬d¼t¡A¨ä¤¤Ãö©óÀË´ú³æ¦ì¹A¬ì°|ªº¯Ê¥¢¡AÃĵؤw§ï¥Ñ³Æ®×¼w

°êEurofins ¶i¦æ¡A¤£¼vÅT¼Ú¬w¨úÃÒ¶i«×¡A¦Ó®Ú¾ÚEMA ¶i«×¡A­YµL­«

¤j°ÝÃD«h¹w­p¨úÃҮɵ{³ÌºC±N¸¨©ó3Q18¡F¦Ó¦bÃöÁ䪺¬ü°ê¥«³õ¤è

­±¡A¥Ø«e«ÝCONTI-PV ¼Æ¾Ú¾ã²z§¹¦¨«á¡A¹w­p±N©ó1Q18 »PFDA ¶}·|

°Q½×¯à§_ª½±µ¥Ó½ÐÃÄÃÒ¡A¥ç©Î»Ý´£¨ÑÃB¥~¸É¥R¸ê®Æ¡A©¡®Éªº¨Mij±N¹ï

Ãĵجü°ê¶i«×±a¨Ó­«¤j¼vÅT¡A¥B¥Ñ©óÃĵإثe¤´±N¦Û¦æ©ó¬ü°ê¥«³õ±À

¼s¾P°â¡A¯à§_«ö¶i«×¤W¥«¥ç±N¹ïÀò§Q°^Äm±a¨Ó¼vÅT¡C

 ªø´Á»ù­ÈÅãµÛ§C¦ô¡A­«¥Ó¶R¶iµûµ¥¡A¥Ø¼Ð»ù210 ¤¸¡G¤¸´I»{¬°¡A¦¹

¦¸CONTI-PV ¼Æ¾Ú¤wÅçÃÒ¥þ·s¤zÂZ¯ÀP1101 ¬°ªvÀøPV ¤W¸û¨ÎªºÃÄ

ª«¡AÃĮĥH¤Î¦w¥þ©Ê¬ÒÀò±o»{¥i¡A¥Hªø´Á¦Ó¨¥½T¹ê¦³°ª©óJAKAFI ªº

»ù­È¡A¥¼¨Ó¾P°â¥i´Á¡F¥Ø«eªºÃöÁä¦]¯À¶È¦b©óªk³W³æ¦ì¤W¥«®Éµ{¡A¦Ò

¶qP1101 ªºµo®i©Ê»P¼ç¦b¥«³õ¡A­«¥Ó¶R¶iµûµ¥¡AµM¦Ò¶qFDA ¶i«×¤´

«Ý1Q18 ·|ij¡A¬Gµ¹¤©¤@©w§é»ù¡A¥Ø¼Ð»ù210 ¤¸¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/12/22 ¤U¤È 02:12:03²Ä 3430 ½g¦^À³
ÃhºÃ³Ìªñªº½æÀ£´N¬O¨Ó¦Û°êµo°òª÷⋯
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/22 ¤U¤È 01:29:04²Ä 3429 ½g¦^À³
§Ú¦bµ¥135±µ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/22 ¤U¤È 12:43:38²Ä 3428 ½g¦^À³
¦º¦_¥J¤S½¶Â¤F

¤S¦³³æµ§1O±iªº½æ³æ¦b¥´

³o¦¸¤U©w¨M¤ß¤£±µ¤F

140¤£¯}´N¤£¦A±µ¤F

¦ý­Y¦³©¯¨£¨ì¡A¨ºªÖ©w¼ö¯P¥[½X

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/22 ¤W¤È 11:47:59²Ä 3427 ½g¦^À³
¦Ó¥B¥Í§Þ²{¦b¬O¬F©²°ö´Óªº­«ÂI²£·~

¤£¥i¯àÀH«KÅý¥~°ê¼t°Ó¨Ó¶R¨«

¤£µM¤j®a«ë¤£±o°¨¤W¨Ó¶¡¼Ú¬ü¤jÃļt¦¬ÁÊ

¤j®a³£»´ÃP§Ö¼Ö

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/22 ¤W¤È 11:43:42²Ä 3426 ½g¦^À³
§Úªº·N«ä¬O­nµØ¦³°êµo°òª÷§ë¸ê¦b¸ÌÀY

¬Û¹ï¨S¦³¤@¯ë¥ø·~¨ÖÁʨº»ò³æ¯Â²³æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2017/12/22 ¤W¤È 11:11:21²Ä 3425 ½g¦^À³
¦w¼w´Ë ¤j

¦³­þªù¥ø·~¨ÖÁʮ׬O¥ý¨ú±o¬F©²¦P·N«á¦A©ñ®ø®§ªº,³£°¨¬O¥ý¬Û¿Ë«á¤~¦A¶ù¨ú,§A¤£¤]¬O¦b«s«èªÑ»ùªí²{¶Ü,¦p¯u¦³¬ð¦p¨ä¨Óªº¨ÖÁÊ®ø®§¹ïªÑ»ù¨S¦n³B¶Ü?

¤j®a¹ïÃĵض}¤ßÂI¼ÖÆ[ÂI¹À~

PS:2/15°£¤i¤j®a¦Y¹Î¶ê¶º,¤½¥qªº¤HÁÙ­n¦£¤½¨Æ,¯uªº¬O¨¯­W¤F!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/22 ¤W¤È 10:55:35²Ä 3424 ½g¦^À³
³o»ò¦h§Q¦h¤£º¦,¬Ý¨Ó«D±oµ¥¨ìßÓÃÒ¨ì¤â¤~·|°Ê¤F

·Ç³Æ¦n²{ª÷

140¥H¤U¦A¨Ó¾ß«K©y

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/22 ¤W¤È 10:46:38²Ä 3423 ½g¦^À³
¨ÖÁʤ]±o¬F©²¦P·N
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2017/12/22 ¤W¤È 09:21:27²Ä 3422 ½g¦^À³
·ÇÃÄÃÒªº¨­¥÷Ãø¹D¨S¦³¥~°Ó¦bÁ»¿Ì³o»ò«K©yªºÃĵضÜ?

·|¤£·|¬ðµM¨Ó­Ó³Q¨ÖÁÊ®ø®§,Åý¤j®a´Z©Ò(±¹¤â)¤£¤Î°Ú?!

ǢǢǢ~~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/22 ¤W¤È 08:55:31²Ä 3421 ½g¦^À³
Q:Libad : §Ú²q,À³¬OÃĵإH«eªº³QÂ÷¾­û¤u¨ü¨ì«Ü¤jªº©e©},¥ÎÆZ¯î¤§¤O³ø´_.

A:±z»¡±o«D±`¦³¥i¯à. 6446 ¤W¿³Âd¤§«á,¦³¤@¬q¶^´T«Ü¥û,90->50 , Å¥»¡³o¦ì¸¹ºÙ¦³«Ü¦h±iªÑ²¼ªº­û¤u©ñ¸Üªº

¥t¥~¢Õºôªº¦Ñ¤j

»{¬°¤zÂZ¯À¬O¹L®Éªº²£«~,©Ò¥H·|¤@ª½¥´À£

¦ý¥Í§ÞªÑ¤£¬O¬ì§ÞÃþªÑ

ºt¤Æ¤£¬O¬å±¼­«½m,¦Ó¬O¦b¦³ªº°ò¦¤W¥[±j©M§ó·s

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªÅ¤]ªÅªÅ10145331  µoªí®É¶¡:2017/12/22 ¤W¤È 06:56:37²Ä 3420 ½g¦^À³
·PÁÂI.G.A¤j´£¨Ñ§ó¶i¤@¨Bªº¸ê°T¡A¥H¤U±À½×¡A­Y¦³²¨º|¿ù»~³B¡A·Ð½Ð«ü¥¿¡C

³q±`¡A¤T´Á¸ÕÅç¬O«üÃöÁä©Ê¸ÕÅç¡AFDA¤£¤Ó¥i¯à§K°£ÃöÁä©Ê¸ÕÅç¡C¤ñ¸û¥¿½Tªº¥Î»yÀ³¸Ó¬O¡G

FDA»{¬°PROUD-PVªº³]­p²Å¦XÃöÁä©Ê¸ÕÅ窺­n¨D¡A±N¨Ó¸ÕÅçµ²ªG¤@¦p¹w´Á¡A¥i¥Ó½ÐNDA¡C

¦ý³o¥y¸Ü­n¦¨¥ß¡A¦³¤G­Ó«e´£¡G°µ¹LSPA¡A¥B¸ÕÅç°õ¦æ´Á¶¡¥¼¦³FDA¤£¦P·NªºÅܧó¡C

¦pªG¡A³o¤G­Ó«e´£¦s¦b¡A²{¦bÃĵإӽÐNDAªº¤èªk»Pµ¦²¤¡A´N©Ç©Çªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GI.G.A10141282  µoªí®É¶¡:2017/12/21 ¤U¤È 11:05:58²Ä 3419 ½g¦^À³
ªÅ¤j¡A·PÁ«ü±Ð¡C

>>­Ë¬O¸gÀÙ¤é³ø2013.10.19ªº³ø¾É©Ç©Çªº¡AFDA ¹ê¦b¤£¤Ó¥i¯à¥X©Ò¿×ªº¡u§KÁ{§É¤T´Á¸ÕÅç¡v¨ç¤å¡C

>>¨Æ¹j¦h¦~¡A¤j·§¤]«ÜÃøÁÙ­ì·í®Éªº®ÉªÅ­I´º¤F¡C

³o³¡¤À§Úı±oªº¥i¥H±qÃĵØÃĪººô¯¸¥h¬Ý Product Pipeline ¹Ï¡A±q§Ú¦³¦L¶H¥H¨Ó (Phase 2 ¤§«á)

PV ¾AÀ³¯g¦b EU ¸ò US ªº¶i«×¤@ª½³£¬Oµ¥ªøªº¡A©Ò¥HÀ³¸Ó¦³³o¦^¨Æ¡C

www.pharmaessentia.com/chinese/product_1.html

¥u¬O¨Æ¹j¦h¦~¡AFDA ªººA«×¦³¨S¦³§ïÅÜ¡A¥²¶·­n¦A¶}·|¤F¸Ñ¤F¸Ñ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2017/12/21 ¤U¤È 11:02:45²Ä 3418 ½g¦^À³
FDA¤j¤O¹ª§j ¤µ¸g«¢¦òÅçÃÒ¥i¦æ

¡u¯u¹ê¥@¬ÉÃÒ¾Ú¡v ¥[³tÁ{§É¶iµ{ ¸`¬Ù¸ÕÅ禨¥»

www.gbimonthly.com/2017/11/15571/

¥H³o½g¤å¨Ó»¡Ãĵئb®¦·OÀøªk¬O¥i¥H¦¬¶°¨ì¸ê®Æ

¨Ò¦p«OÀI¯Á½ß¼Æ¾Ú¡B¹q¤l°·±d»ö¾¹°O¿ý©M¯f±wµn¿ýµ¥

¥i¤£¥i¥H¨Ï¥Î¦b³o¦¸ÃÄÃҥӽСA¤£¤@©w

¦ý¥H«áP1101§å­ã¤@½u¥ÎÃÄ«á

¨ä¥L¾AÀ³¯g¯f±w¤@©w·|off-label use P1101¡A

ÃĵØÃĤ]´N¯à»`¶°¨ì³o¨Çoff-label use±wªÌ¥ÎÃĸê®Æ

¦p«OÀI¯Á½ß¼Æ¾Ú¡B¹q¤l°·±d»ö¾¹°O¿ý©M¯f±wµn¿ýµ¥¸ê®Æ©MÁ{§É¸ê®Æ

¤@°_¦C¬°¥¿¦¡·sªº¾AÀ³¯g©Î·sÃĸɥR¥Ó½ÐÁ{§ÉÀËÅç¼Æ¾Ú¼f¬d¸ê®Æ¤§¤@

ÃĵشN¥i¥H¤Öªá¤@¨ÇÁ{§É¶O¥Î

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªÅ¤]ªÅªÅ10145331  µoªí®É¶¡:2017/12/21 ¤U¤È 10:37:57²Ä 3417 ½g¦^À³
I.G.A¤j¡A¤@¯ë¦Ó¨¥¬ü°ê¤H­«Áô¨p¡A¤ñ¸û¤Ö¥D°Ê¯¸¥X¨Ó¡C

¤£¹L¡A¦nºÞ¶¢¨Æªº¬ü°ê¤H«Ü¦h¡A¯f¤Í¹ÎÅé¹C»¡ªº¯à¤O«Ü±j¡C

­Ë¬O¸gÀÙ¤é³ø2013.10.19ªº³ø¾É©Ç©Çªº¡AFDA¹ê¦b¤£¤Ó¥i¯à¥X©Ò¿×ªº¡u§KÁ{§É¤T´Á¸ÕÅç¡v¨ç¤å¡C

¨Æ¹j¦h¦~¡A¤j·§¤]«ÜÃøÁÙ­ì·í®Éªº®ÉªÅ­I´º¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2017/12/21 ¤U¤È 10:27:19²Ä 3416 ½g¦^À³
¨Æ¹ê¤W¥Ø«e¦³¤@­Óª¬ªp¬O¤ä«ù¥¼§å­ãªº¾AÀ³¯g

±wªÌ¥ÎÃĸê®Æ¦p«OÀI¯Á½ß¼Æ¾Ú¡B¹q¤l°·±d»ö¾¹°O¿ý©M¯f±wµn¿ýµ¥¸ê®Æ©MÁ{§É¸ê®Æ

¤@°_¦C¬°¥¿¦¡Á{§ÉÀËÅç¼Æ¾Ú¼f¬d¸ê®Æ¤§¤@

¤£¹L¦ü¥G¥u¯à¥Î¦b·s¼W¸É¥R¾AÀ³¯g

¥i¥H°Ñ¦Ò³o½g¤å³¹

FDA¤j¤O¹ª§j ¤µ¸g«¢¦òÅçÃÒ¥i¦æ

¡u¯u¹ê¥@¬ÉÃÒ¾Ú¡v ¥[³tÁ{§É¶iµ{ ¸`¬Ù¸ÕÅ禨¥»

www.gbimonthly.com/2017/11/15571/

±q³o½g¤å³¹¬Ý¨Ó¥u­n

FDA§å­ãP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¤@½u¥ÎÃÄ

«á­±¨ä¥L¤zÂZ¯À´N¥HÃÄ«~¥é³æ¼Ð¥Ü¥~¨Ï¥Î¡]off-label use¡^¥¼§å­ãÃÄÃÒªºÁ{§É´N·|«Ü¶¶¤F

¥i¥H¤Öªá¤@¨Ç¶O¥Î

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GI.G.A10141282  µoªí®É¶¡:2017/12/21 ¤U¤È 09:43:39²Ä 3415 ½g¦^À³
>> ¥¿²Îªº¡u®¦·OÀøªk¡v¬O¥Ó½ÐÂå®v¸ò¯f±w¶¡ªºÅv§Q¸q°ÈÃö«Y¡A°£¤Fµo¥Í¤£¨}¨Æ¥ó­n³q³ø©x¤è¾÷ºc¥~¡AÃÄ°Ó¬O¤£¦¬¶°¸ê®Æªº¡C

½Ð±ÐªÅ¤]ªÅªÅ¤j :

ÃÄ°Ó¦b®¦·OÀøªk¦¬¶°¤£¨ì¸ê®Æ¡A¦ý¦pªG³o¨Ç¯f±w¥D°Ê¯¸¥X¨Ó©O ?

§Úªº·N«ä¬O : ±µ¨ü®¦·OÀøªkªvÀøªº¯f±wªÖ©w·|©w´ÁÀˬd»P°lÂÜ¡A¥[¤W¦b¬ü°ê°µ¤HºØÀ³¤]¦h¤¸¤Æ

¦pªG¥L­Ì·P¨ü¨ì³oÃĦ³®Ä¡A¯à´î»´¥L­Ìªº¯gª¬¡B§ïµ½¥Í¬¡«~½è¡B¤£¥Î¾á¤ßÄ~Äò´c¤Æ

¦U¶µÀˬdªº¼Æ­È¤]¶V¨Ó¶V¦n¡A¥L­Ì¬O¤£¬O¥i¥H¶°¦X°_¨Ó¡A§â¥L­ÌÀˬd©w´Á°lÂÜÀˬdªº¦U¶µ¼Æ¾Ú§i¶D FDA ?

¦Ó³o¨Ç¨Ó¦Û¤£¦P¤HºØªº°lÂܼƾڡA·d¤£¦n´N¦³ FDA ­nªº¡C¯f¤Í¹ÎÅé°£¤Fµ¹ FDA À£¤O

¦P®É¥L­Ì¤]§i¶DÂå®v¡A¥L­Ì»Ý­n§ï¥Î³o­ÓÃĪ«¡A½ÐÂå®v¤]¯àÀ°¦£Åý³o­ÓÃĪ«§ÖÂI¤W¥«±Ï¤H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/21 ¤U¤È 09:39:44²Ä 3414 ½g¦^À³
Dr. Claire Harrison discusses many of the updates seen on MPN during ASH 2017

http://www.mpnresearchfoundation.org/Videos-from-ASH-2017

¼v¤ù¤¤¦³´£¤Îropeginterferon¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸êªÌ10141485  µoªí®É¶¡:2017/12/21 ¤U¤È 09:30:45²Ä 3413 ½g¦^À³
²{¦b½Â·s»D¡AÀ~¦º§Ú¤F!!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/21 ¤U¤È 09:30:10²Ä 3412 ½g¦^À³
³o­Óª©¤W¦³¦U¦ì¤j¤j....¹ê¦b¤Ó¦n¤F

§Ú¬Û«H¦³³\¦hµØ¤Í­Ì¤]·Q¥h°Ñ¥[ªk»¡·|¡A¦ý¦]¬°¶ZÂ÷©Î®É¶¡¦]¯ÀµL·å°Ñ¥[....

¬Ý¨ì¤@¨Ç´CÅé©_©Çªº³ø¾É¡A¤p§Ì¥u·Q¦³°Ñ¥[ªº¤j¤j¯àÁÙ­ì¯u¶H

¤£­nÅý¦³¤ß´CÅé»~¾É!!

®¦·OÀøªk´N¬O°µ¥\¼w¡A¦P®É¤]´À·sÃľi¥¼¨Óªº¯f±w¸ò¼s§i¡C

°ª¤HªÅ¤]ªÅªÅ¤jÁ¿ªº»P¤p§Ì²z¸Ñ¬Û¦P

¬Ý¨ì¤µ¤é¥~¸êªº¤j¶R¡A§¹¥þ²Å¦X¤p§Ì¤@¦~¨ÓªºÆ[¹î...

¥~¸ê´N¬O±}±}ªº¦Y¦n³f!!!

¹ï©ó¯S©w´CÅ馳¤ßªº»~¾É...«K©y¤F¥~¸ê...

³y¦¨§ë¸ê¤Hªº·l¥¢....¥i§_¨DÀv!!

¹q«Hĵ¹î¸òª÷ºÞ·|ÃÒ´Á§½....¯uªº¤£¥X¨ÓºÞºÞ¶Ü??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Glee-sen10145657  µoªí®É¶¡:2017/12/21 ¤U¤È 09:17:43²Ä 3411 ½g¦^À³
¦h¦~«eªº¸ê®Æ¡A½Ð±Ð¦U¦ì«e½ú~«e¨ã®Ä¤O¶Ü¡H

Ãĵةt¨àÃÄ ±N´£«e¦b¬ü¤W¥«

¡i¸gÀÙ¤é³ø¢¬°OªÌ¶À¤å©_¡þ¥x¥_³ø¾É¡j 2013.10.19 03:01 am

¥Í§Þ¤½¥qÃĵغX¤U§Ü¯u©Ê¬õ¦å²y¼W¥Í©t¨à·sÃÄP1101¡Aªñ´Á¯}¤Ñ¯îÀò¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¨ç¤å±N¡u§KÁ{§É¤T´Á¸ÕÅç¡v¡A³Ð¥xÆW­º¨Ò¡A¸ÓÃĪ«¥i±æ´£«e¦b¬ü°ê¤W¥«¡A·m§ð¤W¦Ê»õ¬ü¤¸¥«³õ¡C

Ãĵج°®È¬ü¥Í§Þ±M®aªL°êÄÁ³Ð¿ì¡Aªñ¤@¦¸¼W¸ê¦³Áp¹qºaÅA¸³¨Æªø±ä¿³¸Û¡B§»¹F¹q¸³¨Æªø¤ý³·¬õ­Ó¤HºX¤Uªº§ë¸ê°òª÷¡B³»·s¶°¹ÎÃQ®aµ¥¡A¬ì§Þ¡B¶Ç²£¤j©@³£¬ÛÄ~·m¶i¡A­ìªÑªF«h¥]¬A°êµo°òª÷¡B¸gÀÙ³¡Ä£µØ¬Á¼þ¡B¶£®õ§ë¸ê¡B§»¨È­¹«~µ¥¡C

ÃĵةM¼Ú¬w©t¨àÃĤ½¥qAOP¦X§@ªº·sÃÄP1101Á{§É¤T´Á¸ÕÅç¤w±Ò°Ê¡Aªñ´Á¬ü°êFDA¨Ó¨ç«ü¥X¡A¦pªG¼Ú·ùÁ{§É¤T´Á¼Æ¾Ú¥¿­±¡A°ò©ó°ê»ÚÁ{§ÉICHªº­ì«h¡A¬ü°êFDA±N¦Ò¶q¦@¥Î¼Ú·ù¼Æ¾Ú¡AÅýÃĵءuª½±µ³q¹L¡v¤T´ÁÁ{§É¡C

¤]´N¬O»¡¡AP1101¦b¬ü°ê±N§K°µ¤T´ÁÁ{§É¡A¥Ó½Ð¨Ã¨ú±o¤HÅéÁ{§É¸ÕÅç³\¥i«á¡A¥iª½±µ¥Ó½ÐÃÄÃÒ¡F·~¬É«ü¥X¡A³o¬O°ê¤º¥Í§Þ¤½¥q­º¨Ò¥Hºñ¦â³q¹D¦b¬ü¥Ó½ÐÃÄÃÒ¡C

ÃĵØÁ`¸g²zªL°êÄÁªí¥Ü¡AICH¬O¥H°ê»ÚÂåÃĪk³W¨ó©M·|©Ò³W©wªº¡uÀu¨}ÂåÃÄÁ{§É¸ÕÅç³W½d¡v¬°¼Ð·Ç¡A¬ü°ê¡B¼Ú·ù¥Ø«e¦@¥Î¦¹Á{§É¼Ð·Ç¡A¥Ñ©óÃĵغX¤U·sÃÄÁ{§É¸ÕÅç¥þ¨ÌICH³W½d¶i¦æ¡Aªñ´Á¤wÀòFDAªì¨B»{¥i¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªÅ¤]ªÅªÅ10145331  µoªí®É¶¡:2017/12/21 ¤U¤È 08:36:56²Ä 3410 ½g¦^À³
·PÁ¤j¤j­Ìªº»ô¤ß§V¤O¡CEMA¤ÎFDAÃÄÃÒªº¥Ó½Ð¡A¤w¸g¯B²{¥X¤j­Pªº½ü¹ø¡C

EMA´N¥æµ¹AOP¡C

FDA´N¦n¦n¹ªÀy¤Î«jÀy¤½¥q¡A§V¤O¦a»PKOL¡BÅU°Ý¤½¥q°µ¦npre-NDA/BLA meetingªº·Ç³Æ¤u§@¡C

¦A¨Ó¡A¤Ñ¦ö¥xÆW¡B¤Ñ¦ö¯f±w¤]¬O¤£¥i§Kªº¡C

½ÐLibad¤j¡BI.G.A¤j­ì½Ì­Ó¤H³ßÅw¤À¨É¤£¦P¸gÅ窺Äê¶Ý¦n¡C

1. ÁöµM¾ã®Mªºmarketing research (§tÂå®v¤Î¯f±w³X½Í)°µ¤U¨Ó¡Amillions of dollors¶]¤£±¼¡A¦ý¤]®t¤£¦h­n°µ¤F¡C

¦³³o¨Ç¸ê®Æ¡A¤£ºÞ¬O¦Û¥Î¡B»P¤H½Í¦X§@©Î±ÂÅv¡A¤ß¸Ì·|¤ñ¸û¦³©³¡C¨Ò¦p¡G²Ä¤@½uinterferon¦³¤@¸U¤T¤d¤H¦b¥Î¡C

2. ¥¿²Îªº¡u®¦·OÀøªk¡v¬O¥Ó½ÐÂå®v¸ò¯f±w¶¡ªºÅv§Q¸q°ÈÃö«Y¡A°£¤Fµo¥Í¤£¨}¨Æ¥ó­n³q³ø©x¤è¾÷ºc¥~¡AÃÄ°Ó¬O¤£¦¬¶°¸ê®Æªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/12/21 ¤U¤È 07:36:38²Ä 3409 ½g¦^À³
¨S°Ñ¥[ªk»¡·|ªº§ë¸ê¤H¡A´N¥u¯à¿ï¾Ü±µ¨ü´CÅ骺²Ä¤G¤â¸ê°T¡C

§Y¨Ï¦³¤F¿ý¼vÀÉ¡AÁÙ¬O·|¦³«Ü¦h§ë¸ê¤H¥u·|¬Ý´CÅé¸`¿ýªººë²¸ê°T¡C(ÁÙ¬O§Æ±æ¥H«á¯à¿ý¼v)

«Øij¦U¦ì¦h¬Ý¬Ý¼Ú¬üÅv«ÂÂå®v©M¯f¤Í¹ÎÅ骺µû½×¡A¬JµMMPNªº¥D­n¥«³õ¬O¼Ú¬ü¦a°Ï¡A

§A­n­«µøªº¬O¼Ú¬üÂå®v©M¯f¤HªºÆ[ÂI? ÁÙ¬O¥xÆW´CÅé°OªÌªºÆ[ÂI?

¦Ñ¤ý½æ¥Ê¡A¤@©w·|¦Û½æ¦Û¸Ø¡A¤¤¥~ªºÃļt¬ÒµM¡A

¦ýÂå®v©M¯f¤H¬O¥¼¨Ó¼ç¦bªº¨Ï¥ÎªÌ(¦³¨Ç¤w¸g¥Î¹L)¡A§A¥i¥H±q¥L­Ìªºµû»ù¡A¨Ó§PÂ_³oÁû¥Ê¬O§_³f¯u»ù¹ê?

ªk³W³æ¦ìªA°Èªº¹ï¶H¤£¬OÃļt¡A¹ï¤@­Ó¦W¤£¨£¸g¶Çªº¤pÃļt­º¦¸¨Ó¥Ó½ÐÃÄÃÒ¡A¦Û¬OÄYÂÔ§âÃö¡C

µMªk³W³æ¦ìªA°Èªº¹ï¶H¬OÂå®v»P¯f¤H¡A¯à³z¹LKOL»P¯f¤Í­Òij²Õ´ªº¤O¶q¡A¬O«Ü¤£¿ùªºµ¦²¤¡C

Conti-PV¼Æ¾Ú¯à»¡ªAªk³W³æ¦ìª½±µ¥Ó½ÐÃÄÃÒ¡A«h¬Ò¤jÅw³ß¡C

­Yªk³W³æ¦ì­n¨D§ó¦hªº¸É¥R©Êµû¦ô¡APlan B·|§äªº¥D«ùÂå®v¡AÀ³¸Ó·|¬O¨ä¤¤¤@¦ì«Ü¦³Á{§É¸gÅ窺KOL¡C

¬ü°ê¥«³õ±ÂÅv»P§_¡A¨C­Ó§ë¸ê¤H¥i¯à³£¦³¤£¦Pªº·Qªk¡C

¿ï¾Ü±ÂÅvµ¹¤jÃļt¡A©Î³\ÃÄÃҥӽз|¶¶§Q±o¦h¡A¤]¥ý¨ú±o¤@µ§Ã±¬ùª÷©M¨½µ{ª÷¡A

¦pªG¬OÄvª§¿E¯PªºÀù¯gÃĪ«¡A±ÂÅv©Î°â¥X¬O¥xÆW¤½¥q¤£±o¤£ªº¿ï¾Ü¡A¦ý¤½¥q»ù­È´N³Q¨ü­­¤F¡C

MPNÃĪ«ªº¥«³õ¥ÍºA­~²§¡A¥B¥Ø«eÁ٬ݤ£¨ìPV¤@½u¥ÎÃĪº¼ç¦bÄvª§ªÌ¡A¥i¥H¥Î¦hÂI®É¶¡¨Ó´«¨ú§ó¤jªº¾÷·|¡A

¹ï¤zÂZ¯ÀªvÀø¦Ó¨¥¡APV¹L¤F¤§«á¡AET¤]««¤â¥i±o(JAK§í¨î¾¯´N¤£¨£±o¦p¦¹)¡A¦pªG±ÂÅvÀ³¸Ó¬OMPN¤@°_±ÂÅv¡A¨º´N¤Ó¥i±¤¤F¡C

¤µ¦~ªÑªF·|¤¤±qªL°õ¦æªøªº½Í¸Ü¡AÀ³¸Ó¥i¥H±ÀºV¸gÀç¹Î¶¤¤w¸g¨M©w¿ï¾Ü¤@±øÃø¨«ªº¸ô¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GI.G.A10141282  µoªí®É¶¡:2017/12/21 ¤U¤È 06:24:10²Ä 3408 ½g¦^À³
·PÁ¤pªL¤j»P¤p¥¿¥¿¤j«ùÄò´£¨Ñ¨Ó¦Û°ê¥~ MPN ¬É²Ä¤@¤â¸ê°T¡A¥i¥HÁA¸Ñ°ê»Ú±M®aªº¬Ýªk

·í¤Ñªk»¡¤@¶}©l´N¬O¼·©ñ±z­Ì¥ý«e¶Kªº¼v¤ùÁÙ¥[¤W¤¤¤å¦r¹õ¡A¯u¯«¡I

³o¦¸ªk¤H»¡©ú·|ªº¥DÃD¬O¡u¤½¥qÀç¹B¦¨ªG¤Î¥¼¨Ó®i±æ¡v¡A³ø§i¹êÅç¼Æ¾Ú¡A½Í½Í¦æ¾P³W¹º»P¤¶²Ð¦æ¾P¹Î¶¤­Ó¤Hı±o¨ÃµL¤£§´

www.tpex.org.tw/web/regular_emerging/investor_conference/latest/latest.php?l=zh-tw

¡´EMA ³¡¤À

§O§ÑÅo¡A¥Ó½Ð EMA ÃÄÃÒªº¬O AOP¡A¥¦¤~¬O¥D¨¤¡A¦pªGı±oÃĵØÃÄ»¡¤£²M·¡¡AÁÙ¦³ AOP ¥i¥H°Ý

ªk»¡·í¤Ñ¤]»¡¤F¡ARopeg(P1101) ¹w­p©ú¦~¤¤¦¯¥i¨ú±o¼Ú¬wÃÄÃÒ¡A¥B³o¦¸¹A¬ì°|ªº¯Ê¥¢¤£·|¼vÅTÃÄÃÒ¨ú±o®Éµ{

¡´FDA ³¡¤À

ºÞ²z¼h´£¤Î¤½¥q±N©ó 2018 ¦~ 2 ¤ë 15 ¤é¦b¤T¦ì­«­n·N¨£»â³S(KOL)ªº³­¦P¤U»P¬ü°ê FDA Á|¦æ¥¿¦¡·|ij

(ÁöµMªk»¡·í¤Ñ¨S¦³©ú½T»¡¥X¬O­þ¤@¤Ñ¡A¦ý¤]·t¥Üªº«Ü©úÅã¤F¡÷Âû¦~§À¡Bª¯¦~ÀY)

­n¸ò FDA ¶}·|«á¡A¤~·|ª¾¹D¬O¤£¬O­n°µ¾ô±µ¸ÕÅç¡C³Ì¦nªº±¡ªp¬O FDA ÂIÀYµªÀ³ª½±µµ¹ÃÒ¡i³o³¡¤À­nºÉ¥þ¤O¥h°µ¡A¤]­n¾a KOL »P¯f¤Í¹ÎÅéÀ°¦£ Push¡j

­YÁÙ­n¦A°µ¹êÅç¡A¤]¤£»Ý¤Ó¹L´dÆ[¡A¯uª÷¤£©È¤õ·Ò¡I¦ý¹êÅç³]­p®É¡A½Ð¤½¥q¤@©w­n¦n¦n°µ¡A¦A¨Ó­Ó¬ì¾Ç¤Wªº¦¨¥\¡Aªk³W¤Wªº¥¢±Ñ¥i©Ó¨ü¤£¦í§r !

·í¤Ñ¦b³õªº¤H¤£¤Ö¡AGenet ´±§â Q&A ¾ã²z©ñ¥X¨Ó¡A¬O¨S¦³°¾Â÷¤Ó¦h¡F¤]¨S¥²­n¨è·N¦b¬Y¨Ç¥y¤lÅܦâ¥[°Ý¸¹¡A©¾¹ê§e²{§Y¥i¡C

¦ý Genet ¥t¥~¤@½g­«·s³]­pÁ{§Éªº¸ÑŪ´N¦³°ÝÃD¤F¡C³o­Ó·|ijªº¥Î·N¦pªÅ¤]ªÅªÅ¤j²Ä 3537 ½g¦^À³©Ò»¡ :

¡u³o­Ó·|ijªº¥Øªº¡G½Ð±ÐFDA¡A¥Ø«e¤w§¹¦¨ªº¸ÕÅç¡A´N³]­p¦Ó¨¥²Å¤£²Å¦XFDAµû¦ô·sÃÄÀø®Ä¤Î¦w¥þ©Êªº­n¨D¡C

·|ij¶}§¹¤F¡AFDA»¡OK¡A´N°e¥ó¡CFDA»¡NO¡A¤~·|¦³±µ¤U¨Ó­n°µ¬Æ»ò¸ÕÅ窺ijÃD¡C¡v

³Ì«á«Øij¤j®a¯à¿Ë¦Û°Ñ»Pªk»¡·|¡A¦Û¤v¿ý­µ°µ¬ö¿ý¡A¦³ºÃ´b¦Û¤v´£°Ý¡A¤ÖÂI©ê«è¡A¤Ñ§U¦Û§UªÌ¡A¦Û§U¤H«í§U¤§

¤]¦b¦¹¸ÛÀµ©IÆ~¤U¦^¦³¾÷·|´£°Ýªº§ë¸ê¥ý¶i¡A´£°Ý®É½Ð¥Î³Á§J­·¡A¤£µMÂ÷´£°ÝªÌ¤Ó»·ªº¤Hªº³£Å¥¤£¨ì¤]¿ý¤£¨ì­µ°Õ¡A·P®¦

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GI.G.A10141282  µoªí®É¶¡:2017/12/21 ¤U¤È 05:31:57²Ä 3407 ½g¦^À³
1. ¤½¥q¤w©µÅó Marija Sebastian ³Õ¤h¾á¥ô¬ü°ê¦æ¾P°ÆÁ`

¡÷¹L¥h´¿¦b¿ÕµØ»â¾É MF ¤Î PV ¤G½u¥ÎÃÄ Jakavi(Ruxolitinib) ªº¦æ¾P±M®a

2. ©ú¦~ Q1 ·|»P FDA ¶}·|·¾³q (2018/2¤ë¤¤¦¯)

¡÷³o³¡¤À·|¦³­«­nªº KOL ³­¦P°Ñ»P¡A´Á±æ¯à¥H¥XÄlªº¼Ú¬wÁ{§É¹êÅç¼Æ¾Ú»¡ªA FDA¡A­Y»¡ªA¦¨¥\«hª½±µ¨úÃÒ

¡÷­YÁÙ­n¹êÅç¤]¤£·|¬O¬ü°ê­«°µ¤j¤T´ÁÁ{§É¡A¦]¬°­«­n¼Æ¾Ú³£¦³¤F¡A´N¬Ý FDA ÁÙ·Q¬Ý­þ¤@¶ôªº¼Æ¾Ú¡A¦A¸É°µ¤p¹êÅç¡A¯uª÷¤£©È¤õ·Ò

¡÷¬ü°ê¤£¬O¦³¡u®¦·OÀøªk¡v¤w¸g¦b°õ¦æ¤F ? ¤]³\³o¸Ìªº¼Æ¾Ú·|¦³ FDA ·Q¬Ýªº udn.com/news/story/7241/2481711

¡÷»P FDA ´N¬O«ùÄò·¾³q¡A¦³·¾³q¦³¾÷·|¡F¤µ¤Ñ¤S¤£¬O»¡ Ropeg(P1101) «ÜÄê¡AµM«áÁÙ­n¤½¥q¤@ª½¥h¿c FDA

3. ¼Ú¬wÁ{§É¹êÅç¼Æ¾Ú(Conti-PV - 2¦~´Á)³£¤½§G¤F¡A¤w°e¥ó¥Ó½Ð EMA ÃÄÃÒ (¯f¤H«ùÄò¥ÎÃÄ¡B¹êÅç«ùÄò¶i¦æ¤¤¡A®É¶¡©Ôªø¼Æ¾Ú·|§ó¦n)

¡÷¹êÅç¼Æ¾Ú³£Åu¦b¶§¥ú¤U¤F¡A¤µ¦~¤]¤W¤F ASH ±µ¨üÀ˵ø¡A¹w­p 2018 ¤¤¦¯¨ú±o¼Ú¬wÃÄÃÒ¡AAOP ±N¶}©l³Æ³f¡A·|¦³ÃÄ«~¾P°â¦¬¤J

4. ¤½¥q¦ô­p¥¼¨Ó°ª®p¾P°âÁ`ÃB¦³¾÷·|¶W¶V PV ¤G½uÃĪ« Jakavi

¡÷·í®É¦³ÂI·Qª½±µ°Ý¥¼¨ÓªÑ»ù¦³¨S¦³¾÷·|¶W¶V²{¦bªº¤jx¥ú (§óª½±µ©úÁA)

5. Á`µ²¡G

¡÷PV ¦æ¾P±M®a¥[¤J¤FÃĵØÃĪº¬ü°ê¦æ¾P¹Î¶¤ (§ä¹ïªº¤H°µ¨Æ)

¡÷­«¶q¯Å KOL ÆgÁn¤F (Å¥¹L Guideline §a)

¡÷¼Ú¬wªº¹êÅ禨¥\¤F (¥NªíÃĦ³®Ä¡A³o³Ì­«­n !)

¡÷¼Ú¬wÃÄÃÒ¤Q®³¤Eí (ÃÄ«~¦Û¤v¥Í²£¤£¥Îµ¹§O¤H©â¦¨¡B¤]¨É¦³ÃĪ«¾P°âÅv§Qª÷)¡F¬ü°êªº¸Ü¦³¾÷·|ª½±µ¨úÃÒ¡A¦ý©|¥¼§¹¥þ©ú®Ô (Ä~Äòµ¥)

¡÷¬ü°ê¥«³õ¤j¤p½Õ¬d¤F[¬ü°ê¹ï HU ¤£­@¨ü§ï¥Î¤zÂZ¯ÀªvÀø¬ù¦³13000¤H¡A²{¦b§ó¦nªº¤zÂZ¯À Ropeg(P1101) ¥X¨Ó¤F¡A¥[¤W¥¼¨Ó Pegasys §Y±N°±²£¡A³o¨Ç¯f±w¦³¾÷·|Âର¨Ï¥Î Ropeg(P1101)]

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GI.G.A10141282  µoªí®É¶¡:2017/12/21 ¤U¤È 04:51:45²Ä 3406 ½g¦^À³
¼Ú¨t¥~¸ê¤j·§·|·Q»¡«ç»ò³o»ò²³æ´N¦Y¨ì³f¤F¡AÄ~ÄòÀqÀq¦Y
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/21 ¤U¤È 04:33:28²Ä 3405 ½g¦^À³
December, 2017 ¡KThe ASH issue

Dr. Richard T. Silver¡K The Long MPN View.

https://mpnforum.com/

(ºK¿ý)(¤¤¤å½Ķ«Y³z¹Lgoogle½Ķ)

We still need better therapy for the PH(-) MPNs. You know that I am very biased toward interferon as an early intervention for MPN patients. In the United States, we are behind Europe. Our data at Weill-Cornell are almost identical to that of Professor Hasselbach in Denmark, Professor Gisslinger in Austria, and Professor Kiladjian in France; interferon can put the diseases in clinical remission. We have such evidence, as do the French and the Danes.We believe in the early treatment of polycythemia vera and myelofibrosis.

§Ú­Ì¤´µM»Ý­n§ó¦nªºªvÀøPH¡] - ¡^MPNs¡C§Aª¾¹D¡A§Ú«D±`°¾¦V¤zÂZ¯À§@¬°MPN±wªÌªº¦­´Á¤z¹w¡C¦b¬ü°ê¡A§Ú­Ì¸¨«á©ó¼Ú¬w¡C§Ú­Ì¦bWeill-Cornellªº¼Æ¾Ú»P¤¦³ÁªºHasselbach±Ð±Â¡A¶ø¦a§QªºGisslinger±Ð±Â©Mªk°êªºKiladjian±Ð±Âªº¼Æ¾Ú´X¥G¬Û¦P¡C¤zÂZ¯À¥i¥H¨Ï¯e¯f±o¨ìÁ{§É½w¸Ñ¡C§Ú­Ì¦³³o¼ËªºÃÒ¾Ú¡Aªk°ê¤H©M¤¦³Á¤H¤]¬O¦p¦¹¡C§Ú­Ì¬Û«H¦­´ÁªvÀø¯u©Ê¬õ²Ó­M¼W¦h¯g©M°©ÅèÅÖºû¤Æ¡C

We have evidence that in myelofibrosis, early treatment with interferon will cause stable decrease or better in about 70% of patients. We tried to do a randomized trial comparing early treatment to ¡§watch and wait¡¨ but for various reasons that was not possible.

We have single-arm studies which are peer reviewed; the last was published in the journal Cancer, in May 2017. Interferon can even result in marrow remissions in some patients.

§Ú­Ì¦³ÃÒ¾Úªí©ú¡A¦b°©ÅèÅÖºû¤Æ¤¤¡A¬ù70¢Hªº±wªÌ¦­´Á¥Î°®ÂZ¯ÀªvÀø·|¾É­Pí©w¤U­°©Î§ó¦n¡C§Ú­Ì¸Õ¹Ï°µ¤@­ÓÀH¾÷¸ÕÅç¡A¤ñ¸û¦­´ÁªvÀø©M¡§Æ[¹î©Mµ¥«Ý¡¨¡A¦ý¥Ñ©ó¦UºØ­ì¦]¡A³o¬O¤£¥i¯àªº¡C

§Ú­Ì¦³¦P¦æµû¼fªº³æÁu¬ã¨s;³Ì«á¤@½g¦b2017¦~5¤ëªº¡§Àù¯g¡¨´Á¥Z¤Wµoªí¡C¤zÂZ¯À¬Æ¦Ü¥i¥H¨Ï¤@¨Ç±wªÌªº°©Åè½w¸Ñ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2017/12/21 ¤U¤È 04:20:22²Ä 3404 ½g¦^À³
¾÷·|»P­·ÀI:

¾÷·|

1.¹A¬ì°|¬d¼t2¤ë16¸¹/2018,³q¹L¤»¤ë«áÃÄÃÒ¨S¦³°ÝÃD¡A¤£¼vÅTÃÄÃÒ¶i«×.2018,7¤ë¶}©l¦³¦¬¤J,®³¨ìEMA ÃÄÃÒ

2. FDA·|ij 2/15/2018,¯àª½±µ¥Ó½ÐÃÄÃÒ¡A¤£¼vÅTÃÄÃÒ¶i«×.

­·ÀI

1.¹A¬ì°|¬d¼t2¤ë16¸¹/2018,¤£³q¹L¤»¤ë«áÃÄÃÒ´N¦³°ÝÃD¡A¼vÅTÃÄÃÒ¶i«×.

2. FDA·|ij 2/15/2018,¤£¯àª½±µ¥Ó½ÐÃÄÃÒ¡A¼vÅTÃÄÃÒ¶i«×.

­Ó¤H»{¬°¹A¬ì°|¬d¼t2¤ë16¸¹/2018,¥²¶·³q¹L³o¶µ¬OÃĵؤñ¸û¥i¥H´x´¤ªº.«ØijÃĵضɥþ¤½¥q¤§¤O½T«O100% ¸UµL¤@¥¢,¥ý®³¨ì²Ä¤@­ÓÃÄÃÒ.¸U³¾¦bªL¤£¦p¤@³¾¦b¤â.§_«hªÑ»ù§L±Ñ¦p¤s­Ë.FDA ·|ij¥ç¬Û·í­«­n¦ý¨ü¨î©óFDA,¤ñ¹A¬ì°|¬d¼tÄY­«©Ê´N¤£¬O¨º»ò¤j¤F.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/12/21 ¤U¤È 04:13:03²Ä 3403 ½g¦^À³
¤µ¤Ñ¥~¸ê¶R¶W137±i¡A

·í§A¬Ý¨ì¬O¬O¦Ó«Dªº³ø¾É¡A®£Äß¡BÃhºÃ¦Ó§âªÑ²¼±þ¥X¡A

¬Æ¦Ü¬°ªÑ»ùÀq«s®É¡Aµ²ªG³£¶i¤F¥~¸êªº¤f³U¡A

¥~¸ê¬O¤£¬O³Ì«áªºÄ¹®a¡AÅý§Ú­Ì¬Ý¤U¥h

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/12/21 ¤U¤È 01:54:44²Ä 3402 ½g¦^À³
¥u­n°ò¥»­±¤£ÅÜ¡AÄ~Äò«ù¦³¨ì2020¦~¥H¤W¡A°µ¦nªø´Á§Ü¾Ô·Ç³Æ¡AÀx³Æ»È¼u¡A140¥H¤U¦A¥[½X~
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/21 ¤U¤È 01:13:54²Ä 3401 ½g¦^À³
¤j®a¤£­n§n¤F¡A¥ýÅý§Ú­Ì¬°ªÑ»ùÀq«s10¬í¡A10...9...8..7...6...5...4...3...2...1¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/12/21 ¤W¤È 11:55:04²Ä 3400 ½g¦^À³
¼f·Vªº¼ÖÆ[

·í¼Ú¬w¤H¶}©l¨Ï¥ÎÀu½èªº³J¥Õ½è·sÃÄP1101¡A¸¹ºÙ¥þ¥@¬É¥ÍÂå»âÀY¦Ïªº¬ü°êÁÙ­nÄ~Äò¥Î¸û¦H½èªº¤ÆÀøÃÄ?

P1101¡A©{­Y¤W«Òªº¤â©Ò»s³y¡A³Ì±µªñ¤HÅé²£¥Íªº¤zÂZ¯À¡A¹ï©óPV¥iªø´Á¦h¦~¨Ï¥Î¡Adurabilty¡A¤Ö°Æ§@¥Î¡AÃĮīùÄò¡A¯à³q¹LFDA¡A§Ú¬O©êµÛ«Ü¤jªº«H¤ß¡C

¥¦ªº¯S©ÊÅýÃĵبä¥L¹êÅç¡B³W¹º¤¤ªº¾AÀ³¯g¬O¤@¤j¹ª»R¡C

¥t¥~¡A³Ìªñ³o¤@¬q®É¶¡¤½¥q°µ¤F«Ü¦h¨Æ¡A¤]¦³¤@¨Ç¶i®i¡AÀ³µ¹¤©ªÖ©w¡C

¥u¬O¦³¤@¨Ç¹ï©ó»P©x¤è¥æ¯A¤¤ªº²Ó¸`¡A¡¨­YÁ¿¤Ó¦h¡A¦³®É·|³´¦Û¤v©ó¥æ¯A¤£§Qªº¦a¦ì¡¨¡C¦p¦ó´¦ÅSÀ³¥Ñ¤½¥q¦Û¦æ§PÂ_¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2017/12/21 ¤W¤È 11:28:36²Ä 3399 ½g¦^À³
1.À³Áܶ}·|ÁÙ­n¦Û¤v§@¬ö¿ý??

³o¬OÃĵتºªk»¡·|¤£¬O°ê®õÃÒ¨é©ÎG_NETªºªk»¡·|,«ØijÃĵدà°O¿ý©Î¿ý¼v,ÅýµØ¤Í§ë¸ê¤H¯à©Î±o§Ö³t½T¹ê¸ê°T.

2.§A­nªL°êÄÁ¦Û¤v¬ö¿ý¶Ü...

¦³¤H»¡»Ý­nªL°êÄÁ¦Û¤v¬ö¿ý¶Ü? ÃĵبS¦³¨ä¥L¤H?

3.²{³õ¦³¦w±ÆÃĵؤ½¥q¬ö¿ýªº¦ì¸m¶Ü?

¨ºG_NET «ç»ò°O¿ý ? ¤£¯à¦b¦Û¤v¦ì¸m¿ý­µ©Î¥Îµ§¬ö¿ý?

4.¨ì®É¬O­n¥H¥D¿ì³æ¦ì¤½¥¬ªº¬ö¿ý¬°¥DÁÙ¬OÃĵؤ½¥¬¬°¥D??

¥D¿ì³æ¦ì¦³¤½¥¬ªº¬ö¿ý¶Ü? Åýµ¹¤Fg-net¥[ªo²K¾L

5.¥xÆWªºÃÒ¨é°Ó¿ì¹LµL¼Æ¦¸ªk»¡...¯u¨SÅ¥¹LÀ³ÁÜ°Ñ¥[ªº¤½¥qÁÙ¦Û¤v§@·|ij¬ö¿ýªº...

°O¦í¤£¬O·|ij¬ö¿ý.¬OÃĵئۤv§@¦Û¤vªº°O¿ý.½T»{µL»~¦A¥Ñ¤Í¦n´CÅéµo¥¬,¨Ò¦pG-net »¡12/25 FDA­±½Í,¥¿½TÀ³¬°

2/15/2018

6.·R¤§²`³d¤§¤Á¥i¥H²z¸Ñ....¦ýÂû³J¸Ì¬D°©ÀYªº¤è¦¡¯uªº´N¤£¥²¤F....

½×¾Â¦³¨Ç¬OÃĵحû¤u,Å@¥DµL¥i«p«D.¦ýµØ¤Í§ë¸êªÌ,¤~¬O¯u¥¿Ãĵئ³¤O¤ä«ù«á¬Þ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRookie10143115  µoªí®É¶¡:2017/12/21 ¤W¤È 10:30:15²Ä 3398 ½g¦^À³
¦U¦ì¤j¤j¨ä¹ê¹ï¦U´CÅé³ø¾Éªº¦³ºÃ¼{¡A¥i¥Hª½±µ¥´¹q¸Ü°Ý¤½¥q¡A§Ú·Q¤½¥qµo¨¥¤H·|«Ü¼Ö·NÀ°¤j®a¸ÑµªºÃ´b

¤U­±´XÂI¬O§Ú°Ý¤½¥qªºµª®×¡G

1.»PFDA¶}·|®É¶¡¬O¦b107¦~2¤ë15¤é

2.­n¸òFDA¶}·|«á¡A¤~·|¨M©w¬O¤£¬O­n°µ¾ô±µ¸ÕÅç

3.¹ï©óºô¸ô¤Wªº³ø¾É«Ü¦h¬O¿ù»~ªº¡A¦ý¼Æ¶q¤Ó¦h¤F¡A¨Sªk¤@¤@¼á²M¡A½Ð¨£½Ì¡A¤@¤Á¥H¤½¥q¤½§i¬°·Ç

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/12/21 ¤W¤È 10:16:03²Ä 3397 ½g¦^À³
À³Áܶ}·|ÁÙ­n¦Û¤v§@¬ö¿ý??

§A­nªL°êÄÁ¦Û¤v¬ö¿ý¶Ü...

²{³õ¦³¦w±ÆÃĵؤ½¥q¬ö¿ýªº¦ì¸m¶Ü?

¨ì®É¬O­n¥H¥D¿ì³æ¦ì¤½¥¬ªº¬ö¿ý¬°¥DÁÙ¬OÃĵؤ½¥¬¬°¥D??

¥xÆWªºÃÒ¨é°Ó¿ì¹LµL¼Æ¦¸ªk»¡...¯u¨SÅ¥¹LÀ³ÁÜ°Ñ¥[ªº¤½¥qÁÙ¦Û¤v§@·|ij¬ö¿ýªº...

·R¤§²`³d¤§¤Á¥i¥H²z¸Ñ....¦ýÂû³J¸Ì¬D°©ÀYªº¤è¦¡¯uªº´N¤£¥²¤F....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2017/12/21 ¤W¤È 09:42:01²Ä 3396 ½g¦^À³
¨S¦³¤H³W©wÃĵةΰѥ[ªk»¡·|ªº¤H¤£¯à¦Û¤v§@°O¿ý ? ¦pªG¥i¥H¿ý¼v³Ì¦n,³o¨Ã¤£¹Hªk.¨ºG-net ¦³³Q±ÂÅv§@°O¿ý? ÃĵػݥD°Ê¿n·¥¤£­n¨ü¨î©óG-net.Ãĵئ³¯Ê¥¢µØ¤Í©ÎÃĵحû¤u,»Ý«Ø¨¥,¤@¨ý°¾©ZÅ@½Ã¹ïÃĵؤ£¦n§a ! ¤@¨¥°ó,¦n¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/12/21 ¤W¤È 09:14:55²Ä 3395 ½g¦^À³
Libad....³o­Ó·|ij¬O°ê®õÃÒ¨é¥l¶°ªº...·|°È³£¬O¥Ñ°ê®õÃÒ¨é¦w±Æ...

Ãĵإu¬OÀ³ÁܨӶ}·|...§A¦³¬Ý¹L¨Ó°Ñ¥[¶}·|ÁÙ­n¦Û¤v§@·|ij¬ö¿ýªº¶Ü??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/21 ¤W¤È 08:45:38²Ä 3394 ½g¦^À³
18¤U¥b¦~¤~¯à¦³¶i±b¡A¦Ñ¹ê»¡²{¦b¤¶¤JÁÙ¤Ó¦­¡AÃø©Ç¤H®ðµA´²¡A¤@°ï¤H³£»{¬°²{¦b¬O°ªÂI¡A

¤j½L«Ü¥i¯à¦^ÀÉ¡Aµ¥¤j½L¦^ÀɦA¨Ó¦Ò¼{¶R¶i¤]³£ÁÙ¥¼±ß¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/12/21 ¤W¤È 08:36:34²Ä 3393 ½g¦^À³
2017/12/20 ¤¸¤j§ëÅU¬ã¨s³ø§i

ÃĵØÃÄ (6446 TT)

­«­n¨½µ{¸O¹F¼Ð¡Fµ¥«Ý¬ü°êÃÄÃÒ¶i¤@¨B®Ö­ã

¨Æ¥ó

► ¥»¤¤¤ß©ó 12 ¤ë 19 ¤é°Ñ¥[ÃĵØÃĪk»¡·|¡C¤½¥q¼Ú¬w¦X§@¹Ù¦ñ

AOP Orphan Pharmaceutical ©ó 12 ¤ë 10 ¤éªº¬ü°ê¦å²G¯fÂå

¾Ç·|¦~·| (ASH) ¤½¥¬ Ropeginterferon alfa-2b (P1101) ¥Î©ó

ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g (PV) ¯f±wªº CONTI-PV ¬ã¨s³Ì·s«áÄò

µ²ªG¡C¸Ó¶}©ñ¦¡¸ÕÅç (open-label) CONTI-PV ¬ã¨s«Y°w¹ï¥ý«e

°Ñ»P¼Ï¯Ã PROUD-PV ¬ã¨sªº¯f±w¡Aµû¦ô P1101 ¬Û¸û©ó

hydroxyurea (HU) ©Î³Ì¨Î¥i¥ÎªvÀø¥ÎÃÄ (BAT) ªºªø´ÁÀø®Ä¤Î

¦w¥þ©Êµû¦ô¡C¸Ó CONTI-PV ¬ã¨s¤w¹F¨ì¥D­nÀø®Ä«ü¼Ð¡A¨äµ²ªG

Åã¥Ü¦b 24 ­Ó¤ë¤º¡AªvÀø²Õ¹F¨ì¸û°ªªº 70.5%§¹¥þ¦å²G¤ÏÀ³²v

(CHR)¡A°ª©ó HU/BAT ²Õªº 49.3%¡C¦¹¥~¡A¬ã¨sµ²ªG¥çÅã¥Ü

P1101 ¦³Á{§É¤Wªº¯q³B¡A¥ç§YªvÀø²Õ¦b 24 ¤ë¤º¯e¯f¯gª¬§ïµ½

¤Î¹ï©ó JAK2 ¬ðÅÜ°ò¦]­t¾áªº¤À¤l¤ÏÀ³§¡¨£§ïµ½¡C

► ¦P®É¡AºÞ²z¼h´£¤Î¤½¥q±N©ó 2018 ¦~ 2 ¤ë 15 ¤é¦b¤T¦ì­«­n·N

¨£»â³S(KOL)ªº³­¦P¤U»P¬ü°ê FDA Á|¦æ¥¿¦¡·|ij¡C¥Ø«eÃĵØÃÄ

¤w±q AOP Àò±o PROUD-PV ªº¬ã¨s¸ê®Æ¡A¨Ãµ¥«Ý CONTI-PV ¸Õ

Å窺§¹¾ã¸ê®Æ¤ÀªR¡A±N©ó 12 ¤ë 22 ¤é´£¥æµ¹¼Ú¬wÃĪ«ºÞ²z§½

(EMA)¡C

► Ãö©ó EMA ªºÃÄÃÒ®Ö­ã«eªº¬d¼t¤u§@¡AÃĵØÃĤw¦^ÂФH¥ÎÃÄ«~©e

­û·| (CHMP) ©Ò´£ªº°ÝÃD²M³æ¡A¨Ã­pµe¦b 2018 ¦~²Ä¤@©u¨Ï°]

¹Îªk¤H¹A·~¬ì§Þ¬ã¨s°| (ATRI) ¹F¨ì GMP ªk³W¼Ð·Ç¡A³o¤£·|¼v

ÅTÃÄÃÒ¨ú±o®Éµ{¡CºÞ²z¼h¦³«H¤ß±N©ó 2018 ¦~¤¤¨ú±o EMA ³\

¥i¡A¨Ã·¥¥i¯à©ó 2019 ¦~©³¨ú±o¬ü°ê FDA ®Ö­ã¡A»P¥»¤¤¤ß¹w¦ô

®Éµ{¤@­P¡C

► ºÞ²z¼h¤]«Å¥¬±N¦b¬ü°ê¡B¤é¥»¤Î¤¤°ê¦¨¥ß¦Û®a¾P°â¹Î¶¤¡A¨Ã¤w

¦Û Novartis¡BShire ¤Î AgTech ©Û¸u¼ô±x°©Åè¼W¥Í©Ê¸~½F

(MPN) ¾AÀ³¯g¤§­û¤u¡A¥H¥[±j¤½¥q¦b¬ü°êªº¦æ¾Pµ¦²¤¡C

¬ã¨s¤¤¤ß¤§Æ[ÂI

► ¥»¤¤¤ß«ùÄò¬Ý¦nÃĵØÃÄ¡A«Y¦] CONTI-PV ¸ÕÅçµ²ªG¥¿­±¡A¤£¦ý

ÃÒ©ú P1101 ªºªø´Á¦w¥þ©Ê¡A¤]Åã¥Ü¨äÀø®ÄÀu©ó HU/BAT¡C¥»¤¤

¤ß¬Ýªkºû«ù¤£ÅÜ¡A¥ç§Y P1101 ¥i±æ¤À§O©ó 2018/19 ¦~©ó¼Ú¬w

/¬ü°ê¤W¥«¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/21 ¤W¤È 08:22:50²Ä 3392 ½g¦^À³
¦pªG¯u¦pªL°êÄÁµ¦²¤ªø©Ò¨¥¡A»P¥DºÞ¾÷Ãö¨ó°Ó¤º®e¤£¯àÁ¿¡K

¤]Ãø©Ç¤½¥q¹ïFDA°e¥ó¥u¯à§t½k±a¹L

¥~¬Éªº½èºÃ©Ù¶Â¡A¤]¥u¯à°×¤Ú¦Y¶À½¬¡K

¤£¯àÁ¿´N¬O¤£¯àÁ¿¡A³s·Q¥X¨Ó¼á²M¤]«ÜÃøÁ¿²M·¡

¥i¯à­n½T©w§¹¦¨¨ó°Ó¡A©Î¹³EMA°e§¹¥ó¤~¯à¤½§G¤F¡C

¤£¹L¬Ý¤½¥q¿n·¥§G§½¬ü°ê¨Ó¬Ý¡AÀ³¸Ó¬O·t¥Ü¡K

¤Ï¥¿©ú¦~¤G¤ëµ¥®ø®§¤F¡K

¦Ü©ó¼Ú¬w¥«³õÀò§QÃöÁäÁÙ¬O¦b¤H¼Æ¡K

3,000¥H¤W°÷¦Y¹¡¡A¤]¹ï±o°_²{¦bªÑ»ù

5,000¥H¤W·Q¹³ªÅ¶¡´N¤j±o¦h¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/21 ¤W¤È 08:06:19²Ä 3391 ½g¦^À³
³æ¥H¼Ú¬w¾P°â¨Ó»¡¡A¨C¦~eps¤j·§¦h¤Ö?

¬ü°ê¥ý¤£¥Î½Í¤F¡A¤K¦rÁÙ¨S¤@ºJ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2017/12/20 ¤U¤È 11:27:05²Ä 3390 ½g¦^À³
«Ü©_©Ç Q&A ¬°¤°»ò¥ô¥ÑGnet°O¿ýµoªí,¤]³\¥L¥[ªo²K¾L.ÃĵبS¤H°O¿ý?½T»{µL»~«á¥¿¦¡¤½§i?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GBESREMi10143176  µoªí®É¶¡:2017/12/20 ¤U¤È 10:51:43²Ä 3389 ½g¦^À³
¡mªk»¡Q&A¡nÃĵØÃĪL°êÄÁ¦^µª12­Ó°ÝÃD

¤é´Á : 2017/12/20 §@ªÌ : Genet

°Ý¤@¡G°õ¦æªøªí¥Ü¤½¥q§Ö¦³¦n®ø®§¡A½Ð°Ý¬O¤°»ò¼Ëªº¦n®ø®§¡H

µª¡G²{¦b·sÃIJĤT´Áµ²ªG¤w¸g¥X¨Ó¡AÃÄÃÒÁÙ¨S®³¨ì¡A¬O¥DºÞ¾÷Ãöªº°ÝÃD°Ú¡A·íµM§Ú­Ì¹ï³o¶ô¸gÅç¤]¤£¿ù¡F¥h¦~¤é¥»¡B¤¤°ê¡B¬ü°êªº§ë¸ê­pµe¤w¸g³Q¸³¨Æ·|³q¹L¡C

°Ý¤G¡G¸ò¬ü°êFDA¬¢½Íªº¶i«×¦p¦ó¡HFDA·|­n¨D¤p¤T´Áªº¾÷²v¦³¦h¤Ö¡H

µª¡G³q±`¸òºÊºÞ¾÷Ãöªº°Q½×¬O¤£·|¤½¥¬ªº¡A©Ò¥H¤½¥q¥u¯à»¡¡u¥i¯à¡v¡CAOPªº¦b¼Ú·ù¥Ó½ÐÃÄÃÒªºÁ{§É­pµe®Ñ¤w¸g°e¶iFDA¡A¦ýFDAªí¥Ü­n¥ý¬ÝContiÁ{§É¹êÅ窺¼Æ¾Ú¡A©Ò¥H­nµ¥Conti¼Æ¾Ú¡C

¸òFDA¶}·|¡A¤é´Á©w¦b12¤ë25¸¹¡F·|¤£·|¦³¦n®ø®§´N¬O»Ý­n·¾³q¡A³o¦¸½Ð¨ì´X¦ì¤ä«ùinterferon¤zÂZ¯Àªº±M®a¤@°_°Ñ»P°Q½×¡A·|ij¥u¦³¤@­Ó¤p®É¡A©Ò¥H§Ú­Ì·|§â´¤³o¤@­Ó¤p®É¡A¦ý©x­û·|¤£·|¦Ê¤À¦Ê±µ¨ü¡A¦A½Í´N¦n¡A§Ú­Ì·|ºÉ¤O¡C

°Ý¤T¡G¼Ú¬w³¡¤À¤½¥q¤§«e»¡»PAOP¨óij§âÅv§Qª÷©¹¤W´£°ª¡A¬O¤£¬O¦b¨½µ{¸Oªº³¡¤À¤]¬Û¹ï´£°ª¡HFDA¦b°e¥óªº³¡¤À¬O¥ÑAOP¶i¦æªº¡A»Ý¤£»Ý­n´N¼Ú¬wªºÁ{§É¸ÕÅç°µBridge Study©Î¹ï¼Ú¬w¹êÅç¼Æ¾Ú»Ý­n¼W¸É¸ê®Æ¡H¤°»ò®É­Ô·|°eBLA¡H

µª¡Gµy«á¦A¦^µª(³Ì«á¦³¨Ç¨S¦^µª¨ì)

°Ý¥|¡G½Ð°Ý¥H¥«³õ¹w¦ôªºªí¨Ó»¡¡A¤K¸U¦h¤H¸Ì¦³¤­¨ì¤»¸U¤H¨Ï¥ÎHU¡A¤@¸U¦h¤H¨Ï¥ÎInterferon¡A¨ä¥L¤@¸U¦h¤H¨Ï¥Î§OªºÀøªk¡F¤j®a³£¦b½èºÃHU«Ü«K©y¡A¨º¬°¤°»ò¦³¨Ç¤H·|¨Ï¥ÎHU¡A¦³¨Ç¤H·|­n¨Ï¥ÎInterferon¡H

µª¡G³o¬O«D±`Âå¾Çªº°ÝÃD¡A¦ý³o­Ó¸ê®Æ¬O§Ú­Ì¦Û¤v¥h½Õ¬dªº¡A¤£¹L¸ò¹ê»Ú¼Æ¾Ú¤j·§¤£·|Â÷«Ü»·¡F¬°¤°»òÂå¥Í³o¼Ë¥Î­n¡A¬°¤°»ò¯f¤H³ßÅw³o¼Ë¦YÃÄ¡A³o¬OÂå¾Çªº°ÝÃD¡F¦ý³o¦å²G¯e¯f»â°ìªº°ÝÃD¬O³o´X¦~¤~ºCºC³Qª¾¹Dªº¡CHUªº¬O«Ü¤è«K«Ü®e©ö¨Ï¥Î¡A¶}¤FÃįf¤H°¨¤W¥i¥H¦Y¡F¦ýInterferon¬O¥é³æ¥~¨Ï¥Î¡A¯f¤H»Ý­n¥h«OÀI¤½¥q¯S§O¥Ó½Ð¡A¦Ó¥B¦³¨Ç¦{ÁÙ¤£¯à¥Î¡A©Ò¥H«Ü³Â·Ð¡F¦pªG§Ú­ÌªºÃĶ¶§Q³q¹L¡A«OÀI¤½¥q´N·|µ¹¥I(?)¡C

°Ý¤­¡G­è¤~´£¨ìªº°]°È¹w´Á¼Æ¦r³£¬O¬ü°êªº¡A¥i¥H¥[¤J¼Ú¬wªº¼Æ¦r¶Ü¡H

°Ý¡GAOP¦³¯S§O´£¨ì±N¨Ó¦¬¤J¥i¥H¶W¹L10»õ¬üª÷¡A©Ò¥H§Ú­Ì±N¨ÓªºÅv§Qª÷¦³¾÷·|´£°ª¡C¦pªG¥hºâJakafi¦b¬ü°êªº¦¬¤J©M¿ÕµØ¦b¨ä¥L¦a¤èªº¦¬¤J¡A¤j·§¬O¤@¹ï¤@¡A¬ü°ê¥«³õ¤j·§¦û40´X%¡A¼Ú¬w¥[¤é¥»¤j¬ù40´X%¡A¤¤°ê¦û4%¡C¤é¥»¥«³õªº³W¹º»P¬ü°êÃþ¦ü¡A¾ã­Ó¾P°â°ª®p¹w­p¯à5»õ¬üª÷¡C

°Ý¤»¡G¦]¬°¾P°â°ª®p¥i¯à¯à¹F¨ì10»õ¬üª÷©Ò¥HÅv§Qª÷½Õ¾ã¨ì20%¡A¹F¨ì³o­Ó¯Å¶Z¥i¯à¦û¾P°â«Ü¤pªº³¡¤À¡H

µª¡GÅv§Qª÷¬O¦¬¤J¶V°ª´N¶V°ª¡A¹F¨ì10»õ¬üª÷¥H¤W´N¯à¨ú±o20%¡A10»õ¬üª÷¥H¤U´N¬O±q12%°_¸õ¡A¨Ì¯Å¶Z¦³¤£¦P%¼Æ¡F²{¦bIncyte¦~À禬¤j¬ù20´X»õ¡A¿ÕµØ¬ù20»õ¡AIncyte¥ú¬ü°ê¦A¥[¤WÅv§Qª÷¤]®t¤£¦h¤Q¨Ó»õ¡A¦Ó¥BÁÙ«ùÄò¦¨ªø¡C

°Ý¤C¡G½Ð°ÝÃÄ»ù©w»ù¡H¤j¬ù8¸U¬üª÷¡H

µª¡GÀ³¸Ó·|¤ñPegasys°ª¤@¨Ç¡A¤ñJakafi§C¤@¨Ç¡C¥Ø«eÀHµÛ¼Æ¾Ú¶V¨Ó¶V©ú½T¡A²{¦b´N­n·Ç³Æª§¨úÃÄ»ù¡A¾÷·|À³¸Óº¡¤jªº¡Cªk ¤H¦³¦ô¬ù8¸U¬üª÷ªº°ª»ù¡C(³o¼Ëªº°ª»ù¡A¨ì©³¥¼¨ÓªºÄvª§¤O¦p¦ó? ¦]¬°PV¯f±w¬Oªø´Á¥ÎÃÄ¡A¦pªG¨C¦~³£­n8¸U¬ü¤¸¬ù240¸U¥x¹ô¡A¥´­Ó20¦~-30¦~´N»Ý­n2400¸U-7200¸U¥x¹ô? ¤j®a¥i¥H°lÂÜ)

°Ý¤K¡G½Ð°Ý¯e¯f½w¸Ñ¸ê®Æ¥[¤W¥h¤§«á¡A¤£ÅãµÛ¬O¦]¬°µÊŦ¸~¤jªº¼Ë¥»¼Æ¥»¨Ó´N«Ü¤Ö¡AÁÙ¬O¨ä¥L­ì¦]¡H¦b¨Ï¥ÎInterferon«áµÊŦ¸~¤j¦³¦^´_¶Ü¡H

µª¡GÁ{§É¼Æ¾Ú²{¦b¥¿¦b¾ã²z¤¤¡Aªì¨B²q·Q¬O¼Ë¥»¼Æªº­ì¦]¡A¦ý³Ì¥D­nªº­ì¦]¬O«á¨Ó¤~¸É¯gª¬¼Æ¾Ú¡A¥H«e¥u¦³­°¦åÀ£¸ò­°¦å¯×¼Æ¾Ú¨S¦³¥Î¡A¤§«e¥D±i¥i¥HÅýJAK2¬ðÅÜ¡A³o­ÓÁ¿ªk¤Ó·s¤F¡AEMA»¡¥L­Ì­n¬ÝBenifit¡A¥L­Ì¬Ý¤F´X­Ó­@¨ü©Êµ¥µ¥¼Æ¾Ú¡A¦ý¤£¬OÀø®Ä«ü¼Ð¡CµÊŦ¸~¤j³¡¤À¦]¬°¦³7-10%ªº¯f¤H¦³³o¼Ëªº²{¶H¡A©Ò¥H³o¨Ç¼Æ¾Ú´N¤£¬O«ÜÅãµÛ¡A¤ñ¸û°_¨Ó¦n¹³®t¤£¦h¡A¦]¬°·s¼Æ¾Ú¬O«á¨Ó¦bCONTI-PVÁ{§É¤~¸Éªº¡C¦b¨Ï¥ÎInterferon«áµÊŦ¦³ÁY¤p¡A°Æ§@¥Î¨S¦³Jakafi¨º»ò¤j¡C

°Ý¤E¡G¦n¹³2019¦~¤½¥q¤~·|¦³À禬¡A©ú¦~¤½¥qÁÙ¦³«Ü¦h­pµe¦b¶i¦æ¡Aªá¿ú·|¤£·|¦³°ÝÃD¡H

µª¡G¨S¦³°ÝÃD¡A¥Ø«e±b¤WÁÙ¦³¤T¤Q¦h»õ¡A¦Ó¥B©ú¦~¶}©l·|¦³´Xµ§¦¬¤J¡A¦]¬°AOP¶}©l¦³­q³æ¹L¨Ó¡AÁÙ·|¦³¬F©²¸É§U´Ú¡C¯u¥¿¼·´Ú·|¥H¤½§i¤½¥¬¡C

°Ý¤Q¡G¹A¬F°|¹êÅç¬O±µ¤U¨Ó«ç»ò¶i¦æ¡H·í®É¬d¼t«ç»ò¨S¦³µo²{¡H·í®É¤½§iÃÄÃÒµ²ªG·|¦b©ú¦~¤»¤ë¡A²{¦b¶i«×¦³¨S¦³©µ«á¡H

µª¡G¹A¬ì©Ò³]³Æ¦³ÂI¦Ñ¡A¦ý§Ú­Ì°í«ù¥xÆW¤@©w­n¦³¤@­Ó¾ÚÂI¡A·íªì§Ú­Ì´N¦³³Æ®×¦b¼w°ê¡A´Á­­¨ì2¤ë16¸¹¬d¼t¡A2¤ë16¸¹³q¹L¤»¤ë«áÃÄÃÒ´N¨S¦³°ÝÃD¡A¤£¼vÅTÃÄÃÒ¶i«×¡C·íªì¬O¦]¬°¥H¬°GMP´N¥i¥H¤F¡A¨S·Q¨ìEMA¬O­nGLP»{ÃÒ(Àu¨}¹êÅç«Ç¾Þ§@³W½d¡AGood Laboratory Practice, ²ºÙ¬°GLP)¡C

°Ý¤Q¤@¡GÃĪº°Æ§@¥Î¦p¦ó¡H

µª¡G²Ó¸`·|§âASH¸ê®Æ©ñ¦bºô¯¸¤W¡A¥HInterferon°Æ§@¥Î³Ì¤jªº¬O¦Û±þ¡A§Ú­Ì¬O§C©ó5%¡A¦A¨Ó´N¬O¤º¤Àªc¼vÅT¡A§Ú­Ì¦³§C©ó5%¡C

°Ý¤Q¤G¡G¼Ú¬w°e¥ó¦^ÂЬO12¤ë22¸¹¡A¶i«×³£¦³ºû«ù¶Ü¡H¼Ú¬wÃÄÃÒ®³¨ì«á·|¥ý¦b¨º¸Ì¤W¥«¡H

µª¡G²{¦b³£¦b¶i«×¤W¡A¥Ø«e¹w­p7¤ë2¸¹¤§«e·|¦³µ²ªG¡CAOP¤@©w·|¥ý¦b¶ø¦a§Q¤W¥«¡A¥Ø«eAOP¦³­pµe¡A¦ý¤£¯à³zÅS¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2017/12/20 ¤U¤È 10:22:36²Ä 3388 ½g¦^À³
Ãĵتºªk»¡·|»¡ªº¤£²M¤£·¡,©Ò¥HÅý§ë¸ê¤H¤ÎµØ¤Í¤@ÀYÃú¤ô.¤j®a³ÌÃö¤ßEMA ¤Î FDA ¶i«×«o§t½k±a¹L,°{Ã{¨ä¨¥;¦Ó¬O­«´_ªø½g¤j½×³ø§i²³¤H°ºª¾ªºContin¼Æ¾Ú¤Î©|¥¼«æ­¢ªº¦æ¾Pµ¦²¤.ªk»¡·|­n¤Q¤ÀÄYÂÔ,¤£­n«H¤f¶}ªe,­Y¤£½T©w¨S¦³§â´¤,¤£­nÀH·N»¡¥X.»¡¨ì°µ¨ì,µL«H¤£¥ß.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/20 ¤U¤È 09:17:46²Ä 3387 ½g¦^À³
¥J²Ó¦A¬Ý¤F¤@¤UÂûºô...µo²{¥¦¦Û¤v¤å³¹¤º®e¤]¦ü¥G¬Û¤¬¥Ù¬Þ!!

¤@½gª½±µ»¡¬O§_­«§@Á{§É©Î¥H¼Ú¬w¼Æ¾Ú¬°°Ñ¦Ò°µ¤@­Ó»Î±µ¸ÕÅç¡A¦P®É¤S»¡HU¬O¥é³æ¥ÎÃÄFDA¥i¯à¤£©Ó»{¡A©Ò¥H­n­«°µÁ{§É.....

ªL°êÄÁQ&Aªº°Ý¤G¤S»¡AOP¥Ó½Ð¼Ú·ùÃÄÃÒªºÁ{§É­p¹º®Ñ¤w°e¹FFDA¡AFDAªí¥Ü­nµ¥conti-PV¼Æ¾Ú¥X¨Ó....

(À³¸Ó¬OªLµ¦²¤ªøªº¦^µª)

anyway,ªí¥Ü¤p§Ì¥ý«e¬ÝªkÀ³¸Ó¬O¥¿½Tªº¡C

FDA¹ïproud-PV¼Æ¾ÚµLªk±µ¨üª½±µ¥Ó½ÐÃÄÃÒ¡A­nµ¥conti-PV¼Æ¾Ú¥X¨Ó¡A¦A¨M©w¤U¤@¨B¨ü²z»P§_!!

²{¦bconti-PV¼Æ¾Ú«G²´¡A´Nµ¥2018Q1·|½Í¦A¨ó°Ó±µ¨ü°e¥ó»P§_.....©Î¸É°µ.....

(ªÅ¤]ªÅªÅ¤j»P°]°È¦Û¥Ñ¤H¤jÁ¿ªk¥ç¬Ûªñ)

¦¹¥~¡B½Ð°ÝªÅ¤]ªÅªÅ¤j...¦³°Ñ¥[ªk»¡·|¶Ü??

¤£µM«çª¾¹D¬O¤f»~???

¥t¥~...

·|­û¡Gttseng1310145885 µoªí®É¶¡:2017/12/20 ¤W¤È 11:55:40²Ä 3517 ½g¦^À³

µL½]¤§½Í ¬Q¤Ñ§Ú¥þµ{¦bªk»¡·|

®Ú¥»¨S¦³´£¨ì³o¤@ÂI ¤Ó¦n¯º¤F§a

³o­ÓQ&A¯u¬O­Óù¥Íªù!!!

¦pªG¦³¼v­µÀÉ´N¦n¤F.......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2017/12/20 ¤U¤È 08:19:57²Ä 3386 ½g¦^À³
§Ú²q,À³¬OÃĵإH«eªº³QÂ÷¾­û¤u¨ü¨ì«Ü¤jªº©e©},¥ÎÆZ¯î¤§¤O³ø´_.
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/20 ¤U¤È 07:35:42²Ä 3385 ½g¦^À³
§Ú¤]ÆZ¦n©_¬°¦óÂûºô¹ïÃĵؼĵø¨º»ò²`?

¦³­þ¦ì¤j¤j¥i¥H¦³¤ñ¸û«ÈÆ[ªº¸ÑÄÀ¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/20 ¤U¤È 07:32:58²Ä 3384 ½g¦^À³
§Ú·Q¡K³o´N¬OÂûºô­nªº¡C

¥Î¤@°ï¦³ªº¨Sªº½èºÃ¨Ó©Ù±þ¤@¤Áªº§Q¦h¡K

¨C¦¸¦³¤°»ò§Q¦h¥X¨Ó¡A¥¦´N­¢¤£«æ«Ýªº²Ä¤@®É¶¡´£¥X½èºÃ¡C

¤£ºÞ¬O§_¯u¹ê¡K¥¦½T¹ê°Ê·n§ë¸ê¤H«H¤ß

³o­Ó¤³¯uªºµ²«Ü²`¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/20 ¤U¤È 07:09:05²Ä 3383 ½g¦^À³
´N²z©Ê°Q½×,§Ú¤Ï¦Ó»{¬°¹ïÃĵؤ£¯à¤Ó¹L©ó¼ÖÆ[,

§ÚÁ`ı±oÃĵئ³¦bÁô¿f¨Ç¤°»ò~

ªÅ¤j»¡±o¦n,Âà¸üªÅ¤jªº¤å¦r¦p¤U:

Â÷2¤ë15¤éÁÙ¦³50¦h¤Ñ¡A¤½¥q¦n¦n»PKOL¤@¦P§V¤O¡A»¡ªAFDA±µ¨ü¡G

´N¯e¯fªvÀø¦Ó¨¥¡A¥Î²Ä¤@½uÃĪ«ªº¦­´Á¯f±w¡A

CONTI-PVÅã²{ªºdurability¡A¬Û¸û©óPROUD-PVªºµÊŦ¸~¤j§ó­«­n¡C

³o¼Ë©Î³\¤°»ò¸ÕÅç³£¤£¥Î°µ¡A´N¥i¥H°e¥ó¡C¦pªGµLªk»¡ªAFDA¡A¤£­n©ì¡A»{©R»°§Ö°µ¥t¤@­Ó¸ÕÅç¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/20 ¤U¤È 05:56:15²Ä 3382 ½g¦^À³
°]°È¦Û¥Ñ¤H¤j¡K

·PÁ¤j¤jªºÄÀºÃ¡A­Ó¤Hı±o§Aªºµª®×À³¸Ó¬O¥¿¸Ñ¡C

¨Ì§Úªº»{ª¾¡A²Ä¤@¦~¼Æ¾ÚÅã¥Ü«D¦H©Ê¡A©Ò¥HFDA·Qµ¥²Ä¤G¦~¼Æ¾Ú¥X¨Ó¦A¨M©w¡K³o­Ó¦X²z

²{¦b²Ä¤G¦~¼Æ¾Ú«G²´¡A©Ò¥H¦A¨ó°Ó¬O§_¯àª½±µ°e¥ó¡A©Î¦A¸É°µ­Ó¾ô±µ¸ÕÅç¡K

¤Íµ½ªº´CÅé¥H¾ô±µ¸ÕÅç¨ÓµÛ¤å

µM¤£¤Íµ½ªº´CÅé«oª½±µ¥H¤£©Ó»{¼Æ¾Ú»P­«°µÁ{§É¨ÓµÛ¤å¡K

­ü~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªÅ¤]ªÅªÅ10145331  µoªí®É¶¡:2017/12/20 ¤U¤È 05:55:22²Ä 3381 ½g¦^À³
¹ï©óMoneyDJ·s»Dªº¡¨ÃĵØÃĪñ´Á¤]¥¿»P¬ü°êFDA¨ó°ÓPV¦b¬ü°ê¾ô±µÁ{§Éªº³]­p¡¨¡A­Ó¤H¬Oı±o©Ç©Çªº¡C²z¥Ñ¦p¤U¡G

2¤ë15¤éªº·|ijÀ³ÄÝpre-new drug application/biologics license application meeting

³o­Ó·|ijªº¥Øªº¡G½Ð±ÐFDA¡A¥Ø«e¤w§¹¦¨ªº¸ÕÅç¡A´N³]­p¦Ó¨¥²Å¤£²Å¦XFDAµû¦ô·sÃÄÀø®Ä¤Î¦w¥þ©Êªº­n¨D¡C

·|ij¶}§¹¤F¡AFDA»¡OK¡A´N°e¥ó¡CFDA»¡NO¡A¤~·|¦³±µ¤U¨Ó­n°µ¬Æ»ò¸ÕÅ窺ijÃD¡C

Â÷2¤ë15¤éÁÙ¦³50¦h¤Ñ¡A¤½¥q¦n¦n»PKOL¤@¦P§V¤O¡A»¡ªAFDA±µ¨ü¡G

´N¯e¯fªvÀø¦Ó¨¥¡A¥Î²Ä¤@½uÃĪ«ªº¦­´Á¯f±w¡A

CONTI-PVÅã²{ªºdurability¡A¬Û¸û©óPROUD-PVªºµÊŦ¸~¤j§ó­«­n¡C

³o¼Ë©Î³\¤°»ò¸ÕÅç³£¤£¥Î°µ¡A´N¥i¥H°e¥ó¡C¦pªGµLªk»¡ªAFDA¡A¤£­n©ì¡A»{©R»°§Ö°µ¥t¤@­Ó¸ÕÅç¡C

»¡­ÓÃD¥~¸Ü¡A¬ü°ê¤j¤½¥q¤ñ¦W¤£¨£¸g¶Çªº¥xÆW¤p¤½¥q¦³»¡ªA¤O¦h¤F¡C

§ä­Ó¥i¾aªºpartner¡AÅý§O¤H¤]ÁÈ¿ú¡A¦Û¤v¬Ù¨Æ¤S¥i¾Ç¸gÅç¡A¦ó¼Ö¤£¬°¡H

¤é¥»¤pÃļt(Ono¡A¤p³¥)ªºOpdivo­Y¥¼»PBMS¦X§@¡A¬O§_¦³¤µ¤é­·¥ú¡H

BMS¦³ªvÀøCMLªºSprycel¡AB¡BC¨x¡BÀù¯gÃĪ«¬ãµo¤]¬Û·í¦³¦W¡A¹ê¦b¬O¤@­Ó¤£¿ùªº¿ï¾Ü¡A¥u¬O¤£ª¾¥¦ªº¤f¦³¦h¤j¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°]°È¦Û¥Ñ¤H10132540  µoªí®É¶¡:2017/12/20 ¤U¤È 04:59:46²Ä 3380 ½g¦^À³
·Ó¤½¥q¤§«e»P FDA ·¾³qµ²½×¡G

¡y­Y P1101 ¦b¼Ú¬w¶i¦æ¤§²Ä¤T´Á¤HÅé¸ÕÅç¼Æ¾Ú¡A¤w¥iÃÒ¹êÀø®Ä¤Î¦w¥þ©ÊÅãµÛÀu©ó¨ä¹ï·Ó²ÕÃĪ«¡A¥B AOP ¦P·N FDA ¥i

¨ì¼Ú¬w¶i¦æÁ{§É¤§¹ê¦a¼f¬d¨Ó½T»{©Ò¦³ªº¸ÕÅç¼Æ¾Ú¡A«h¤½¥q¿ï¾Ü¤£¦b¬ü°ê¶i¦æ²Ä¤T´Á¤H¸ÕÅç¬O¥i¥H±µ¨üªº¡C¡z

²{¦b¦]¬°²Ä¤G¦~¤~Àu©ó¹ï·Ó²Õ¡A©Ò¥H³o³¡¥÷¼Æ¾Úªº§e²{¡A2018/2/15 »P·| FDA ®É¡Aªk³W³æ¦ì«ç»ò¬Ý«Ý³o¼Æ¾Ú¬OÃöÁä¡A FDA ¹ï¼Æ¾ÚÁÙ¦³¨ä¥L·Qªk¡A´N·|»Ý­n°µ¤p¤T´Á(Bridge trial)¡C

PV ¥«³õ³W¼Ò¡A¼Ú¬w­n¤ñ¬ü°ê¤j¡AÁöµMÃÄ»ù¼Ú¬w¬ù¬O¬ü°êªº¤C~¤K§é¡A¦ý P1101 ¦b¼Ú¬wÁ{§É¡AÂå¥Í¼ô±x«×°ª¡A¬Û¹ï¦Ó¨¥ÃÄ«~º¯«×³t«×·|¤ñ¬ü°ê§Ö¡A¹ïÃĵØÃĪº²{ª÷¬y¦³¤@©wªºÑºª`¡A©Ò¥H 2018 ¦~¤½¥q¥Ø«eµL¼W¸êªº³W¹º¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/20 ¤U¤È 04:06:50²Ä 3379 ½g¦^À³
¬ü°ê¾ô±µÁ{§Éªº³]­p....

¬Ý¨ÓÃĵتº¬ü°ê¹ÚÁÙ¦³ÂI¶ZÂ÷

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/12/20 ¤U¤È 03:57:48²Ä 3378 ½g¦^À³
ÃĵØÃĤjÂà°©¾a¬ü°ê¥«³õ¡F²£«~½uº¥Áͧ¹¾ã§U§Q°ò

MoneyDJ·s»D 2017-12-20 11:45:00 °OªÌ ¿½¿Pµ¾ ³ø¾É

ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)·sÃļƾګG²´¤U¡AÃĵØÃÄ»P¦X§@¹Ù¦ñAOP¦b¸Ó»â°ì²Ä¤@½u¥ÎÃÄRopeg(°Ó«~¦WBESREMI)¡A¤w¦b¼Ú¬wÃÄÃÒ¬dÅ綥¬q¡A¥«³õ¹w´Á¡A©ú(2018)¦~¦³±æ¶¶§Q¨úÃҥͲ£¡C¤½¥q¤]ÀÀ¿n·¥¥¬§½¬ü°ê¥«³õ¡A¨Ã³W¹º¸ÓÃÄ«~¦b¦å¤pªO¼W¥Í¯g(ET)ªº¤T´ÁÁ{§É¡Aªk¤H»{¬°¡A2019¦~«á±N³°Äò¦³¹ê½èѺª`¡A¥t©ó¨xª¢»P§ÜÀù»â°ìªº¥¬§½¡A¤]³v¨B¨ü¨ìÃöª`¡C

ÃĵØÃĬO»EµJ¤j¤À¤lÃĪ«¬°¥Dªº·sÃļt¡A¤]¬O°ê¤º¤Ö¼Æ·sÃļt¤¤¨ã³Æ¬ãµo¡B¥Í²£¦Ü¦æ¾P¤@±øÀs¯à¤OªÌ¡A¥Ø«e¸ê¥»ÃB21.89»õ¤¸¡C¦Ó¤½¥q®Ö¤ß§Þ³N¥­¥x¦b©ó¶W°ª¯Â«×ªº·s«¬ªø®Ä¤zÂZ¯À¡A¦]¯Â«×¥i¹F98%¥H¤W¡A¥i­°§C¶Ç²Î¤zÂZ¯À´o¤Hªº°Æ§@¥Î¡A¦b¦å²GªvÀø»â°ì¦³¤F·sµo®i¡A¶i«×³Ì§Ö¥Î©óPVªºRopeg¡A«Y»P¼Ú¬w¨u¯f¥ÎÃĨ£ªøªºAOP¦X§@¡A¤T´ÁÁ{§É«á´Á¼Æ¾Ú¤½¥¬«G²´¡A24­Ó¤ëªºÀø®Ä«ü¼Ð¤£¦ý¹F¼Ð¡A¥B¦³½Õ¸`¯e¯fªº¥\¯à¡AÅý¸gÀç¹Î¶¤¹ï¸ÓÃÄ«~¦¨¬°PV¤@½u¥ÎÃÄ¡A¬Ýªk¼ÖÆ[¡C

ªk¤H»{¬°¡A¦]¸ÓÃļڬwÃÄÃÒ¤w¦b¼fij¶¥¬q¡A¶¶§Qªº¸Ü¡A2018¦~¥i±æ¶¶§Q¨úÃÒ¡A¥D­n±N¥ÑAOPª½Àç¡AÃĵØÃÄ«h¥i¨Ì·Ó¾P°â¦¬¨ú­ì®Æ¡B»s³y»P³¡¤À§Q¼í¤À¨É¡C¦Ü©ó¬ü°ê¥«³õ¡A«h¥ÑÃĵØÃīإߪº¹Î¶¤¦ÛÀç¡A¥Ø«e¤w«õ¨¤´ÀPV¤G½u¥ÎÃÄJakafi¥´¤U¼Ú¬w¥«³õªº­«­n¥DºÞ¡A¾áºõ¬ü°ê¹Î¶¤¥D¨ÆªÌ¡A¥[±j¬ü°ê¥«³õªº¥¬§½¡C

ªk¤H»{¬°¡AJakafi¤@¦~ªº¥þ²y¾P°âÃB¶W¹L14»õ¬ü¤¸¡A¨ä¤¤¦b¬üªº¨Ï¥Î¯f±w¬ù4,500¤H¡A¼Ú¬w¥«³õÀ³¸Ó¤]¬Û·í¡C¬Û¸û©óPV¤@½u¥ÎÃįf±w¶W¹L8¸U¤H¡A®t¶Z¤£¤p¡A¦Ó¥HRopegªº°Ó·~¤Æµ¦²¤¡A¦~¤ä¥XÀ³¸Ó¤]¦³¾÷·|¤£°ª©óJakafiªº7~8¸U¬ü¤¸¡A¦³§Q¨Ï¥ÎªÌªºÂX±i¡A¥u­n¦æ¾Pµ¦²¤±o©y¡A°ª®p¾P°âªºÁ`ÃBÀ³¶W¹LJakafi¡C

ÃĵØÃĪñ´Á¤]¥¿»P¬ü°êFDA¨ó°ÓPV¦b¬ü°ê¾ô±µÁ{§Éªº³]­p¡AÀò¦@ÃÑ«á±N¥¿¦¡±Ò°Ê¡A¥[³t¬ü°êÃÄÃÒªºÀò­ã¡C¥t¤½¥q¤]¦P¨B³W¹ºETªº¤T´ÁÁ{§É¸ÕÅç¡A¤]¬ß2018¦~±Ò°Ê¡C

¥t¤½¥q·s«¬¤zÂZ¯À¦b¨xª¢¤WªºÀ³¥Î¡A¤]Âê©wÁÙ«D¤fªAÃÄ¥i¨ú¥NªºB¨x»PB¨x©MC¨x¦X¨ÖªvÀøªº¥«³õ¡A«áªÌÄÝ©ó¨u¨£¯e¯f»â°ì¡A«eªÌªºÁ{§É¸ÕÅç«h³W¹º¦b¥xÆW¡BÁú°ê¡B¤é¥»¤Î¶V«n¦P¨B¶i¦æ¡C

¦¹¥~¡AÃĵØÃıÂÅv¤Þ¶iªº¤fªAµµ§ü¾J¡A«n¬ü¹Ù¦ñ¦b¨ÅÀù¾AÀ³¯gªº¤T´ÁÁ{§É¸ÕÅç¡A¤w¦b¶i¦æ¤¤¡A®Ú¾ÚÃĵØÃÄ»P¥xÆW¥DºÞ¾÷Ãö¨óij¡A¥u­n¸ÓÁ{§É¸ÕÅç´Á¤¤¤ÀªR¹F¼Ð¡A´N¥i¥Ó½Ð¥xÆWÃÄÃÒ¡AÂX¼W²£«~½u¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2017/12/20 ¤U¤È 03:48:21²Ä 3377 ½g¦^À³
°²¦p©ú¦~1Q©MFDA¶}·|ªºµ²ªG:¤£¥Î¦A°µÁ{§É,¥i¥H°e¥ó,¨º¬O¤j§Q¦h¡C¦pªGÁÙ­n°µ¤pÁ{§É,¨º¬O¤p§QªÅ¡C³Ì­«­nªº¬OEMA°e¥ó¥Ó½ÐÃÄÃÒ¥²¶·¶¶§Q,©ú¦~¤W¯Z¦~¥u­n¯à¶¶§Q¨ú±oEMAÃÄÃÒ,AOP¶}©l½æÃÄ´N¦³¬¡¤ô¶i±b,´N¬O¤j§Q¦h¡C¦pªG®³¨ì¤@½uÃÄÀ³¸Ó«Ü¤£¿ù,«áÄòÁÙ¦³³\¦h°ê®a¤Î³\¦h¯e¯f³£ÄÝ¥¼¨Óªº¹Ú¡C´N³o»ù¦ì¥uµ¥EMA¨úÃҭȱo!¨ä¥Lªº³£¥u¬O¥[¤À¦Ó¤w¡CÃÄÃÒ¨ú±o´N·|¦³³\¦h¤H±¹¤â¤£¤Î!¤]·PÁ£¡ºôªº´£¿ô¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2017/12/20 ¤U¤È 03:46:59²Ä 3376 ½g¦^À³
ÁÙ¦³¾÷·|¡A³o¦ìFDA·s¥ô§½ªø¦b¤@¨Ç·s»D©M¬Fµ¦¬Ý¨Ó¹ï·sÃħå­ã¬O¤ñ¸û¼eÃPªº

FDA¤£为药°µ¥D¡H

www.yypharm.com/?p=12433

¸`¿ý³¡¤À¤º®e¦p¤U

¡i·s闻¨Æ¥ó¡j¡G¤µ¤ÑFDA¦b¤­¤ë©Ú绝Therapeutic MDªº¤îµh药TX-004HR¦Z«Å¥¬将¨ü²z¨ä¤W¥«¥Ó请¡A¦]¦¹©ñ弃¤F对这个产«~¤@¦~¦w¥þ©Ê数Õuªº­n¨D¡C¨ü¦¹®ø®§¼v响TXMD¤@«×¤W扬116%¡A³Ì¦Z¥H¤W扬31%¦¬盘¡C这¬O¤µ¦~FDA²Ä¤T¦¸§ï变¥ß场¡A7¤ëFDA©ñ弃¤F对Amicusªº¨u见¯fFabry药ª«ªº¦w¥þ©Ê试验­n¨D¡A¦}给¤©¨ä§Ö³t审§å³q¹D资®æ¡C8¤ëFDA则³j§K¤Fþ÷来/IncyteªºJAK§í¨î剂baricitinibªº¦w¥þ©Ê试验­n¨D¡A为þ÷来节约¤F¤@¦~¥bªº开发时间¡C¤µ¦~FDA¤]¦b¤T´Á临§É¦sºÃªº±¡úG¤U§å­ã¤FPortolaªºXa¦]¤l§í¨î剂Betrixaban¡A¥O¤H质ºÃFDA¬O§_¦b©ñ宽执ªk¤Ø«×¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/20 ¤U¤È 02:57:24²Ä 3375 ½g¦^À³
§Úı±o²{¶¥¬q

À³¸Ó³æ¯Â¥H¼Ú¬wªº¼ç¦b¥«³õ¨Óµû­ÈÃĵØ

¬ü°ê¤£½T©w©Ê¤Ó¤j ¼È®É¤£¯à¦C¤J

§Ú·Q³o¤]¬O¬°¦ó¥Ø«e¥Ø¼Ð»ù³£¤£¶W¹L200

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/20 ¤U¤È 02:54:30²Ä 3374 ½g¦^À³
¥t¥~¡A¤½¥q¥Ø«e³£¤w¸g¦b¶i¦æ¬ü°ê¦æ¾P§G§½

¯S©w´CÅéºÙFDA¤£»{¦PHUªºPK¼Æ¾Ú¹ê¦b¤£¦X²z¡K

·íªì¬ü°ê³£¦P·N¥H¼Ú¬w¼Æ¾Ú¬°Á{§É¤F

¬Ý´CÅéÄÀ¥Xªº¤½¥q»¡ªk¡K¬O©ú¦~²Ä¤@©u°e¥ó©Î¬¢½Í°e¥ó¨Æ©y¡K

¬Ý¨Ó¤½¥q¯uªº¸Ó¼á²M¤@¤U¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/20 ¤U¤È 02:35:01²Ä 3373 ½g¦^À³
¦U¦ì¤j¤j

³o¥i¤S¬O¤@­Óù¥Íªù¡K

¨ì©³¦³°Ñ»Pªº¤j¤j¬O§_¦³Å¥¨ìQ&A¡K

¥t¨ì©³©ú¦~²Ä¤@©u¬O¬¢½Í°e¥ó¬O©y¡AÁÙ¬OÁ{§É¨Æ©y¡K

¥ý«eFDA¦P·N¥H¼Ú¬wÁ{§É¼Æ¾Ú°e¼f¶Ü¡H

¤S¦ó¨Ó³]­pÁ{§É¤§»¡¡K

¦pªG»¡¡AFDA¹ïproud-PV¦³ºÃ¼{¡A­n¨Dµ¥conti-PV¼Æ¾Ú¡K³o­Ó§Ú¬Û«H¡C

¦ýÂûºô¸ò¬Y¨Ç¤j¤j´£¨ì¥Ó½ÐÁ{§É¡K³o­Ó®t¶Z¤Ó¤j¤F§a¡I

¸É°µ¡K©Î³\¤ñ¸û¥i¯à§a¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gucss10142657  µoªí®É¶¡:2017/12/20 ¤U¤È 02:27:58²Ä 3372 ½g¦^À³
¨Ì·Ó¤½¥q»¡©ú¦æ¾Pªº¸Ü³N¤Î´CÅé¥Xªº·s»D½Z¨Ó¬Ý¡A¬ü°ê¥i¯à»Ý¸É°µÃöÁä©ÊÁ{§É¡A¬Ý¨Ó¼Ú¬w¥ý½æ¡A¬ü°ê­n¦A·¾³q¡A§ë¸ê¤H­nªº¸ê°TÁ`¬O§t½k±a¹L¡A¤ß¸Ì¯u¤£²n!­n¦³ªø´Á§Ü¾Ôªº·Ç³Æ!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/20 ¤U¤È 02:20:38²Ä 3371 ½g¦^À³
²z©Êªº°Ý­Ó°ÝÃD,

½Ð°Ý¥H«e¦³¬OEMA ¼f®Ö³q¹L,µM«áFDA ¤£¥ÎÁ{§É´N¥i¤W¥«ªº¦¨¥\®×¨ÒÃÄ«~¶Ü?

¦]¬°§ÚÁ`ı±oÃĵئb³o­Ó³¡¤À¤@ª½¬O«Ü¼ÖÆ[@@

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªÅ¤]ªÅªÅ10145331  µoªí®É¶¡:2017/12/20 ¤U¤È 02:18:25²Ä 3370 ½g¦^À³
¦Ü©ó»PFDA­n½Í¬Æ»ò¡H­Ó¤H±À·Q¡G¤@¤è­±¬OªL³Ð¿ì¤H¹ïNDAªºªk³W¤£¼ô¡A¥t¤@¤è­±¬O¹Î¶¤¤£Ä@¥L¦h»¡¦h¿ù¡A©Ò¥H´N§t½k±a¹L¡C

¤£¹L¡A¸â¸³¨Æªø­Ë¬O³zÅS¤@ÂI°T®§¡GFDA­«µødurability¡C

¸â¸³¨Æªø¬OFDA¥X¨­¡A»¡¸Ü¬Û¹ï«O¦u¡A¦ý¤]¤ñ¸û¯à®»¦íªk³W³æ¦ìÃö¤ßªº­«ÂI¡C

¥t¤@­ÓsplenomegalyªºÄ³ÃD¡A¦o¦³´£¨ì¦­´Á¯f±wµÊ¸~¤j¬Û¹ï¸û¤Ö¡A¸û¤£®e©ö®³¨Ó·í¥D­nÀø®Ä«ü¼Ð¡C

·íµM¡A³o¼Ëªº»¡ªkFDA¯à¤£¯à±µ¨ü¡A´N¬Ý¤@¦P¥h»PFDA·¾³qKOL (Key opinion leader)ªº»¡ªA¥\¤O¤F¡C

³o¤G­ÓKOLªº½T¤£¿ù¡A¯à§ä¨ì³o¼Ëªº¤H¿ï¬O­È±oºÙÆg¡C

ÁöµMPVªº¬ãµo¡A¬Oªñ¤Q¦~¨Ó¤~¤ñ¸û¦³¬ð¯}¡A¦ýFDAµ´¤£¬O¹³ªL³Ð¿ì¤HÁ¿ªº¨º»ò¤£³ô¡C

¦n¦n·Ç³Æ¸ê®Æ¡A»¡¤§¥H²z¡A¤~¬O¤ý¹D¡C

¬ü°ê§ä¨ì¦³¸gÅ窺¤H¡A¨Ó°µmarketing¤]¬O¦n¨Æ¡A¦ý¬O¥þ³¡Ãĵئۤv·d¡A´N¥O¤H¾á¤ß¤F¡C

«Ü§Ö¡A´N­n¦bÂå¾Ç·|¿ì¤½¶}ªºsatellite meeting³oÃþªºmedical event¡A¦p¦ó°Ï¤ÀÂå¾Ç±Ð¨|»PÃÄ«~«Å¶Ç¡A¤À¤o®³®º«Ü­«­n¡C

¥HªL³Ð¿ì¤H¦bªk»¡·|«H¤f¶}ªe¡G³o­Ó¡B¨º­Ó³£¥i¥H¨Ó«Å¶ÇªººA«×¡A¦b¬ü°ê½æÃÄ¡A¥u©È¤£§®¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/12/20 ¤U¤È 02:15:46²Ä 3369 ½g¦^À³
¥t¥~¡A¤½¥q¥Ø«e¤w¦³½Ð¤@¦ì¥j³Õ¤h­t³d§ë¸ê¤HÃö«Y¡A¦pªG¤j®a¦³¥ô¦ó°ÝÃD¡A¥ç¥iª½±µ½Ð±Ð¦o~~~
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/12/20 ¤U¤È 02:10:35²Ä 3368 ½g¦^À³
¬Q¤Ñ§Ú¦b²{³õ¡A§Ú´±ªÖ©wªL³Ð¿ì¤H¬O»¡2018¦~2¤ë15¤é(¥LÁÙ»¡¬OÂû¦~§Àª¯¦~ÀY)»PFDA¶}·|°Q½×«áÄò¬ü°ê³¡¤À¬O§_­n°µÁ{§É¡B¦p¦ó°µµ¥µ¥¡C

¥t¥~¦³µØ¤Í°Ý¨ì¬°¤°»ò¤£»°§Ö°eFDA©O?

ªL³Ð¿ì¤H»P¸â¸³¨Æªø¬Q¤Ñ¤]¦³´£¨ì¦]¬°EMA¬O¥i¥H¥ý°e¥ó«á¸É¸ê®Æ¡A©Ò¥HAOP¤~±Ä¨ú¥ý°e¥ó(«e12­Ó¤ëªº¼Æ¾Úµ²ªG)¡B¦A¸É¥ó(«á12­Ó¤ëªº¼Æ¾Úµ²ªG)¡F¦ý¬ü°êFDA¬O­n¨D©Ò¦³¸ê®Æ§¡³Æ»ô¤~¶}©l¼f¡A§_«h¸ê®Æ³£¬O°ï¦b­Ü®w(ªL³Ð¿ì¤H»¡ªº)¡C

¤p§Ì«D±M·~¥ÍÂå¤H­û¡A¥u¬O´N²{³õÅ¥¨ìªº¤À¨É~~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GªÅ¤]ªÅªÅ10145331  µoªí®É¶¡:2017/12/20 ¤U¤È 01:42:52²Ä 3367 ½g¦^À³
Russel¤j¡A³o¤£¯à§¹¥þ©ÇGenet¡A¦]¬°ªL³Ð¿ì¤Hºû«ù¨ä¯S¦³ªºªí¹F¤è¦¡¡G¼ö±¡¦³¾l¡B·Ç½T«×¤£¨Î¡C

ªL³Ð¿ì¤Hªº½T¬O»¡12¤ë25¡A¦ý¤]»¡¨º¤@¤é¬OµØ¤H°£¤i¡A¦]¦¹²q´ú¬O2¤ë15¤éªº¤f»~¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/20 ¤U¤È 01:41:47²Ä 3366 ½g¦^À³
¬Q¤Ñªºªk»¡·|

©ú©ú¬Oªk»¡·|¡A¤£¬OªÑªF·|

¦ý 70% ³£¬O¦Ñ­±¤ÕªºªÑªF

¨S¦³¦h¤Öªk¤H¨Ó

¥«³õ»{¦P«×¤£°÷

¿ì¦A¦hªºªk»¡·|³£¨S¥Î

¤½¥q¤£¥i¯à¤£ª¾¹D¥«³õ·Qª¾¹Dªº¬OÔ£

³oÀÉÀ³¸Ó¬O¨S¦³¥D¤O

§_«h¤µ¤Ñ³o»ò¦hªº¥Í­p§Q¦h

À³¸Ó­n©Ô°ª¨Ó¥X³f

¤§«áÁÙ¬Oı±o

¦³¥«³õ·Q¤F¸ÑªºªF¦è

¦A¶}ªk»¡·|

§_«h´NÀqÀq¦a°µ§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/20 ¤U¤È 01:40:39²Ä 3365 ½g¦^À³
®Ú¾Ú Dr. Srdan Verstovsek»¡ªk

¥i¯àPV¬ü°ê¥Ó½ÐÃÄÃÒ¡A¥²¶·¦A§@Á{§É¸ÕÅç¡C

­Y¬O¦p¦¹¡A¤£ª¾¦ó®É¡A¤~¥i¨ú±o¬ü°êÃÄÃÒ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/20 ¤U¤È 01:28:14²Ä 3364 ½g¦^À³
Excerpt from "MPN Updates From an Expert Panel" - Dr. Ruben Mesa

https://www.youtube.com/watch?v=LFnCd8qTyDs

(¦³¤¤¤å¦r¹õ)

PharmaEssentia Corp.

µo§G¤é´Á¡G2017¦~12¤ë19¤é

A ¡§super panel¡¨ of MPN experts Dr. Mark Heaney, Dr. Rami Komrokji, Dr. Ruben Mesa, Dr. Jamile Shammo, as well as Andrew Schorr, gathered to discuss the latest news and developments related to research and treatment of myeloproliferative neoplasms (MPNs). The experts all shared their perspective on the ¡§headlines¡¨ from this year¡¦s meeting, including updates on JAK inhibitors in development, news on interferon, diagnostic testing, the story that somatic mutations tell, and the overwhelming interest in the study of MPNs.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/20 ¤U¤È 01:22:21²Ä 3363 ½g¦^À³
An Interferon Update From an MPN Expert - Dr. Srdan Verstovsek

PharmaEssentia Corp.

µo§G¤é´Á¡G2017¦~12¤ë19¤é

https://www.youtube.com/watch?v=A6DeaujxITI

(¦³¤¤¤å¦r¹õ)

Dr. Srdan Verstovsek, an MPN expert and researcher from MD Anderson Cancer Center, provides an update on the latest news from the conference. Dr. Verstovsek provides details about a new treatment being studied for anemia in patients with myelofibrosis as well as the two-year results of a European study of interferon for polycythemia vera (PV) treatment.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤¸®ð¤j¨k«Ä10142490  µoªí®É¶¡:2017/12/20 ¤W¤È 11:56:15²Ä 3362 ½g¦^À³
§Ú¥i¥HÅé·|Anderson¤jªº·P¨ü

«ëÅK¤£¦¨¿û§r

¤µ¤Ñ¥Í§Þ«ü¼Æ¤jº¦­C~

Ãĵثo...

­ü~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gttseng1310145885  µoªí®É¶¡:2017/12/20 ¤W¤È 11:55:40²Ä 3361 ½g¦^À³
µL½]¤§½Í ¬Q¤Ñ§Ú¥þµ{¦bªk»¡·|

®Ú¥»¨S¦³´£¨ì³o¤@ÂI ¤Ó¦n¯º¤F§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/20 ¤W¤È 11:38:49²Ä 3360 ½g¦^À³
§Ú¤ñ¸û¦n©_ªº¬O¡K

·s»D´£¨ìªº³£¬O©ú¦~²Ä¤@©u»PFDA­±½ÍÃÄÃҥӽСK

¦ÓÂûºô«o»¡12/25»PFDA¬¢½Í¬O§_­«·s³]­p¬ü°êÁ{§É¡K

¸t½Ï¸`FDA¦³¤W¯Z???

¨ì©³¬O½Ö¦b³yÁÁ¡K¦³°Ñ»Pªº¤j¤j¥i§_¤À¨É¤@¤U!!

¤½¥q¤]¸Ó¥X¨Ó¼á²M¤@¤U§a¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/20 ¤W¤È 11:31:50²Ä 3359 ½g¦^À³
§Ú«ëÅK¤£¦¨¿ûªü

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/20 ¤W¤È 11:24:37²Ä 3358 ½g¦^À³
§O©Ç¸o¦w¤j¤F

¹q¤lªÑ³£º¦Â½¤FÃĵØÁ٤ѤѤû¥Ö¡AÃø©Ç¥O¤H¥Í®ð

¦Ñ¸Ü¤@¥y

·U¨ì«á­±´NÂ÷¦¨¥\·Uªñ

¦n¦Y¦nºÎ¡A¥[ªo¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/20 ¤W¤È 11:03:39²Ä 3357 ½g¦^À³
¨ä¹ê¤]¤£¥Î¤Ó³d©Ç¦w¤j,

¥u¯à»¡Ãĵئۤv¤Ó¤£ª§®ð,

Ãø¥Hµ¹§ë¸êªÌ¼ÖÆ[ªº¥¿¯à¶q~

ÁÙ¬O¨º¥y¸Ü,´N¥­±`¤ß¬Ý«Ý¤Ï¦Ó·|ı±o¨Æ¨Æ¶¶¤ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GºÖ«°10145527  µoªí®É¶¡:2017/12/20 ¤W¤È 10:50:03²Ä 3356 ½g¦^À³
¦w¥S.........

¦³®É­Ô,§Ú¯uÃhºÃ§A¬OÂûºô¬£¨Ó¶Ãªº........

¬Ý§Aªº¨¥½×,·Pı¤W§A¤ñ¸û§Æ±æÃĵض^........!!!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/12/20 ¤W¤È 10:40:52²Ä 3355 ½g¦^À³
¤¤¸Î¯E¹©¤jº¦.....½Þ¨SªÎªÎ¨ìª¯......
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/20 ¤W¤È 10:26:22²Ä 3354 ½g¦^À³
³o¸Ì¤Ó¦hµL¥i±ÏÃĪº¼ÖÆ[ªÌ

§Ú­Ì¬Ý¬Ý200¥ý¨ìÁÙ¬O120¥ý¨ì

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/20 ¤W¤È 10:02:21²Ä 3353 ½g¦^À³
¸s¯q¤]¦³³Ì·s³ø§i,¥Ø¼Ð»ù200

¼Ú·ùÃÄÃҬݰ_¨ÓÀ³¨S°ÝÃD

­«ÂIÁÙ¬O¦b¦bFDA±µ¤£±µ¨ü¥H¥Õ¤H¬°¥Dªº¼Ú·ù¼Æ¾Ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/20 ¤W¤È 09:59:27²Ä 3352 ½g¦^À³
¤£­n»¡190¡A¦~©³«e¯à¬Ý¨ì150´N°½¯º¤F¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/20 ¤W¤È 09:48:31²Ä 3351 ½g¦^À³
°ê²¼§ëÅU¦³³Ì·s³ø§i,°ê²¼ªº«È¤á¥i¥H¤Wºô§ä,¥Ø¼Ð»ù190
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/20 ¤W¤È 09:27:43²Ä 3350 ½g¦^À³
Ä~Äò¦n¦Y¦nºÎ¾i­@¤ß~

§Q¦hªG¯u¬O¤j¤á§@»ùªº¦n¾÷·|~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GBESREMi10143176  µoªí®É¶¡:2017/12/19 ¤U¤È 09:18:02²Ä 3349 ½g¦^À³
¤µ¤é(12/19)ªk»¡§ë¼v¤ù:

mops.twse.com.tw/nas/STR/644620171219M001.pdf

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/19 ¤U¤È 08:56:19²Ä 3348 ½g¦^À³
·sÃļtÃĵØÃÄ (6446-TW) ªí¥Ü¡AP1101 ¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g (PV) ²Ä¤T´ÁÁ{§É«áÄò Conti-PV ³Ì·sÁ{§Éµ²ªG¹F¼Ð¡AÅã¥Ü¥i´£¨Ñ±wªÌ¦³»ù­È¥B¦w¥þªº·s«¬ªø´ÁªvÀø²Ä¤@½u¥ÎÃÄ¡A±N¥[³t¬ü°êÃÄÃҥӽе{§Ç¡A¹w­p©ú¦~²Ä 1 ©u¦A»P¬ü FDA ­±½Í¡C

ÃĵØÃĪí¥Ü¡APV ±wªÌ¨Ï¥Î P1101 ¤À§OªvÀø 12 ­Ó¤ë¤Î 24 ­Ó¤ëªº²Ä¤T´ÁÁ{§É¸ÕÅ礣¦ý¬Ò¹F¨ì¹w´ÁÀø®Ä«ü¼Ð¡A®Ú¾Úªø´Á°lÂܪº Conti-PV Á{§É¸ÕÅçµ²ªG¡A§óÆ[¹î¨ì P1101 ¨ã¦³¿W¯Sªº½Õ¸`¯e¯f¯à¤O¡A¥i¥HÅý¯f±w¦bªø´ÁªvÀø®ÉÀò±o³Ì¤j§U¯q¡AÃÒ¹ê P1101 ¥i¬° PV ±wªÌ´£¨Ñ¤F¦³»ù­È¥B¦w¥þªº²Ä¤@½uªvÀø¤è¦¡¡A¤½¥q±µ¤U¨Ó±N¥[³t±À°Ê P1101 ªvÀø PV ·sÃĦb¬ü°ê¤Î¨È¬wªº¤W¥«³W¹º¡C

ÃĵØÃÄ«ü¥X¡A¥Ø«e P1101 ¤w¥Ñ¼Ú¬w¹Ù¦ñ AOP ¤½¥q¦V EMA ´£¥XªvÀø PV ²Ä¤@½u¥ÎÃĤ§¤W¥«³\¥i¥Ó½Ð¥B¶i¤J¼f¬d¶¥¬q¡A¦Ó©ú¦~¤½¥q±N§â­«¤ß©ñ¦b¥[³t±À°Ê¬ü°ê¥«³õªº¦æ¾P¥¬§½¡C

¾Ú¤F¸Ñ¡AÃĵØÃÄ»P AOP ©Òñ­qªº¦X¬ù¡A¥¼¨Ó P1101 ±N¥Ñ AOP ­t³d¼Ú¬wªº¾P°â¡A¦ÓÃĵØÃıN´N¾P°âªºª¬ªp¡A©â¨ú¤@©w¾P°â¤ñ­«ªºª÷ÃB¡A¥t¥~ AOP ¤]¥²¶·±N¤U³æµ¹ÃĵØÃĤ¤¬ì¼t¶i¦æ¥Í²£¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/12/19 ¤U¤È 08:04:06²Ä 3347 ½g¦^À³
(6446)·sÃĶi¤JÅ¥µP¶¥¬q¡AÃĵØÃÄ¥[³t±À°Ê¬ü°ê¦æ¾P¥¬§½

¤é´Á¡G2017/12/19

¡i°]°T§Ö³ø¡þ¦ó¬ü¦p³ø¾É¡jÃĵØÂåÃÄ( 6446 )Ropeg(P1101)¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)¤w¶i¤JÅ¥µP¶¥¬q¡Aªñ¤é¤½¥¬ªº²Ä¤T´ÁÁ{§É«áÄòConti-PVªºÁ{§Éµ²ªG¤]¹F¼Ð¡C¸³¨Æªø¸â«C¬h¤µ(19)¤éªí¥Ü¡A¦]À³Ropeg¥¼¨Ó¦b¬ü°ê¤Î¨È¬w°ê®a¤W¥«¡A¤wµÛ¤â±j¤Æ¦æ¾P§G§½¡A²{¤]³W¹ºET(¦å¤pªO¼W¥Í¯g)ªºÀ³¥Î¡A¥Ø¼Ð©ú¦~¦V¬ü°êFDA´£¥X¤T´ÁÁ{§É¥Ó½Ð¡C

ªñ¤é¤½¥¬ªº²Ä¤T´ÁÁ{§É«áÄòConti-PVªºÁ{§Éµ²ªG¡A¤£¦ý¬Ò¹F¨ì¹w´ÁÀø®Ä«ü¼Ð¡A®Ú¾Úªø´Á°lÂܪºConti-PVÁ{§É¸ÕÅçµ²ªG§óÆ[¹î¨ìRopeg¨ã¦³¿W¯Sªº½Õ¸`¯e¯f¯à¤O¡AÃÒ¹êRopeg¬°PV±wªÌ´£¨Ñ¤F¦³»ù­È¥B¦w¥þªº²Ä¤@½uªvÀø¤è¦¡¡C

ÃĵØÃĪí¥Ü¡A¼Ú¬w¹Ù¦ñAOP¤½¥q©ó¤µ¦~2¤ë23¤é¦VEMA´£¥XP1101(°Ó«~¦WBESREMI)ªº·sÃĤW¥«³\¥i¥Ó½Ð¥B¶i¤J¼f¬d¶¥¬q¡A±µ¤U¨Ó±N¥[³t±À°ÊRopegªvÀøPV·sÃĦb¬ü°ê¤Î¨È¬w¡A¥]¬A¤é¥»¡BÁú°ê¡B¥xÆW¤Î¤¤°êªº¤W¥«³W¹º¡C¸â«C¬hªí¥Ü¡A©ú¦~±N§â­«¤ß©ñ¦b¥[³t±À°Ê¬ü°ê¥«³õªº¦æ¾P¥¬§½¡A¦P®É¤]·|³W¹ºRopeg¦bETªºÀ³¥Î¡C

°õ¦æªøªL°êÄÁªí¥Ü¡A¦b¬ü°ê¡APV¤ÎET¯f±w³q±`¬O¥Ñ°ò¼hÂåÀøÂå®v©Î¬O¥Ñ¨äÂà¶E¦Ü¦å²G¸~½F¾Ç®a¶EÂ_¥X¨Ó¡A¨Ã¥Ñ¤j«¬ÂåÀø¤¤¤ßªº¦å²G¸~½F¾Ç®aµ¹¤©ªvÀø¡C§Ú­Ì±N²v¥ý»P¯f¤Í¹Î¶¤¡BÅv«Â·N¨£»â³S«Ø¥ß¨}¦n¤¬°Ê¡ARopeg±N·|¦¨¬°ªvÀøPVªº¥D¬y¡C

¦b¬ü°ê¡A¥Ø«e¨Ï¥Î²Ä¤G½u¥ÎÃÄJakafiªºPV¯f±w¬ù¦³4,500¤H¡A¥Ø«e²Ä¤@½u¥ÎÃĪºPV¯f±w¬ù¦³85,000¤H¡A¨ä¤¤¥]¬A¦³ªñ52,000¤H¨Ï¥ÎHU¤Î¶W¹L13,000¤H¨Ï¥Î¶Ç²Î¤zÂZ¯À©ÎPegasys¡A¥¼¨ÓP1101¦¨¥\¤W¥««á¡A¦³¾÷·|¥i¨ú¥N¥Ø«e¥«­±¤Wªº¤zÂZ¯À¡A¦¨¬°¦­´ÁªvÀøªº³Ì¨Î¿ï¶µ¦¨¬°²Ä¤@­ÓFDA®Ö­ãªº²Ä¤@½u¥ÎÃÄ¡A¨Ã¦³¼ç¤O¶W¶VJakafi¾P°âªº­¿¼Æ¦¨ªø¡C

ÃĵØÃĪí¥Ü¡A¥Ø«e§Ú­Ì¦³ªñ10¦ì¸gÅçÂ×´IªºÁ{§ÉÂå®v»PÅU°Ý¨ó§U§Ú­ÌÁ{§Éªk³Wªº¶i®i¡A±N³z¹L«Ø¥ßKOL´£­Ò¹Î¶¤¡AÂX¤j¨Ã²`¤ÆRopegªº«~µP»{ª¾¡A¤½¥q¤]¦bªñ´Á©µÅóMarija Sebastian³Õ¤h¾á¥ô¬ü°ê¦æ¾P°ÆÁ`¡ADr. Sebastian¹L¥h´¿¦b¿ÕµØ»â¾ÉMF¤ÎPV¤G½u¥ÎÃÄJakavi¥þ²yªº¦æ¾P¡A¥¼¨Ó±N¥NªíÃĵØÃÄ»PÅv«ÂÂåÀø¹ÎÅ餬°Ê¡A¨Ã²ÎÄw³W¹ºRopeg©ó¬ü°ê¤Î¨È¬w¥«³õªº¦æ¾P¡C

¦¹¥~¡AÃĵØÃĤ]³W¹ºÂX¤j¨ä¥L¾AÀ³¯g¡A¨ÏRopeg¥«³õ»ù­È·¥¤j¤Æ¡A°£À³¥Î¦bªvÀøET¡A¦b¨x¯f³¡¤À¡A¥Ñ©óC¨x¦P®É¦³B«¬¨xª¢¦X¨Ö·P¬V¤§¯f¤H¦bªvÀø¤W¤´¦³¬Û·í¤jªº­·ÀI¡A¥¼¨ÓRopeg¥iÀ³¥Î¦bªvÀøB/C«¬¦X¨Ö·P¬V¯f±w¡F¦¹¥~¡A¤@¯ë¤fªAÃĤ]¸ûÃøªv¡ºC©ÊB¨x±wªÌ¡A¥¼¨ÓRopeg±N¥i¥Î©óªvÀøºC©ÊB¨x±wªÌ¡A¤×¨ä¬OªvÀøE§Ü­ì¤ÎCore§Ü­ì¶§©ÊªººC©ÊB¨x±wªÌ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/19 ¤U¤È 08:02:46²Ä 3346 ½g¦^À³
6446¡^19¤éÁ|¦æªk¤H»¡©ú·|¡AÁ`¸g²z黄¥¿¨¦ªí¥Ü¡AºX¤U·sÃÄRopeg¡]P1101,°Ó«~¦WBESREMI¡^¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^²Ä¤T´ÁÁ{§ÉConti-PV¤§Á{§É¼Æ¾Ú¤j´TÀu©ó¹ï·Ó²Õ¡A¼Ú¬w¨úÃÒ«ü¤é¥i«Ý¡A¤]¥¿»P¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¨ó°Ó¤¤¡A¥[§Ö¥Ó½ÐÃÄÃÒ¸}¨B¡A¨Ã±Ò°Ê¥þ²y¦æ¾P¥¬§½¡C

ÃĵØÃÄ19¤éªk»¡·|¥Ñ°õ¦æªøªL°êÄÁ¥D«ù¡A¥Lªí¥Ü¡ARopeg±N·|¦¨¬°ªvÀøPVªº¥D¬y¡A¤£¶È¦]¬°Ropeg¦³·¥¨Îªº¼Æ¾Ú¤ÎÁ{§Éµ²ªG°µ¤ä¼µ¡AÃĵاó²v¥ý»P¯f¤Í¹Î¶¤¡BÅv«Â·N¨£»â³S«Ø¥ß¨}¦n¤¬°Ê¡A¥´¤U¦æ¾P°ò¦¡CÃĵØ19¤éªÑ»ù¦¬146¤¸¡A¤Wº¦1¤¸¡C

Ãĵتí¥Ü¡APV±wªÌ¨Ï¥ÎRopeg¤À§OªvÀø12­Ó¤ë¡]Proud-PV¡^»P24­Ó¤ë¡]Conti-PV¡^ªº²Ä¤T´ÁÁ{§É¸ÕÅ礣¦ý¬Ò¹F¨ì¹w´ÁÀø®Ä«ü¼Ð¡A®Ú¾Úªø´Á°lÂܪºConti-PVÁ{§É¸ÕÅçµ²ªG§óÆ[¹î¨ìRopeg¨ã¦³¿W¯Sªº½Õ¸`¯e¯f¯à¤O¡AÃÒ¹êRopeg¬°PV±wªÌ´£¨Ñ¤F¦³»ù­È¥B¦w¥þªº²Ä¤@½uªvÀø¤è¦¡¡A±µ¤U¨Ó±N¥[³t±À°ÊRopegªvÀøPV·sÃĦb¬ü°ê¤Î¨È¬w¡]¥]¬A¤é¥»¡BÁú°ê¡B¥xÆW¤Î¤¤°ê¡^ªº¤W¥«³W¹º¡C

Ãĵثü¥X¡A¥Ø«e°£¼Ú¬w¹Ù¦ñAOP¤½¥q¤w¦VEMA´£¥XªvÀøPV²Ä¤@½u¥ÎÃĤ§Ropeg¤W¥«³\¥i¥Ó½Ð¥B¶i¤J¼f¬d¶¥¬q¡A¦ÓÃĵØÃÄ©ú¦~±N§â­«¤ß©ñ¦b¥[³t±À°Ê¬ü°ê¥«³õªº¦æ¾P¥¬§½¡A¦P®É¤]·|³W¹ºRopeg¦bETªºÀ³¥Î¡C

Ãĵتí¥Ü¡A¥HRopeg°µ¬°ªvÀøPVªº²Ä¤@½u¥ÎÃĦæ¾P¬ü°ê¥«³õ¾Ö¦³¤U¦CÄvª§Àu¶Õ¡A¥B¬O¥i¹F¨ìªø´Á¸Ñ½wªº°ß¤@¥i¯à©Ê·sÃÄ¡CÀu¶Õ¥]¬ARopegªø´Á¨Ï¥Î»·¤ñHU¾Ö¦³·¥¨Îªº¦w¥þ©Ê¤Î­@¨ü©Ê¡A»PPegasysµoªí¤§Á{§É¼Æ¾Ú¬Û¤ñ¡A¨ã¦³ÅãµÛ¸ûÀuªº­@¨ü©Ê¤Î¸û°ªªº³Ì¤j­@¨ü¾¯¶q¡A¥BµL¥Õ¦å¯fÂàÅܤÎÄ~µo©ÊÀù¯gªº¨Æ¥óµo¥Í¡A¤]¥i­°§CJAK2¬ðÅÜ°ò¦]­t¾á¡C

Ãĵضi¤@¨B«ü¥X¡A¦b¬ü°ê¡A¥Ø«e¨Ï¥Î²Ä¤G½u¥ÎÃÄJakafiªºPV¯f±w¬ù¦³4,500¤H¡A¥Ø«e²Ä¤@½u¥ÎÃĪºPV¯f±w¬ù¦³8.5¸U¤H¡A¨ä¤¤¥]¬A¦³ªñ5.2¸U¤H¨Ï¥ÎHU¤Î¶W¹L1.3¸U¤H¤H¨Ï¥Î¶Ç²Î¤zÂZ¯À©ÎPegasys¡A¥¼¨ÓP1101¦¨¥\¤W¥««á¡A¦³¾÷·|¥i¨ú¥N¥Ø«e¥«­±¤Wªº¤zÂZ¯À¡A¦¨¬°¦­´ÁªvÀøªº³Ì¨Î¿ï¶µ¦¨¬°²Ä¤@­ÓFDA®Ö­ãªº²Ä¤@½u¥ÎÃÄ¡A¨Ã¦³¼ç¤O¶W¶VJakafi¾P°âªº­¿¼Æ¦¨ªø¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/19 ¤U¤È 05:34:42²Ä 3345 ½g¦^À³
¥D¤OÁÙ¨S¥X§¹³f¡A©Ò¥HÁÙ¤£¯à¸ò§AÁ¿¹ê¸Ü¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/19 ¤U¤È 05:32:16²Ä 3344 ½g¦^À³
³Ì¥D­nªº¬O²Ä¤@¶¥¬qEMA ªº°ÝÃD¨ì©³³B²z±o¦p¦ó?

²Ä¤G¶¥¬q¬O¦ó®É°eFDA ?

µ²ªG³o2­ÓÃöÁä³£¨S³ø§i?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/19 ¤U¤È 05:07:58²Ä 3343 ½g¦^À³
¤½¥q¤]¦bªñ´Á©µÅóMarija Sebastian³Õ¤h¾á¥ô¬ü°ê¦æ¾P°ÆÁ`¡ADr. Sebastian¹L¥h´¿¦b¿ÕµØ»â¾ÉMF¤ÎPV¤G½u¥ÎÃÄJakavi¥þ²yªº¦æ¾P¡C

¤W­±³o¥y¸ÜÁٺ⦳«GÂI¡A¦Ü¤ÖÁYµu¬ü°ê¦æ¾P±À¼sªº¾Ç²ß¦±½u¡A«õ¨¤¦P»â°ìªºÅv«Â¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2017/12/19 ¤U¤È 05:00:34²Ä 3342 ½g¦^À³
¸¨¸¨ªø~(¼Æ¾Ú«Ü¦n¤£¬O¬Òª¾)

³£¨S¦³´£¨ì®É¶¡ªí°Ú,A®`!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/19 ¤U¤È 04:58:15²Ä 3341 ½g¦^À³
¤jº¦¹ê¦b¬O¦³Ãø«×,ÁÙ¬O¦¬½L¨£¬õ´N«Ü·P®¦¤F~
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/19 ¤U¤È 04:48:22²Ä 3340 ½g¦^À³
6446)Ä~¤é«e©ó¬ü°ê¦å²G¯fÂå¾Ç·|¦~·|¤½¥¬Ropeg(P1101)¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É«áÄòConti-PV¤§³Ì·sÁ{§Éµ²ªG¹F¼Ð¡AÅã¥ÜP1101¥i¬°PV±wªÌ´£¨Ñ¦³»ù­È¥B¦w¥þªº·s«¬ªø´ÁªvÀø²Ä¤@½u¥ÎÃÄ¡A¤½¥q¤µ(19)¤éªí¥Ü¡A°£Ä~Äò§¹¦¨ªvÀøPV·sÃĪº¼Ú·ù»P¬ü°êÃÄÃҥӽе{§Ç¥~¡A±N¥[³t¸¨¹êRopeg¥Î©óPVªº¬ü°ê¤Î¨È¬w¥«³õ¦æ¾P¥¬§½¡C

ÃĵØÃĪí¥Ü¡APV±wªÌ¨Ï¥ÎRopeg¤À§OªvÀø12­Ó¤ë(Proud-PV)»P24­Ó¤ë(Conti-PV)ªº²Ä¤T´ÁÁ{§É¸ÕÅ礣¦ý¬Ò¹F¨ì¹w´ÁÀø®Ä«ü¼Ð¡A®Ú¾Úªø´Á°lÂܪºConti-PVÁ{§É¸ÕÅçµ²ªG§óÆ[¹î¨ìRopeg¨ã¦³¿W¯Sªº½Õ¸`¯e¯f¯à¤O¡A¥iÅý¯f±w¬Ý¨ì§Æ±æ¨Ã¦bªø´ÁªvÀø®ÉÀò±o³Ì¤j§U¯q¡AÃÒ¹êRopeg¬°PV±wªÌ´£¨Ñ¤F¦³»ù­È¥B¦w¥þªº²Ä¤@½uªvÀø¤è¦¡¡A¤½¥q¬°¦¹·P¨ì¬Û·í®¶¾Ä¡A±µ¤U¨Ó±N¥[³t±À°ÊRopegªvÀøPV·sÃĦb¬ü°ê¤Î¨È¬w¡A¥]¬A¤é¥»¡BÁú°ê¡B¥xÆW¤Î¤¤°êªº¤W¥«³W¹º¡C

ÃĵØÃÄ«ü¥X¡A¥Ø«e°£¼Ú¬w¹Ù¦ñAOP¤½¥q¤w¦VEMA´£¥XªvÀøPV²Ä¤@½u¥ÎÃĤ§Ropeg¤W¥«³\¥i¥Ó½Ð¥B¶i¤J¼f¬d¶¥¬q¡A©ú¦~¤]±N§â­«¤ß©ñ¦b¥[³t±À°Ê¬ü°ê¥«³õªº¦æ¾P¥¬§½¡A¦P®É¤]·|³W¹ºRopeg¦bETªºÀ³¥Î¡F¤½¥q°õ¦æªøªL°êÄÁªí¥Ü¡A¬Û«HRopeg±N·|¦¨¬°ªvÀøPVªº¥D¬y¡A¤£¶È¦]¬°Ropeg¦³·¥¨Îªº¼Æ¾Ú¤ÎÁ{§Éµ²ªG°µ¤ä¼µ¡A¥D­n§ó¬O²v¥ý»P¯f¤Í¹Î¶¤¡BÅv«Â·N¨£»â³S¤w«Ø¥ß¨}¦n¤¬°Ê¡C

ÃĵØÃĪí¥Ü¡A¥HRopeg°µ¬°ªvÀøPVªº²Ä¤@½u¥ÎÃĦæ¾P¬ü°ê¥«³õ¾Ö¦³¤U¦CÄvª§Àu¶Õ¡A¥B¨ä¬O¥i¹Fªø´Á¸Ñ½wªº°ß¤@¥i¯à©Ê·sÃÄ¡A¥]¬AµL½×¦b¦å²G¾Ç¡B¤À¤l¥Íª«¾Ç¤ÎÁ{§É¤ÏÀ³¤W¡A¬ÒÅã¥Ü¨ä¥H¤T´ÁÁ{§Éªø»·Àø®ÄÃÒ©úÀu©ó²{¦³ªºªvÀø¤è¦¡¡Fªø´Á¨Ï¥Î»·¤ñHU¾Ö¦³·¥¨Îªº¦w¥þ©Ê¤Î­@¨ü©Ê¡F»PPegasysµoªí¤§Á{§É¼Æ¾Ú¬Û¤ñ¡A¨ã¦³ÅãµÛ¸ûÀuªº­@¨ü©Ê¤Î¸û°ªªº³Ì¤j­@¨ü¾¯¶q¡FProud/Conti-PVÁ{§É¼Æ¾ÚÅã¥Ü¡AµL¥Õ¦å¯fÂàÅܤÎÄ~µo©ÊÀù¯gªº¨Æ¥óµo¥Í¡F¥i­°§CJAK2¬ðÅÜ°ò¦]­t¾á¡B¥i¸Ñ½w¯e¯f¡F¤À§O¨ü¨ì¬ì¾Ç¿Ô¸ß©e­û·|¡A¥H¤Î¯f¤Í·|¹ï¤zÂZ¯Àªº·¥¤O¤ä«ù¡F¦h¦ì«ÂÅv·N¨£»â³S°Ñ»P¬ü°êIITÁ{§É¸ÕÅç¤Î®¦·OÀøªk¡F¨ä±N´£¨Ñ·sªºPV¤ÎETªºªvÀø¤è°w¡A¥ç¥i©M©ñ¦å¤@°_°µ¬°¦­´ÁªvÀø¡C

ÃĵØÃÄ«ü¥X¡A¦b¬ü°ê¡APV¤ÎET¯f±w³q±`¬O¥Ñ°ò¼hÂåÀøÂå®v©Î¬O¥Ñ¨äÂà¶E¦Ü¦å²G¸~½F¾Ç®a¶EÂ_¥X¨Ó¡A¨Ã¥Ñ¤j«¬ÂåÀø¤¤¤ßªº¦å²G¸~½F¾Ç®aµ¹¤©ªvÀø¡A¦Ó¦b¬ü°ê¦³31®aMPN¤¤¤ß¡A¯f±w¥i¦b¶EÂ_«á±µ¨ü¤¤¤ßªº±M·~ª¾ÃÑ©MªvÀø¡AµM¦Ó¡A¬ü°ê¦å²G¸~½F¾Ç®a»{¬°¡A¦b¥Ø«e²{¦æ¥i¥ÎªºÃĪ«ªvÀø¤U¡APV¯f±wÁÙ¦³«Ü¦h¥¼³Qº¡¨¬ªºÂåÃĻݨD¡A¥D­n¬O¦]¬°¦bÁ{§É¤WÆ[¹î¨ì¦å®ê®ê¶ëªº­·ÀI°ª¡A³y¦¨¤ß¦åºÞ·N¥~µo¥Í¡A©Ò¥H¤j³¡¤ÀÂå®vªºªvÀøµ¦²¤¬O¿n·¥¹w¨¾¤ß¦åºÞ·N¥~µo¥Í¡C

ÃĵØÃĶi¤@¨B«ü¥X¡A¦b¬ü°ê¥«³õ¡A¥Ø«e¨Ï¥Î²Ä¤G½u¥ÎÃÄJakafiªºPV¯f±w¬ù¦³4,500¤H¡A¥Ø«e²Ä¤@½u¥ÎÃĪºPV¯f±w¬ù¦³85,000¤H¡A¨ä¤¤¥]¬A¦³ªñ52,000¤H¨Ï¥ÎHU¤Î¶W¹L13,000¤H¨Ï¥Î¶Ç²Î¤zÂZ¯À©ÎPegasys¡A¥¼¨ÓP1101¦¨¥\¤W¥««á¡A¦³¾÷·|¥i¨ú¥N¦b¥Ø«e¥«­±¤Wªº¤zÂZ¯À¡A¦¨¬°¦­´ÁªvÀøªº³Ì¨Î¿ï¶µ¡B¦¨¬°²Ä¤@­ÓFDA®Ö­ãªº²Ä¤@½u¥ÎÃÄ¡A¨Ã¦³¼ç¤O¶W¶VJakafi¾P°âªº­¿¼Æ¦¨ªø¡C

ÃĵØÃĪí¥Ü¡A¥Ø«e¤½¥q¦³ªñ10¦ì¸gÅçÂ×´IÁ{§ÉÂå®v»PÅU°Ý¨ó§UÁ{§Éªk³W¶i®i¡A¥]¬ADr. Richard Silver¡BDr. Srdan Verstovsek¤ÎDr. Ruben Mesaµ¥¡A¨ä¤¤Dr. Mesa§ó¬O¬ü°êNCCN guideline¤§MPN¤p²Õ¥D®u¡A¹ïÁ{§ÉªvÀøÁͶլO¨ã¦³¼vÅT¤OªºÃöÁä¤H¤h¤§¤@¡A°£¤F¦³¹ê¤O°í±jªºÅU°Ý¹Î°µ«á¬Þ¥~¡A¥Ñ©ó©t¨àÃĪº¾P°â¼Ò¦¡¤£¦P©ó¤@¯ë±M§QÃĪ«¡A¦]¦¹¤½¥q±N³z¹L«Ø¥ßKOL´£­Ò¹Î¶¤¡AÂX¤j¨Ã²`¤ÆRopegªº«~µP»{ª¾¡A¬Û«HRopeg·|«P¨ÏÃĵØÃĦ¨¬°¬ü°êPV¤ÎETÃĪ«¥«³õªº»â¾ÉªÌ¡C

ÃĵØÃĶi¤@¨Bªí¥Ü¡A±N´£¤É»PÂå¥Í¤ÎÂåÀøºôµ¸³sµ²¡A¨Ã¦b¬ü°ê«Ø¥ßPV¿Ô¸ß©e­û·|¨Ã¶i¦æ¥þ°ê©Ê¤Î¦a¤è©Êªº±MÃD¬ã°Q·|»PºtÁ¿¡B¬ã¨sµoªí­pµe¡B°õ¦æÃöÁ䪺Á{§É¸ÕÅç¡A±À¼sRopeg¬OªvÀøPVªº²Ä¤@½uÃĪ«¥H¨ú¥NHUªº«~µP§Î¶H¡A¨ÃÂX¤jRopegªº¥«¥e²v¡A¦³Å²©ó¦¹¡A¤½¥q¤]¦bªñ´Á©µÅóMarija Sebastian³Õ¤h¾á¥ô¬ü°ê¦æ¾P°ÆÁ`¡ADr. Sebastian¹L¥h´¿¦b¿ÕµØ»â¾ÉMF¤ÎPV¤G½u¥ÎÃÄJakavi¥þ²yªº¦æ¾P¡A¥¼¨Ó±N¥Nªí¤½¥q»PÅv«ÂÂåÀø¹ÎÅ餬°Ê¡A¨Ã²ÎÄw³W¹ºRopeg©ó¬ü°ê¤Î¨È¬w¥«³õªº¦æ¾P¡C

¦¹¥~¡AÃĵØÃÄ¥ç«ü¥X¡A¤½¥q±N³W¹ºÂX¤j¨ä¥L¾AÀ³¯g¡A¨ÏRopeg¥«³õ»ù­È·¥¤j¤Æ¡A°£À³¥Î¦bªvÀø¦å¤pªO¼W¥Í¯g¡A¦b¨x¯f³¡¤À¡A¤]±NÀ³¥Î¦b¹ï¯f¤H³Ì¦³®Äªº±Ú¸s¡A¦b¼sŪ¤åÄm¤Î»PÅv«Â»â³SÂå®v°Q½×«á¡AÁö¥Ø«e¤fªA¤p¤À¤lÃĪ«ªv¡²v¤w¬Û·í°ª¡A¦ýC¨x¦P®É¦³B«¬¨xª¢¦X¨Ö·P¬V¤§¯f¤H¡A¦bªvÀø¤W¤´¦³¬Û·í¤jªº­·ÀI¡A¥¼¨ÓRopeg¥iÀ³¥Î¦bªvÀøB/C«¬¦X¨Ö·P¬V¯f±w¡F¦¹¥~¡A¤@¯ë¤fªAÃĤ]¸ûÃøªv¡ºC©ÊB¨x±wªÌ¡A¥¼¨ÓRopeg±N¥i¥Î©óªvÀøºC©ÊB¨x±wªÌ¡A¤×¨ä¬OªvÀøE§Ü­ì¤ÎCore§Ü­ì¶§©ÊªººC©ÊB¨x±wªÌ¡A¦b³oÃþ¯f¤H¡A¤åÄmÅã¥Ü¨ä¦³®Ä©Ê¥i¹F60~70%¡A¬°¤@¯ëB¨x±wªÌªº2~3­¿¥H¤W¡A¦Ó­@¨ü©Ê¤]¸ûPegasys§ó¦n¡C

ÃĵØÃħó«ü¥X¡A¦Û¥D¶}µoªºRopeg¬O¤@ºØ¥þ·sªºalfa-2bªø®Ä«¬¤zÂZ¯À¡A±ÄÂù©Pª`®g¤@¦¸¡A¥B¸g¥Ñ¤wª¾ªºªvÀøPV¤§ÃöÁä»P«áÄò¤T´ÁÁ{§É¸ÕÅç¡B¤w§¹¦¨ªºªvÀøB¨x¤§¤G´ÁÁ{§É¸ÕÅç¡A¥H¤Î°õ¦æ¤¤ªº¤G­ÓªvÀøC¨x¤§¤G´ÁÁ{§É¸ÕÅç¡A¬ÒÅã¥ÜRopeg¬O¦w¥þ¥B¾Ö¦³¸û°ªªº­@¨ü©Ê¡B¸û§Öªº¯f¬r¤ÏÀ³²v¥H¤Î§C°Æ§@¥Î¡A«D±`¦³¾÷·|¦¨¬°ºC©Ê¨xª¢¯f±w¥ÎÃĪº·s¿ï¾Ü¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/19 ¤U¤È 04:33:50²Ä 3339 ½g¦^À³
ǢǢǢ

©ú¤Ñ­Y¤jº¦´Nµ¹¥¦©ç©ç¤â

­Y¨Sº¦¦A§â¥¦¥s¥X¨Ó½|¤@½|

¤Ï¥¿¶¢µÛ¤]¶¢µÛ¡D¡D¡D

¦³¥hªº¤H¥á¨Ç°T®§¥X¨Ó»D­»«§

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/19 ¤U¤È 03:45:11²Ä 3338 ½g¦^À³
ªk»¡·|«eº¦1¶ô¿úÅý§A­Ì¶R«O·x¦çªA¡AÁÙ¤£§Ö¤U¸÷ÁÂ¥D¶©®¦¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±i±M­û10145380  µoªí®É¶¡:2017/12/19 ¤U¤È 03:17:07²Ä 3337 ½g¦^À³
À³¸Ó»¡¦b¤£¨}¤ÏÀ³ªº¬Y¨Ç³¡¥÷¦p~GGT¡F¤º¤Àªc¥¢½Õ¡Fºë¯«»Ùê¡F¤ßŦ/¦åºÞ¡K¡K

P1101¦H©óHU

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±i±M­û10145380  µoªí®É¶¡:2017/12/19 ¤U¤È 03:01:32²Ä 3336 ½g¦^À³
©Ò¥H~³Ì±`¨£ªº¤£¨}¤ÏÀ³¤è­±

P1101¦H©óHU?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2017/12/19 ¤W¤È 11:56:05²Ä 3335 ½g¦^À³
¯÷½Ķ¥þ¤å¦p¤U, ¨Ñ¦U¦ì§ë¸ê¥ý¶i°Ñ¦Ò¡C

Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera

·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101 ¦bPV¾AÀ³¯g¤W¦³µÛªø´Á®Ä¯q

Published Online: 11:01 AM, Fri December 15, 2017

µo¥¬®É¶¡¡G 2017,12,15 ¬P´Á¤­

A novel pegylated formulation of interferon alfa-2b achieved a significantly higher rate of complete hematologic response (CHR) compared with hydroxyurea (Hydrea) in patients with polycythemia vera (PV), according to 2-year findings from the follow-up phase III CONTI-PV randomized trial.1

®Ú¾ÚÁ{§É¤T´Á©µ¦ù©ÊªºCONTI-PVÀH¾÷©Ê2¦~´Á¦¨ªG¤¤¥i¥Hµo²{, ·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101©MHU¬Û¤ñ¦³µÛÅãµÛªº°ª¦å²G¾Ç¤ÏÀ³²v(CHR)¡C

After 24 months of treatment and follow-up, patients treated with ropeginterferon alfa-2b had a CHR rate of 70.5% versus 49.3% with hydroxyurea (P = .0101). Ropeginterferon alfa-2a achieved the composite endpoint of CHR and improved disease burden in 49.5% of patients versus 36.6% for hydroxyurea, a difference that did not reach statistical significance (P = .1183).

¦b24­Ó¤ëªºÁ{§É°lÂÜ«á¥i¥H¬Ý¨ì, ¬Û¸û©óHU²Õªº49.3% §¹¥þ¦å²G¾Ç¤ÏÀ³²v(CHR Rate), P1101²Õ¦³µÛ70.5%ªº§¹¥þ¦å²G¾Ç¤ÏÀ³(P­È = 0.0101)¡C¦b½Æ¦XºÝÂI«ü¼Ð ¡]composite endpoint¡A§t§¹¥þ¦å²G¾Ç¤ÏÀ³²v¤Î¯e¯f¯gª¬ªº§ïµ½)¤W¡AP1101 ²Õ¹F49.5¢H ¡A¦ÓHU²Õ¬°36.6¢H (p = 0.1183), ¦ý²Î­p«ü¼Ð¥¼¹F¨ìÅãµÛ®t²§(P= 0.1183)

Ropeginterferon alfa-2a also achieved partial molecular response almost twice as often as the long-time standard therapy, as reported at the 2017 ASH Annual Meeting in Atlanta.

¦p¨È¯SÄõ¤j2017¦~¦å²G¦~·|(ASH)¤W©Ò³ø¾Éªº¡A·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101ªº³¡¤À¤À¤l¤ÏÀ³´X¥G¬Oªø´Á¼Ð·ÇªvÀøªº¨â­¿¡C

¡§Ropeginferferon alfa-2b appears more efficacious than hydroxyurea in the long run, showing high and durable hematological responses and symptom improvement,¡¨ said Heinz Gisslinger, MD, professor of hematology at the Medical University of Vienna in Austria. ¡§The safety and tolerability of ropeginterferon alfa-2b remain excellent beyond the second year of treatment.

¶ø¦a§Qºû¤]¯ÇÂå¬ì¤j¾Ç¦å²G¾Ç±Ð±ÂHeinz Gisslinger³Õ¤h»¡¡G¡§ªø´Á¨Ó¬Ý¡A·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¤ñHU§ó¦³®Ä¡A§e²{°ª«×¥H¤Îªø®Äªº¦å²G¾Ç¤ÏÀ³¥H¤Î¯gª¬§ïµ½¡C¡§·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101ªº¦w¥þ©Ê©M­@¨ü©Ê¦b²Ä¤G¦~ªvÀø«á¤´µM«Ü¦n¡C

¡§The unique disease modification capability of interferon and its potential to improve progression-free survival are suggested by the observed effects on mutant JAK2 and other molecular markers.¡¨

±q¹ïJAK2¬ðÅÜ¥H¤Î¨ä¥L¤À¤l¼Ð°Oªº¼vÅT©ÊÅã¥Ü¥X¡A¤zÂZ¯À¿W¯Sªº¯e¯f­×¹¢¯à¤O¤Î¨ä´£°ªµL´c¤Æ¦s¬¡®É¶¡(PFS)ªº¼ç¤O¡C

Used since the 1980s to treat PV, interferons have consistently achieved high rates of hematologic response and improved other clinical outcomes. Ropeginterferon alfa-2b is a monopegylated formulation of interferon alfa-2b administered every 14 days initially and then once monthly during long-term maintenance treatment. The phase II PEGINVERA study demonstrated the feasibility, efficacy, and tolerability of long-term maintenance therapy with ropeginterferon alfa-2b for PV.

¦Û1980¦~¥N°_¤zÂZ¯À¥Î©óªvÀøPV¶}©l¡A¤zÂZ¯À«ùÄò¹F¨ì°ªªº¦å²G¾Ç¤ÏÀ³²v¨Ã§ïµ½¤F¨ä¥LÁ{§Éµ²ªG¡C·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¬O³æ¤@¤Æ¦Xª«ªº¤zÂZ¯Àalfa-2b¡Aªì´Á¬°¨C14¤Ñª`®g¤@¦¸±µµÛ¦bªø´Áºû«ùªvÀø´Á¶¡¨C¤ëª`®g¤@¦¸¡CÁ{§É¤G´Á¸ÕÅçPEGINVERA¬ã¨s¤¤, ÃÒ©ú¤F¨Ï¥Î·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¦bPV¾AÀ³¯g¤WªºªvÀø§e²{ªø´Áªº¥i¦æ©Ê¡B¦³®Ä©Ê©M­@¨ü©Ê¡C

Gisslinger reported findings from a continuation phase of the randomized phase III PROUD-PV trial, which compared outcomes after 12 months of treatment with ropeginterferon alfa-2b and hydroxyurea. Patients in the control arm were also able to switch to best available therapy instead of hydroxyurea at the investigators discretion.

Gisslinger¹ï©óÀH¾÷©ÊÁ{§É¤T´ÁPROUD-PV¸ÕÅ窺«ùÄò¶¥¬q¦¨ªG¶i¦æ³ø§i, ¸Ó¸ÕÅç¹ï©ó12­Ó¤ë«áP1101²Õ©MHU²Õªºµ²ªG¶i¦æ¤ñ¸û¡C¹ï·Ó²Õªº¯f±w¥i¥H®Ú¾Ú¬ã¨sªÌ§PÂ_§ï¥Î³Ì¨ÎªvÀø¤è®×¦Ó«DHU¡C

At the 12-month landmark, ropeginterferon alfa-2b demonstrated noninferiority to hyaluronic acid, achieving a CHR rate of 43.1% as compared with 45.6% for the control arm. As reported at the 2016 ASH Annual Mee

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/19 ¤W¤È 09:52:20²Ä 3334 ½g¦^À³
«Ü¦hºô¯¸Åã¥Ü¬Q¤Ñ¥~¸ê¶R3±i½æ1±i¡A¶R¶W2±i¡A¬O¤£¬O¦³²Î­p¿ù»~?

Âd¶R¨é°Ó¶i¥XÅã¥Ü¤j¼¯©M¤j©M°ê®õ´N¶R¦n´X¤Q±i¤F¡A«ç»ò¥i¯à2±i?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/18 ¤U¤È 10:16:11²Ä 3333 ½g¦^À³
¥­±`¤ß¬Ý«Ý©ú¤Ñªºªk»¡^_^

´N·í§@½m­@¤ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/18 ¤U¤È 08:39:43²Ä 3332 ½g¦^À³
¦pªG¦³¥h°Ñ¥[ªº¤j¤j,¥i¤£¥i¥H½Ð°Ý¤½¥q¤@¤U

¥H¥Ø«e¤½¥¬¤G¦~¼Æ¾Ú,ºâ¬Û·í¤£¿ù,4¤ë¤¤¤G¦~Á{§É¤w§¹¦¨

²z·íÀ³¸Ó9-10¤ë,´N¯à§¹¦¨¼Ú·ù°ÝÃD,©M°e¬ü°ê¥Ó½ÐÃÄÃÒ

¬°¦ó¿ð¿ð¤£¨£°Ê§@,·U±ß¤@¤Ñ±M§QÅv´N¤Ö¤@¤Ñ

¹ê¦b¹ï¤½¥qªº°õ¦æ¤O·P¨ìºÃ°Ý

·PÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gttseng1310145885  µoªí®É¶¡:2017/12/18 ¤U¤È 08:10:58²Ä 3331 ½g¦^À³
¼ç¤ô¤F¦n¤[ ¤â¤WªºÃĵئѦ­´N¶R¤Fº¡¤â

©ú¤Ñ¤]·|¥h°Ñ¥[ªk»¡·| §Æ±æ¤½¥q¯àÄÀ¥X¨Î­µ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/12/18 ¤U¤È 06:47:13²Ä 3330 ½g¦^À³
¹ï©ó©ú¤Ñªºªk»¡.....¦Ñ¸Ü¤@¥y

¨S¦³´Á«Ý´N¨S¦³¶Ë®`......

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü«Â10140483  µoªí®É¶¡:2017/12/18 ¤U¤È 06:31:20²Ä 3329 ½g¦^À³
½Ð°Ý¤½¥q¦³®ø®§¤°»ò®É­Ô·|¦^ÂÐEMA°ÝÃD¶Ü?12/22¤w¸g§Ö¨ì¤F,¦å²G¦~·|ªºdata¤]¦­´N¥X¨Ó¤F,·|©ì¨ì³o»ò«á­±¬O¦^µª¤£¥X¨ÓÁÙ¬O¦³¤°»ò¦Ò¶q¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°¶¤j¤j10136951  µoªí®É¶¡:2017/12/18 ¤U¤È 05:24:27²Ä 3328 ½g¦^À³
©ú¤Ñªk»¡·|¦@Á¸²±Á|

®É¶¡: 106/12/19 14 ®É 00 ¤À

¦aÂI¡G°ê®õ«Ø³]¤j¼Ó¡]¥x¥_¥«´°¤Æ«n¸ô2¬q218¸¹12¼Ó¡^

¾Ü­n°T®§¡G¤½¥qÀç¹B¦¨ªG¤Î¥¼¨Ó®i±æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/18 ¤W¤È 08:23:49²Ä 3327 ½g¦^À³
¤d±i¤j¤áÄw½X«ùªÑÄ~Äò´î¤Ö¡A´²¤á«ùªÑ¤ñ¦³¦b¼W¥[¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/17 ¤U¤È 03:54:03²Ä 3326 ½g¦^À³
Interferons: a promising potential therapy for MPN

µo§G¤é´Á¡G2017¦~7¤ë28¤é

https://www.youtube.com/watch?v=TUzSDQISwKk

Ruben Mesa, MD, FACP, from the Mayo Cancer Clinic Center, Rochester, MN, USA, provides us an insight into the potential of treating patients with myeloproliferative neoplasms (MPN) with interferons. Here, he discusses the PROUD-PV study (NCT01949805), a Phase III trial comparing the efficacy and safety of the novel interferon AOP2014 against hydroxyurea in treating polycythemia vera, and notes that there may be selectivity in the interferon for clones of MPN. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/12/17 ¤U¤È 01:07:06²Ä 3325 ½g¦^À³
Dr. Brady Stein ¬O¬ü°êMPN¨â¤jÅv«Â¥~¡Aªñ´X¦~³vº¥¹ñÅSÀY¨¤ªº·s¨q(´¿¨üDr. Ruben Mesa«ü¾É)¡A¤]¬O¥Ø«eNCCN Guidelines-MPN¤p²Õ¦¨­û¤§¤@¡C

¦b¤W¶gOncLiveªº³o½g³ø¾É¤¤¡A¥L½Í½×¤F²{¦æ¬ü°êNCCN Guidelines-MPNªº·§ªp¡A«Ü­È±o¤@Ū¡C

Expert Discusses Guidelines, Next Steps With MPNs

www.onclive.com/web-exclusives/expert-discusses-guidelines-next-steps-with-mpns

¸`¿ýPV³¡¤Àªº¨â¬q¸Ü:

The next is PV. What is different in the 2016 and 2017 range are the changing diagnostic criteria. The hemoglobin threshold has been lowered, so that we¡¦re not missing cases of PV. It¡¦s important to make a proper diagnosis because there¡¦s a natural therapeutic [pattern] that will follow if we confirm the diagnosis of PV. Here we have guideline representation to help outline about the hematocrit target with phlebotomy, the use of aspirin, and which patients might be candidates for cytoreduction. It is so important. In terms of therapies for PV, hydroxyurea is widely used. It¡¦s not necessarily used based on evidence; its use is based on experience and a lack of other good options.

There are other options that are currently being studied. One, of course, is pegylated interferon. There are important, randomized, phase III, high-quality studies comparing this class of medications to hydroxyurea. Having evidence to decide on first-line therapy is important for PV. Second-line therapies are well defined. With ruxolitinib (Jakafi)¡Xthere are data to use this as a second-line therapy in the small number of patients in whom hydroxyurea is inadequate. In terms of other agents, there are more agents in development for PV than there are certainly in ET and not as many in myelofibrosis. However, we are slowly changing to new developments and, hopefully, we will have approved drugs for the frontline setting. We already have an approved drug for the second-line setting.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/16 ¤W¤È 11:03:26²Ä 3324 ½g¦^À³
www.tccf.org.tw/old/medecine/nm_3_2.htm
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/12/16 ¤W¤È 11:03:03²Ä 3323 ½g¦^À³
Targeted Oncologyªº³ø¾É: («D¤½¥q·s»D½Z)

www.targetedonc.com/conference/2017-ash-mpn/ropeginterferon-alfa2b-has-longterm-benefits-in-polycythemia-vera

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/16 ¤W¤È 10:48:56²Ä 3322 ½g¦^À³
norway.twsthr.info/StockHolders.aspx?stock=6446

®Ú¾Ú¤W­z¸ê®Æ

>400±iªºªÑªF´î¤Ö¤F87±i®w¦s

©M²Ä¤@ª÷°ª¶¯¤W©P½æ¥Xªº±i¼Æ®t¤F26±i

¥Nªí>400±i¤jªÑªF¦³¤H½wºC§C±µ

§Ú¬Û«H¨ä¥L¤pÃB§ë¸ê¤H¬O¤£·|¦A¥[½X¤F

¯à§_§l¤Þ¨ä¥Lªk¤H¶R½L¤~¬O­«ÂI

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/16 ¤W¤È 08:21:27²Ä 3321 ½g¦^À³
ASH 2017 Coverage: An Interferon Update From an MPN Expert

Published on December 15, 2017

https://patientpower.info/video/ash-coverage-an-interferon-update-from-an-mpn-expert

As part of our coverage of the 2017 American Society of Hematology (ASH) meeting in Atlanta, Dr. Srdan Verstovsek, an MPN expert and researcher from MD Anderson Cancer Center, provides an update on the latest news from the conference. Dr. Verstovsek provides details about a new treatment being studied for anemia in patients with myelofibrosis as well as the two-year results of a European study of interferon for polycythemia vera (PV) treatment. Tune in to learn more. 

Sponsored by PharmaEssentia.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Goblongata10141266  µoªí®É¶¡:2017/12/16 ¤W¤È 12:02:39²Ä 3320 ½g¦^À³
·PÁ¤pªL¥S´£¨Ñ¡AÃöÁä³Ì«á¤@¥y¸Ü

(Professor Ruben Mesa)

¡uAt the moment our current US guidelines say interferon or hydroxyurea as the physician and the patient choose. But this may leads more toward IT REALLY SHOULD BE INTERFERON.¡v

¬Ý¨Ó²Ä¤@½u¥ÎÃÄ & Âå®v¥ÎÃÄ·Ç«h

«ü¤é¥i«Ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/15 ¤U¤È 07:54:02²Ä 3319 ½g¦^À³
¤pªL¤j¤j¡K

´N¦n¤ß¤@ÂI¡AÀ°¤j¥ë­«ÂI½Ķ¤@¤U¡C

·P®¦吔¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/12/15 ¤U¤È 07:33:39²Ä 3318 ½g¦^À³
ASH¦å²G¯e¯f¦~·|«á¡A²Ä¤@­Ó°w¹ïMPN»â°ìªº±M®aµû½×³ø¾É¡C

patientpower.info/video/mpn-news-from-ash-headlines-and-updates-from-an-expert-panel

¼v¤ù²Ä6:25¦Ü7:30¤ÀÄÁ¡A¬°¬ü°êMPN¨â¤jÅv«Â·N¨£»â³S¤§¤@ Dr. Ruben Mesa (¦P®É¬°¬ü°êNCCN Guidelines-MPN¤p²Õªº¥D®u)¡A°w¹ïropeginterferon³Ì·sÁ{§Éµ²ªGªºµû½×¡A©M¹ï«áÄòNCCN Guidelineªº¬Ýªk(³Ì«á¤@¥y¸Ü¬OÃöÁä)¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/15 ¤U¤È 04:23:47²Ä 3317 ½g¦^À³
¤ô°Õ

¤£¹L

³oºØ­W¤é¤lÀ³¸Ó¤£¦h¨£¤F

©Ò¥H­Y­n­W¤¤§@¼Ö­n¤Î®É

¤@¦~«á¤j®a¤@©w·|Ãh©À¥¦ÁÙ¬O1¦Ê¦h¤¸ªº·³¤ë

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/12/15 ¤U¤È 03:42:24²Ä 3316 ½g¦^À³
¤j½L¥ð¥«¡AÃĵض^......

³o­Ó¦³¦n¯º.......§Ú¤]±µ¤@­Ó....

¤j½L·s¬K¶}¬õ½L....Ãĵض^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/12/15 ¤U¤È 02:46:10²Ä 3315 ½g¦^À³
¤½§i¥»¤½¥q¨üÁÜ°Ñ¥[°ê®õÃÒ¨éÁ|¿ì¤§ªk¤H»¡©ú·|

²Å¦X±ø´Ú²Ä¥|±ø²ÄXX´Ú¡G12

¨Æ¹êµo¥Í¤é¡G106/12/19

1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G106/12/19

2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G14 ®É 00 ¤À

3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G°ê®õ«Ø³]¤j¼Ó¡]¥x¥_¥«´°¤Æ«n¸ô2¬q218¸¹12¼Ó¡^

4.ªk¤H»¡©ú·|¾Ü­n°T®§¡G¤½¥qÀç¹B¦¨ªG¤Î¥¼¨Ó®i±æ

5.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡GµL

§¹¾ã°]°È·~°È¸ê°T½Ð¦Ü¤½¶}¸ê°TÆ[´ú¯¸¤§ªk¤H»¡©ú·|¤@Äýªí©Îªk»¡·|¶µ¥Ø¤U¬d¾\¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/15 ¤U¤È 12:35:39²Ä 3314 ½g¦^À³
¦³¤H·|¥h¤U¶gªºªk»¡¶Ü?
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/15 ¤W¤È 10:49:19²Ä 3313 ½g¦^À³
¤p°¨¤j.¬OµR¤û¥Ö~

­Ë¬O¯E¹©¤S¥´¦^­ì§Î·Ç³Æ¦V¤U¤F~

«e´X¤Ñªº¯E¹©¸ò¤¤¸Îªº¤jº¦,À³¸Ó¬O¤H¬°©ïÃâ§a~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/15 ¤W¤È 10:23:46²Ä 3312 ½g¦^À³
ǢǢǢ

¯u¤û¥Ö

¤@¼Ë¦n¦Y¡A¦nºÎ¡A¯¬¦n¹B¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/15 ¤W¤È 09:56:28²Ä 3311 ½g¦^À³
¤j½L¤j¶^¡AÃĵض^

¤j½L¤jº¦¡AÃĵض^

¤j½L½L¾ã¡AÃĵض^

¤j½L¥ð¥«¡AÃĵض^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2017/12/15 ¤W¤È 08:45:50²Ä 3310 ½g¦^À³
ÃĵطsÃÄ©é½æ¦V¬ü°ê

2017-12-15 03:07¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É

ÃĵØÂåÃÄ¡]6446¡^¥»¤ë19¤é±NÁ|¦æªk»¡·|¡A±N»¡©úºX¤U¨u¯f¦å²G·sÃÄP1101»P¹ï·Ó²ÕHU¹ï·Óªº¡uÁ{§É¤T´Áb¶¥¬q¸ÕÅç¡v¡]Phase IIIb¡^µ²ªG¥H¤Î¥¼¨Ó¦V¬ü°ê¥Ó½ÐÃÄÃÒªº³Wµe¡A¹w´Á¤]±N·|´¦ÅS¸Ó²£«~¦b¬ü°ê¾P°âªº­pµe¡C

Ãĵتí¥Ü¡A¸g¹L24­Ó¤ëªº´ú¦¡¡AÅã¥ÜP1101¬°ªø´ÁªvÀø PV ¯f±w´£¨Ñ§ó¨ã»ù­È¥B¸û¨ÎªºªvÀø§Î¦¡¡A¸Ó¤½¥q®Ú¾ÚÁ{§É±M®aµû¦ô¡A±N·m§ð²Ä¤@½u¥ÎÃÄ¡C

P1101¬O¤@­Ó³Ð·sªº¡Bªø®Äªº¡B³æ¤@»E¤A¤G¾Jªº²ãÓi»Ä¤zÂZ¯À¡A¨C¨â©P¬I¥´¤@¦¸¡Aªø´Á¨Ï¥Î¥i¥H©µªø¨ì¨C¤ë¬I¥´¤@¦¸¡A±N¥i¦¨¬°¥þ²y²Ä¤@­Ó³Q®Ö­ã¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV) ªº³Ð·sªø®Ä¤zÂZ¯À¡C

Ãĵتñ´Á¦b2017¦å²G¦~·|(ASH) «Å¥¬¥¿¦b¶i¦æªº CONTI-PV¤§³Ìªñµ²ªG¡ACONTI-PV§Y¸Ó¤½¥q¹Ù¦ñAOP¦b¼Ú¬w©Ò°õ¦æªºPhase IIIb¸ÕÅç¡C

Ãĵذõ¦æªøªL°êÄÁªí¥Ü¡A¸Ó¤½¥q¤U¤@¨B¤]·|¦V¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^´£¥XBLA¡]¥Íª«»s¾¯¤W¥«¼f¬d¡^¥Ó½Ð¡C

Ãĵثü¥X¡ACONTI-PV ¬°¶}©ñ©Ê¡A¦h°ê¦h¤¤¤ßªºPhase IIIbÁ{§É¸ÕÅç¡A¸Ó¸ÕÅç«Y°w¹ï¥ý«e°Ñ»P¼Ï¯ÃÁ{§É¤T´Á PROUD-PV ªº±wªÌ¡A¨Ï¥Î P1101 ¬Û¸û©ó¨Ï¥Î Hydroxyurea (HU) ©Î³Ì¨Î¥i¥ÎªvÀø¥ÎÃĪºªø´ÁÀø®Ä¤Î¨ä¦w¥þ©Êµû¦ô¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/14 ¤U¤È 05:03:38²Ä 3309 ½g¦^À³
¦w¥S:

¤H®a¨º»ò¨¯­W¨ÓÅU½LÁÙ³Q§A¾´¡K

²ö«D¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/14 ¤U¤È 01:32:16²Ä 3308 ½g¦^À³
¨C¤Ñ³£¦b©Ô§À½L¡A¤â¤£·|»Ä¶Ü? «¢«¢«¢¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2017/12/14 ¤W¤È 11:31:50²Ä 3307 ½g¦^À³
¬ü°ê¹ï·sÃħë¸ê¤ñ¥xÆW¦n¡A¦ýIncyteªÑ²¼¥Ó½ÐÃÄÃÒ«á¤@¼Ë¶^¤F¤@¬q¡A½L¾ã¤F¤@¦~¡A¥~°êªº¤ë«G¤ñ¸û¶ê¶Ü?

¤j·§·|¦³¤H¦b·Q¡A¥Ó½ÐÃÄÃÒ´N¤@©wº¦¡A³oºØ½L¾ã¥Nªí¤£¥¿±`? ¬Ý¬Ý¬ü°êIncyteªºªÑ»ù¡A2014¦~ÃÄÃҥӽЫá¤@¼Ë¤U¶^¡A½L¾ã¤@¦~¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¬K©M´º©ú10141799  µoªí®É¶¡:2017/12/14 ¤W¤È 10:39:33²Ä 3306 ½g¦^À³
¬ü°êIncyteªÑ²¼¤]¬O¦b2014¦~ªì¥Ó½ÐJakafi¬ü°ê¤G½uÃÄÃÒ«á¤U¶^½L¤F¤@¾ã¦~¡A¨ì¦~©³®³¨ìÃÄÃÒ«á¤~¤Wº¦¡AµM«á¤@¸ô¦V¤W¤£¦^ÀY¡A¤§«á¤@¸ôº¦¨ì2016¦~ªì结ª½¸zÀù©M¯Ø¸¢Àù¹êÅ祢±Ñ¡A¤£¹L¦]¹êÅ祢±Ñ¤U¶^ªºªÑ»ù³Ì§CÂI¤]¨S¦³¶^¨ì2014¦~ªº§CÂI¡A¥i¥H»¡IncyteªÑ²¼ªº³o¨â¦~§¹¥þ¬Ý¤£¨ì¶^¨ì2014¦~¨º®ÉªºªÑ»ù§CÂI¤F¡A³o¨â¦~·Q¾ß«K©y¦A¤]¨Sªk¾ß¨ì2014¦~®³¨ìÃÄÃÒ«e½L¾ã¤@¦~®É¤@¼Ëªº«K©y»ù®æ¤F¡C

¬ü°êÃļt®³¨ìÃÄÃÒ«e¤@¼Ë½L¤F¤@¾ã¦~¡AÃĵØÃIJ{¦b³o¼Ë¤]¤£¥Î¤Ó¾á¤ß¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/14 ¤W¤È 10:38:33²Ä 3305 ½g¦^À³
¤p°¨¤jªº­@¤O¯u¬O¥O¤H¨ØªA~

¥i¥H¾ú¸g10´X¶ô¨ì200¤S¨ì²{¦b~

ÃĵتºªÑ»ù¤w¸g¬OµR¤û¥Öµ¥¯Å¤F~

´N¦pRussell¤j©ÒÁ¿,

´NÀR«ÝÃÄÃÒªº¨ì¨Ó§a~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/14 ¤W¤È 09:55:44²Ä 3304 ½g¦^À³
¤j½L¦­§âÃĵØÃĹq¨ìÃz
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/14 ¤W¤È 09:47:35²Ä 3303 ½g¦^À³
«¢«¢¡AÁÙ¬Oº¦¤£°Ê¡A¦³°÷¤û¥Ö

¤£¹Lºâ¤F¡D¡D¡D

§Ú±q10´X¶ô©ê¨ì200¦h¤S¶^¦^40¥XÀY¡D¡D¡D

¤µ¤Ñ¥¦¤w¦b»âµý¶¥¬q¤F

´NºâªÑ»ù¨Sªø¶i

°ò¥»­±­Ë¬O¶i¨B¤F¤£¤Ö

¤@¼Ë¦n¦Y¡A¦nºÎ¡A¥[ªo°Õ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/13 ¤U¤È 09:26:46²Ä 3302 ½g¦^À³
¦w¥S:

§A³£¬ÝªÅ¤@¦~¦h¤F¡A«ç»òÁÙ¦b¥s½æ??

¶R¶i66±i¡B½æ¥X100±i...

¨º»ò¨¯­W´N¬°¤F²b½æ¥X34±i???????

¥H¤µ¤Ñªº½L¶Õ¡A¦³¤ß¥X³f¤@¦¸´N¥X§¹¤F

¦pªG»¡³o¬O¬°¤F±±½L....©Î³\§Ú·|¤ñ¸û»{¦P!!

¤ñ¸û¦P·N¥ý¶i¤j¸ò¤pªL¤jªº¬Ýªk...

³o¤@¡B¤G¦~¨Ó¡A¥Í§Þ¨º»ò®z¶Õ¡AÃĵتºªí²{¤w¸gºâ¨¾¦uªº«Ü¦n¤F

³£«ù¦³¨º»ò¤[¤F¡A²{¦b­n®³ÃÄÃÒ¤F¤~­n©ñ±ó??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/12/13 ¤U¤È 08:46:58²Ä 3301 ½g¦^À³
À£¨­®aªº¡B­É¿ú¶Rªº¡B¨S°µ§ë¸ê²Õ¦Xªº¡B¦b¥G¸êª÷®Ä²vªº¡A¦b¾á¤ß¬O§_·|¯}©³®É¡Aªº½T¥i¥H¦Ò¼{´î«ù©Î¥X³õ¡C

´£¿ôÂ÷¶}®É¡A¤£­n¥ß¨è±N¦^¦¬ªº¸êª÷°l¤J§Oªº¼Ðªº¡A°È¥²¥ý°±¬ÝÅ¥¡A­«·s«ä¦Ò§ë¸êµ¦²¤»P²Õ¦X¡C

¤E¤ë¥÷¦³¤@¦ì¤£­@¤[½Lªº§ë¸ê¤H¡A¦b¨â­Ó¥æ©ö¤é½æ¥X150±i6446¡A¥ß¨è¥þ¼Æ°l¤J¨ä¥L¼Ðªº¡A¤£¨ì¨â­Ó¤ë²{®M800¦h¸U¡A±b¤WÁ«·l¬ù40%¡C

­Ó¤H»{¬°¡A°l¨D¸êª÷®Ä²v¬OÁ¿¨DÁZ®Äµû¤ñªº°òª÷¸g²z¤H©Ò­n¦b¥Gªº¨Æ¡A¤@¯ë§ë¸ê¤H(¤£ºÞ¬O´²¤á¹ê¤á¤j¤á)°l¨D¸êª÷®Ä²v´N«Ü¦MÀI¡A

«Ø¥ß§ë¸ê²Õ¦X¤ñ°l¨D¸êª÷®Ä²v¨Ó±o­«­n¡A¤]»ÝÅé»{¨ì¬JµM¬O§ë¸ê²Õ¦X¡A´N·|¦³ªº«ùªÑº¦¡B¦³ªº¶^¡B¦³ªº»D­·¤£°Ê¡C

¤µ¦~²y©u¥H¨Ó¡A¦b¥~¬É²yµû¤£Â_ªº¼NÁn¤U¡A²y¶¤¤¤¥X²{¤F¤@¦ì³Ì¨Î¨¾¦u²y­û¡C

¦b³\¦h¨ä¥L²y¶¤¬ÛÄ~³QÄéÃzÄx¯}©³®É¡A6446ÁÙ¯àºû«ù¦u¦b¯U´T°Ï¶¡½L¾ã¡A¤£¦P¤§³B´N¦b©ó²y­ûªº²Õ¦¨¡C

¬Ý¤£À´²yÁɪºÆ[²³¡A¤£·P¿E³o¦ì²y­ûº}«Gªº¨¾¦u´Nºâ¤F¡AÁÙ´Á±æ¨¾¦u²y­û¤]­n¯à¤WÄx±o¤À¡C

§ó¦³´X­Ó¬ÝÀ´ªºÆ[²³¡A´X­Ó¤ë¨Ó¤£Â_¤W¤U¦Y³o¦ì²y­ûªº¨§»G¡A´N¬°¤F¨C¶gÁȨâ¤T¶ôªº¶Rµæ¿ú¡A¤H®a­n¬O³Q§Ë±o¤£°ª¿³¥i¯à´N¤£ª±¤F¡C

¦pªG¹ê¦b¤£º¡·N¡A»P¨ä¦bºô¸ô¤Wµo¨cÄ̦ӵL©Ò§@¬°¡A¤]§ïÅܤ£¤F¦Û¤vªº§ë¸êÁZ®Ä¡C

§Ú¤£·|Á¿ºC¨«¤£°e¨ººØ­·²D¸Ü¡A¦ý­n¦A¤T´£¿ôÂ÷¶}«á­n¥ý°±¬ÝÅ¥¡A¤]¯¬ºÖÂ÷¶}ªº¤H¦³º¡·Nªº§ë¸êÁZ®Ä¡C

(³Q§ÚÁ|¨Ò¨ìªº¨º¦ìºô¤Í½Ð§O¨£©Ç¡A±zªº·s¼Ðªºªø´ÁÀ³¸Ó¤]«Ü¤£¿ù¡A§Æ±æ±z«Ü§Ö¯àÂàÁ«¬°¬Õ¡C)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/13 ¤U¤È 07:34:37²Ä 3300 ½g¦^À³
IPO ªº»ù®æ¤£¬O159¶Ü?

³o¼Ë½æ¤£¬O½ß¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/13 ¤U¤È 05:55:27²Ä 3299 ½g¦^À³
¤¸¤j´°«n³o­Ó¤ÀÂI

IPO¤§«á´N¤@ª½½æ

¦Ü¤µ½æ¤F¤­¦Ê¦h±i

¤]´N¬O²Ö¿n®w¦s¬O­tªº¤­¦Ê¦h±i

¤]³\¬O¥h¦~Äv¼Ð¨ìªº¤j¤á¦b½æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2017/12/13 ¤U¤È 05:24:52²Ä 3298 ½g¦^À³
ÃĵØÃÄ21»õªÑ¥»¡A¨C¤Ñ¦¨¥æ¶q´X¨Õ±i¡A¬°¤°»ò¡H¡HÄw½X¤Ó¶°¤¤¥þ¦b©¾¹ê¤á¤â¤¤¡A³sº¦°±¤]¬O´X¨Õ±iÂê¦í¤@¸ô¨ì©³¡A

Â÷¼Ú·ùÃÄÃÒ¬ù¤@©u®É¨è¡A¦¹®É¤~¬O­«­n®É¨è¡A³Q¬~....µL±m«ùªÑ¤G~¤T¦~........¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤U¤È 04:05:35²Ä 3297 ½g¦^À³
²Ä¤@ª÷°ª¶¯¡A¤Ñ¤Ñ¤Wºt¤p©Ô¤j¥X

143.00¶R¶i11±i¡A½æ¥X30±i

143.50¶R¶i51±i¡A½æ¥X60±i

144.00¶R¶i02±i¡A½æ¥X10±i

144.50¶R¶i02±i

¥t¤@­Ó¤¸¤j´°«n¤ÀÂI¤]¦b¥X³f¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2017/12/13 ¤U¤È 03:26:50²Ä 3296 ½g¦^À³
Pharmaessentia announces favorable two-year results of ropeginterferon alfa-2b in polycythemia vera

µo§G¤é´Á¡G2017¦~12¤ë10¤é

https://www.youtube.com/watch?v=MKIiZKEWITQ

Pharmaessentia announces favorable two-year results of ropeginterferon alfa-2b in polycythemia vera at the american society of hematology (ash) annual meeting 2017

Ropeginterferon alfa-2b is a novel, long-acting, mono-pegylated proline interferon. It is administered once every two weeks, or monthly during long-term maintenance, and is expected to be the first interferon approved for PV worldwide. PharmaEssentia discovered and manufactures Ropeginterferon alfa-2b and has exclusively licensed the rights for the novel molecule in the field of Myeloproliferative Neoplasms (MPNs) to AOP Orphan for European, Commonwealth of Independent States (CIS), and Middle E...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¯«©_³Ç§J10144658  µoªí®É¶¡:2017/12/13 ¤U¤È 02:57:19²Ä 3295 ½g¦^À³
«Ü¦n¡A¤£¬O¤@ª½¦Û¤v»¡¦Ó¤w¡C­n¥«³õ»{¦P¤~¦³¥Î§r¡A¥i¥H±N¸êª÷Âà¨ì¦³®Ä²vªº¦a¤è¡A¤£¥Î¤@ª½¦º©ê¡C¤µ¤Ñ¥xªÑº¦¦h¤Ö¡HÃĵثo¤Ï¦V¶^¦h¤Ö¡H¥X¥X¶q¤F¡A¦A°l¦^¤]¤£¿ð¡C³»¦h´N®t¤@®Ú¦Ó¤w¡A¤Ï¥¿¦nªºªÑ²¼¤]¤£·|¥uº¦¤@¤Ñ¡A¤£¬O¶Ü¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤U¤È 01:34:34²Ä 3294 ½g¦^À³
§Úª¾¹D¬ÝªÅ¦b³o¸Ì¤£°Q³ß

¦ý¬O³Ìªñ¨C¤Ñ³£¬O½L¤¤¥X¤j³æ

§À½L§C±µ¤@¨Ç¦^¨Ó¤p©Ô§@»ù¹j¤ÑÄ~Äò¥X

¨C¤Ñ¶^­Ó1%©ÎªÌ2%¥ª¥k¡A·Å¤ôµN«Cµì¡AÅý§A·Q¶]³£¤£·Q¶]

©Ô§À½L´N¬O«ÜºD±`ªº¤@ºØ¥X³f¤è¦¡

¤£¥Î§Ú»¡©ú¤j®aÀ³¸Ó³£ª¾¹D

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤U¤È 01:23:07²Ä 3293 ½g¦^À³
¨ä¹ê¤£¥uÄw½X§e²{¥X³fª¬ºA

³s½u«¬¤]¬OÃø¬Ýªº¨«ªÅ±Æ¦C

©Ò¥H¨ì©³¤ä¼µ²{¦b¶R¶iªº²z¥Ñ¦b­þ¸Ì?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤U¤È 01:06:25²Ä 3292 ½g¦^À³
§Ú¶Kªº¥u¬O«ÈÆ[¶R½æ¶i¥X¼Æ¾Ú

©Î³\³oÃ䦳¥D¤O¦s¦b·Q¾É¤Þ¨¥½×¡A·QÅý¦Û¤v¥X³f§ó¶¶§Q¤]¤£¤@©w

§Ú¶K­Ó¨é°Ó¶i¥XÅý¤j®a¦Ü¤Ö¦h¤@­Ó¶i¥X§PÂ_ªº¨Ì¾Ú

³o¨Ç¼Æ¦r³£¬O¨Æ¹êªº¦s¦b¡A¤£¬O§Ú­Ó¤Hªº·N¨£

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤U¤È 01:01:56²Ä 3291 ½g¦^À³
Äw½X¶K¥X¨ÓÅý¤j®a¬Ý¬Ý½Ö¦b­Ë³f

¨Æ¹ê´N¬O²Ä¤@ª÷°ª¶¯´X¥G¥e¤F¨C¤Ñ¦¨¥æ¶q1/3

©Î³\¦³¤H·|µ¥«Ý³o­Ó¤ÀÂI°±¤î½æ¥X¤~·Q¶i

·Q¶R¦b¬Û¹ï§CÂI §Ú¥u¬OµL²á¶K¶K

¦Ó¥B¥L¤]¤£¬O³Ì¤j©@

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2017/12/13 ¤U¤È 01:00:59²Ä 3290 ½g¦^À³
ªÑ»ù¤@¾ã¦~ªºªí²{¥u¦³¤S´e¤S³¾¥i¥H§Î®e!

¸Óº¦¤£º¦,§¤¦b¤j½L¬Û¹ï°ªÂIªº®öÀY¤W­·ÀI½T»{«Ü°ª«Ü°ª~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±i±M­û10145380  µoªí®É¶¡:2017/12/13 ¤U¤È 12:41:26²Ä 3289 ½g¦^À³
ÃÙ¦P¤pªL¤jªº»¡ªk Äw½Xªº¶i¥X¤º¦æªº§ë¸ê¤H³£¯à±q¥æ©ö©ú²Ó¤¤¬Ý¥XºÝ­Ù ¹ê¦bµL»ÝÂI¥X ²¦³º~¦¿´ò¤@点³Z¡FÁ¿¯}µL­È¿ú~

¦³«H¤ßªº´NÄò©ê¡AµL«H¤ßªº´N·¬´äÀH¤H¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/13 ¤U¤È 12:40:40²Ä 3288 ½g¦^À³
¦w¥S

§A¬ÝªÅ¤w¸g«Ü¤[¤F¡K

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤U¤È 12:36:48²Ä 3287 ½g¦^À³
§O»¡¯}140¤F

¥D¤O¶}©l±ó¾i

§Ú¬Ý«Ü§Ö¯}IPO·s§C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2017/12/13 ¤U¤È 12:33:29²Ä 3286 ½g¦^À³
²{¦b¤HÁÙ¦b¬ü°ê¡A¤U¶g¤£´N¦^¨Ó­n¶}ªk»¡·|¤F?

¤£²Å¦X­Ó¤H´Á±æ©Î¦³ºÃ¼{ªº¡A§â´¤¾÷·|¸ò¸gÀç¹Î¶¤´£°Ý©Î¹ï¸Ü¡A§O¹³ªÑªF·|¯ë°Ñ»PªºªÑªF³o»ò¤Ö¡C

¥t¥~¡A¤j¦h¼Æªº¤H³£·|¬ÝÄw½X¶i¥X¡A«Øij¤£¥Î¶K¥X¯S©w¨é°Óªº¶i¥X¡A¨¥µü¤W¤]½Ð´L­«¨C­Ó§ë¸ê¤Hªº¥æ©ö¦æ¬°¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­n¦³¦n¹B®ð10145611  µoªí®É¶¡:2017/12/13 ¤U¤È 12:20:07²Ä 3285 ½g¦^À³
­n¦³¤ß²z·Ç³Æ¯}140¥H¤U¡A

³o°¦ªÑ²¼¤w¸gÅý¤H«H¤ß¤£¨¬¤F¡A

­Y³s³oªi¥Í§ÞªÑ¦bº¦ªº¶Àª÷´ÁÁÙ·|©¹¤U±´¡A

´N¤£­n¦A´Á±æ«á­±ªº§Q¦h¡ã

¦]¬°FDAÁٻݭn«Ü¤[¡A§Y¨Ï°¨¤W¤½§G°eFDA,

§Úı±o¤]¥u¬O¤@¤é¦æ±¡¡ã^_^

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/13 ¤U¤È 12:17:56²Ä 3284 ½g¦^À³
¤½¥q12/19­n¥l¶}ªºªk»¡·|
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¹Å10138576  µoªí®É¶¡:2017/12/13 ¤W¤È 11:57:39²Ä 3283 ½g¦^À³
³o¥s°µ¨C¤Ñ³£µ¹§Æ±æ¡A®É±`³£¦b¥¢±æ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤W¤È 11:57:24²Ä 3282 ½g¦^À³
¤½¥q¤f¤fÁnÁn­n¬°ªÑªF¿Ñ¨ú³Ì¤j§Q¯q

³s¸Ó»¡ªºªF¦è³£¤£¥X¨ÓÁ¿­Ó²M·¡

¥H¬°«O«ù½pÀq´N¬O°ª­·«G¸`

¨S¦³­n§A­Ì»¡¤£¤Á¹ê»Úªºº}«G¸Ü

¦Ü¤Öµy·L¸Ñ»¡ªñ´Áµo®i°Ê¦V

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤W¤È 11:51:45²Ä 3281 ½g¦^À³
¼oª«¥D¤O³s©Ô³£¤£·Q©Ôª½±µ¥X³f

³£30±i¡B20±i¦A¥á

µM«á¥Î1±i¡B2±i©Ô»ù

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Glee-sen10145657  µoªí®É¶¡:2017/12/13 ¤W¤È 11:38:42²Ä 3280 ½g¦^À³
ªñ´Á¤¸¤j´°«n¤]½æ¤£¤Ö¡ã¤£ª¾¦³¦ó¤º²[

¸Ü»¡¤µ¦~¶RÃĵØ...¯uªº¬O½m­×¾i¡A´NÄ~Äò­×¦æ§a¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p°¨10135228  µoªí®É¶¡:2017/12/13 ¤W¤È 10:51:33²Ä 3279 ½g¦^À³
ªÑ²¼ªº°ªÂI©¹©¹¦b¼ÖÆ[¤W²£¥Í

¸Õ·Q·í®Éªº¯E¹©­Ì¦h»ò¼ÖÆ[

ªÑ»ù¤w¤ÏÂà¤U±þ¤F¡A¯E¤Í­Ì¯É¯É¬~½L»¡¡B³{§C¤j¶R»¡¡D¡D¡Dµ²ªGªÑ¤ý¦w¦b¡H

¤ÏÆ[ÃĵاQ¦h¤£º¦¡A¤@¤ù´dÆ[

©¹©¹§CÂI³£¦b´dÆ[¤¤µo¥Í¡D¡D¡D

ÅZµM¦^­º¡A§A·|Ååı·í®ÉµL­·¤]µL«B

¥Í§ÞªÑ¥i¥H3¦~¤£º¦

¤@¥¹¤jº¦·|º¦¨ì±¹¤â¤£¤Î

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2017/12/13 ¤W¤È 10:12:45²Ä 3278 ½g¦^À³
¥H²{¦bªº¨«¶Õ...¹ï19¸¹ªºªk»¡·|¥Rº¡¼~¼{....

§Q¦h¶V¦h¶^¶V¦h....»¡¨Ó»¡¥h...¤@¤Á³£¬OªÅ½Í....

®³¨ìÃÄÃÒ¦A¶}ªk»¡§a....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2017/12/13 ¤W¤È 10:11:10²Ä 3277 ½g¦^À³
¤µ¤Ñ½L¤¤¤S¦³¤H¤@ª½¦b¥X¤j³æ

¤£¥X·N®Æ¤S¬O²Ä¤@ª÷°ª¶¯

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gco10141285  µoªí®É¶¡:2017/12/13 ¤W¤È 10:03:21²Ä 3276 ½g¦^À³
½Ð±Ð¥ý¶i­Ì¡G¦pªG6446©ú¦~­n¿ì²z²{¼W¨Ó½Ä¨ë¥þ²y¤Î¬ü°êÃÄÃÒ£¿¦æ¾P¡A¬O§_¥iµø¬°¬O§Q¦h¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G®ÇÆ[ªÌ10141545  µoªí®É¶¡:2017/12/13 ¤W¤È 07:39:20²Ä 3275 ½g¦^À³
ª©¤W´£¨Ñ±M·~¸ê°Tªº¤j¤j¥O¤H´L·q

¨SÀò§QÁ`¬OÄw½X©wªÑ»ù¡AÀò§Q¬°¯u¬O­Ó¤H·Qªk´²¤á¦ÊªÑ¾Ç²ß¡A°Ï¶¡Àò§Q­n±Ë±o½æ¥X¡A´Á±æ¤½¥qÄò§V¤O¦³µ²ªG¡A¤j¤j­Ì³£¯àÀò§Q¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G®ÇÆ[ªÌ10141545  µoªí®É¶¡:2017/12/13 ¤W¤È 07:23:20²Ä 3274 ½g¦^À³
­Ó¤H·Qªk
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2017/12/12 ¤U¤È 09:54:49²Ä 3273 ½g¦^À³
²Ä¤@ª÷°ª¶¯¥u¤£¹L§â11¤ëªì¥[½Xªº½æ¥ú,¦A½æªÖ©wÁ«¿ú¥X

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµØ½ü10141250  µoªí®É¶¡:2017/12/12 ¤U¤È 09:31:12²Ä 3272 ½g¦^À³
¤j®a§O³o»ò¬ª®ð, ¦pªGı±oªñ´ÁªÑ»ùªí²{¤£¨Î, ¨º¤£§«¬Ý¬Ý¤¤¸Î

¬Ý¬Ý´¼Àº¤µ¦~ªºªí²{, ¯E¹©´N§ó§O´£¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2017/12/12 ¤U¤È 09:26:51²Ä 3271 ½g¦^À³
µð....

³o¤@ÂIªº«ùªÑ¸ò¶R½æ«Ü­È±o°Q½×¶Ü??

¬Ý¨Ó³ÌÃѳfªºÁÙ¬O¥~¸ê

105/12/12«ùªÑ11,395±i

106/12/12«ùªÑ17,187±i

¤@¸ô±}±}ªº¦Y...ºCºCªº¦Y.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2017/12/12 ¤U¤È 08:47:10²Ä 3270 ½g¦^À³
²Ä¤@ª÷°ª¶¯

¥h¦~IPO¤§«á¶}©l¶R¤J

®w¦s³Ì°ª¬O¤µ¦~ªº 11/29 2653 ±i

¤µ¤Ñ 12/12 ®w¦s 2432±i

Á`¦@½æ¤F221±i

¬Ý°_¨Ó¤£¤Ó¹³ªk¤H¤á

¦ý¦³³oºØ¹ê¤Oªº¤H

«o¤£¦A¸³ºÊ«ùªÑ¦W³æ¸Ì­±

À³¸Ó´N¬O«n³¡ªº­Ó¤H¤j¤á

¦pªG¦A¥Î²Ä¤@ª÷°ª¶¯¤µ¦~¶R¶WªºÁ`ÃB¨Ó¬Ý

²Ä¤@¦Wªº®w¦s´N¬O6446

µM«á¬O6452 2317 1472 2809

¬Ý¨Ó³o­Ó¤j¤á

¤£©ÈÅý¤Hª¾¹D

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
²Ä¤@­¶¤W¤Q­¶¤W¤@­¶303132333435363738¤U¤@­¶¤U¤Q­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

ÃĵØÂåÃÄ

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!